On this page
Quick Reference
Overview and Recommendations
Background
- •Hemophilia A is an X-linked recessive bleeding disorder caused by pathogenic variants in the F8 gene, leading to deficient or dysfunctional coagulation factor VIII (FVIII). This impairs the intrinsic tenase complex, reducing thrombin generation by 10⁵-fold and predisposing to spontaneous and trauma-related bleeding, particularly into joints and soft tissues [1].
- •The disease affects approximately 1 in 5,000 to 10,000 male births worldwide, making it one of the most common inherited bleeding disorders. Up to 75% of affected individuals globally remain undiagnosed, especially in resource-limited settings, underscoring the need for targeted screening of at-risk families [1].
- •Severity is dichotomized by baseline FVIII activity: severe (<1 IU/dL) with spontaneous bleeding, moderate (1-5 IU/dL) with occasional spontaneous or trauma-related bleeds, and mild (>5 to <40 IU/dL) with bleeding only after significant injury or surgery. FVIII activity ≥40 IU/dL is generally asymptomatic [1, 10].
- •The underlying F8 mutation type is the primary determinant of clinical severity and inhibitor risk. Intron 22 inversion accounts for 40-45% of severe cases, while missense mutations predominate in mild/moderate disease. Neutralizing anti-FVIII antibodies (inhibitors) develop in 25-35% of patients with severe hemophilia A and are the most significant treatment-related complication [13, 28].
- •The 2021 ISTH nomenclature reclassified female F8 variant carriers into five distinct categories (asymptomatic, symptomatic, mild, moderate, severe) based on personal bleeding history and FVIII level, replacing the historical 'carrier' label and acknowledging that many females experience clinically significant bleeding [6, 7].
- •A subset of patients exhibit 'discrepant hemophilia A,' where FVIII activity differs between one-stage clotting and chromogenic assays due to specific F8 missense mutations. Chromogenic assay is the confirmatory test and better reflects true bleeding risk, preventing underdiagnosis or misclassification [10].
Evaluation
- •Suspect hemophilia A in any male with a history of spontaneous hemarthroses (especially ankles, knees, elbows), easy bruising, prolonged bleeding after dental extraction or surgery, or intracranial hemorrhage (ICH) in infancy. A three-generation family history revealing X-linked inheritance is highly suggestive [88, 111].
- •Ask about the age at first significant bleed: severe disease often presents in infancy with excessive bruising after crawling or ICH after birth. Moderate disease may present in childhood with bleeding after minor trauma, while mild disease can remain undiagnosed until adulthood after a surgical challenge [81].
- •Examine for joint swelling, warmth, and limited range of motion in acute hemarthrosis. Chronic arthropathy presents with fixed flexion deformities, crepitus, muscle atrophy, and reduced gait. In neonates, ICH may manifest as lethargy, seizures, vomiting, or bulging fontanelles [88, 111].
- •Order a complete blood count (CBC), prothrombin time (PT), and activated partial thromboplastin time (aPTT). An isolated prolonged aPTT with normal PT is the classic screening abnormality. A mixing study (1:1 with normal plasma) that corrects immediately suggests a factor deficiency; failure to correct after incubation indicates an inhibitor [124, 96].
- •Perform a one-stage clotting assay for FVIII activity (FVIII:C) as the initial gold-standard diagnostic test. A level <40 IU/dL confirms the diagnosis and defines severity: <1 IU/dL (severe), 1-5 IU/dL (moderate), >5 to <40 IU/dL (mild). Normal FVIII:C essentially excludes hemophilia A [124].
- •In mild hemophilia A (FVIII:C 5-40 IU/dL), perform a chromogenic FVIII:C assay to detect discrepant hemophilia A, where the one-stage assay may overestimate FVIII activity. The chromogenic assay is the confirmatory test and better predicts bleeding risk [70].
- •Measure von Willebrand factor (VWF) antigen and activity (ristocetin cofactor) to exclude von Willebrand disease type 2N, which also causes low FVIII:C due to defective VWF binding. This is essential in any patient with low FVIII and normal VWF levels to confirm true hemophilia A [33].
- •If the mixing study fails to correct after 2-hour incubation, perform the Nijmegen-modified Bethesda assay to detect and quantify FVIII inhibitors (neutralizing antibodies). A titer ≥0.6 Bethesda units (BU) is considered positive; >5 BU defines high-titer inhibitors [118].
- •Offer genetic counseling and F8 gene sequencing for confirmation of the diagnosis, determination of mutation type (critical for inhibitor risk stratification), carrier testing in female relatives, and prenatal diagnosis. The mutation type predicts inhibitor risk: null mutations (large deletions, nonsense) carry the highest risk [13, 18, 126].
- •In female patients with low FVIII:C, assess for skewed X-inactivation, Turner syndrome mosaicism, or von Willebrand disease type 2N. A three-generation pedigree and evaluation of personal bleeding history with menstrual and postpartum bleeding are essential [6, 33, 129].
- •Diagnostic criteria for acquired hemophilia A (AHA) include new-onset bleeding in an older adult without prior bleeding history, isolated prolonged aPTT that does not correct on mixing study, low FVIII:C, and a positive Bethesda assay for anti-FVIII autoantibodies. Unlike congenital disease, AHA often presents with ecchymoses and muscle hematomas rather than hemarthroses [20, 75, 98].
- •Also consider other causes of isolated prolonged aPTT: lupus anticoagulant (does not correct with mixing but may show prolonged dilute Russell viper venom time), factor IX deficiency (hemophilia B), and factor XI deficiency. Specific factor assays for FIX and FXI should be performed if FVIII is normal and clinical suspicion remains high [124].
Management
- •For acute major bleeds (intracranial hemorrhage, retroperitoneal, gastrointestinal, large muscle with compartment syndrome) in patients without inhibitors: administer FVIII concentrate 50 IU/kg IV bolus immediately, followed by 25 IU/kg every 8-12 hours. For life-threatening bleeds, give initial bolus of 50-100 IU/kg and maintain FVIII activity >80% for 7-14 days [148].
- •For acute minor bleeds (hemarthroses, superficial hematomas) in patients without inhibitors: administer FVIII concentrate 25-40 IU/kg IV; a single dose may suffice. For hemarthroses, rest, immobilize the joint, and apply ice. Avoid weight-bearing until pain and swelling resolve, typically 24-48 hours [148].
- •For patients with inhibitors who present with an acute bleed: use a bypassing agent. First-line options are recombinant activated factor VII (rFVIIa) 90 mcg/kg IV every 2-3 hours or activated prothrombin complex concentrate (aPCC, FEIBA) 50-100 U/kg IV every 12 hours (maximum 200 U/kg/day). Do not administer aPCC and rFVIIa concurrently due to additive thrombosis risk [143].
- •In patients with inhibitors who are on emicizumab prophylaxis: rFVIIa 90 mcg/kg is the preferred first-line bypassing agent for acute bleeding. Avoid aPCC in this setting if possible, as the combination has been associated with thrombotic microangiopathy and thromboembolic events [144, 154, 169].
- •For mild hemophilia A (FVIII >5 IU/dL) with a known response to desmopressin (DDAVP test dose): administer DDAVP 0.3 mcg/kg IV (over 15-30 minutes) or intranasal (1.5 mg/mL, 150 mcg per spray, 1 spray for <50 kg, 2 sprays for ≥50 kg). DDAVP raises FVIII 2-4 fold; repeat every 12-24 hours but limit to 2-3 doses to avoid tachyphylaxis and hyponatremia [124, 283].
- •Initiate primary prophylaxis for all patients with severe hemophilia A (FVIII <1 IU/dL) starting before age 2 years, ideally by 12 months, to prevent joint damage. Standard regimens include FVIII concentrate 25-40 IU/kg three times weekly (or every other day), or extended half-life products like efanesoctocog alfa 50 IU/kg IV once weekly [45, 76, 165, 169].
- •For patients without inhibitors, non-factor prophylaxis with emicizumab (Hemlibra) is a first-line alternative to FVIII concentrates: loading dose 3 mg/kg subcutaneously weekly for 4 weeks, then maintenance 1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks. In HAVEN 3, emicizumab reduced annualized bleeding rate (ABR) by 96% vs on-demand therapy [156, 169].
- •For patients with inhibitors, first-line prophylaxis is emicizumab (same loading and maintenance dosing as above), which reduced ABR by 87% in HAVEN 1 vs no prophylaxis. Immune tolerance induction (ITI) with daily high-dose FVIII should also be considered to eradicate the inhibitor; success rates are 60-80% [154, 169, 181].
- •For patients with severe hemophilia A without inhibitors or anti-AAV5 antibodies, gene therapy with valoctocogene roxaparvovec (Roctavian) is an option: single IV infusion of 6×10¹³ vg/kg. Pre-treatment evaluation includes screening for anti-AAV5 antibodies, liver fibrosis (transient elastography <8 kPa), and active hepatitis. Post-infusion, monitor ALT weekly for 12 weeks; ALT elevation >1.5× baseline triggers corticosteroid therapy [183, 167, 186].
- •Newer non-factor agents for prophylaxis include concizumab (anti-TFPI, 0.15 mg/kg SC once daily) and marstacimab (anti-TFPI, 150 mg SC once weekly). In the explorer7 and BASIS trials, these agents reduced ABR by 86-92% vs on-demand therapy and are emerging as alternatives for patients with and without inhibitors [155, 158, 159].
- •What NOT to do: avoid NSAIDs (ibuprofen, naproxen) and aspirin in all patients with hemophilia A due to antiplatelet effects. Avoid intramuscular injections unless absolutely necessary. Do not use desmopressin for acute bleeding in patients with severe hemophilia A (FVIII <1 IU/dL) or in those with unknown DDAVP response. Do not combine aPCC and rFVIIa [148].
- •Refer all patients with severe hemophilia A, moderate disease with a severe bleeding phenotype, or any patient with an inhibitor to a specialized hemophilia treatment center (HTC). Referral is also indicated for women with symptomatic hemophilia A carriers, patients considering gene therapy, or those with recurrent bleeding despite adequate prophylaxis [169].
- •Discharge criteria after a treated acute bleed: cessation of bleeding (no further swelling, pain controlled, stable hemoglobin), ability to ambulate or use joint without severe pain, and a plan for transition to or continuation of prophylaxis. Ensure outpatient follow-up with hematology within 1-2 weeks [148].
- •For major surgery or invasive procedures, achieve FVIII trough >80-100% on day of surgery and maintain >50% for 5-10 days postoperatively. Administer a bolus of FVIII concentrate 50 IU/kg immediately before incision, then continue with 25-40 IU/kg every 8-12 hours or continuous infusion. Mechanical thromboprophylaxis is preferred; pharmacologic prophylaxis is not routinely indicated [148, 209].
Board Review — High Yield
- •Intron 22 inversion, most common F8 mutation in severe hemophilia A (40-45%); causes complete FVIII deficiency due to homologous recombination.
- •One-stage clotting assay, gold-standard initial diagnostic test for FVIII activity; chromogenic assay needed for discrepant mild hemophilia.
- •Bethesda assay, detects and quantifies FVIII inhibitors (≥0.6 BU positive; >5 BU high-titer); essential before surgery or for unexplained bleeding.
- •SIPPET trial, recombinant FVIII carries 1.87-fold higher risk of inhibitors vs plasma-derived FVIII/VWF in previously untreated patients with severe hemophilia A.
- •Emicizumab, bispecific monoclonal antibody mimicking FVIIIa; given subcutaneously weekly to monthly; reduces ABR by 87-96% in patients with and without inhibitors.
- •HAVEN 1 and 3 trials, established emicizumab prophylaxis vs on-demand in inhibitor (87% ABR reduction) and non-inhibitor (96% ABR reduction) patients.
- •Efanesoctocog alfa (Altuviiio), once-weekly extended half-life FVIII; XTEND-1 trial showed mean ABR 0.7 and 86% zero bleeds; maintains FVIII >40% for most of the week.
- •Valoctocogene roxaparvovec (Roctavian), AAV5-based gene therapy for adults without inhibitors or anti-AAV5 antibodies; single IV infusion sustains median FVIII 5.8 IU/dL at 5 years, eliminating need for prophylaxis in 88%.
- •Hemophilic arthropathy, results from recurrent hemarthrosis driving synovial inflammation and cartilage destruction; prevented by early prophylaxis (Joint Outcome Study: 93% normal MRI vs 55% with episodic therapy).
- •Acquired hemophilia A, autoantibodies against FVIII cause bleeding in older adults without prior history; treated with bypassing agents, emicizumab, and immunosuppression (steroids ± cyclophosphamide or rituximab).
Deep Dive — Evidence Details
1. Definition, Classification & Nomenclature
- ▸Hemophilia A is an inherited **F8**-related FVIII deficiency or dysfunction causing impaired secondary hemostasis. [1][306]
- ▸The supplied diagnostic threshold is **FVIII activity <40% of normal**, with exclusion of von Willebrand disease and other causes of low FVIII. [1]
- ▸Severe HA is characterized by residual FVIII activity **<1%** and recurrent joint or muscle bleeding. [4][306]
- ▸Bleeding phenotype may be more severe than the laboratory grade suggests; a major ISTH-BAT grade 4 event can support classification as a severe bleeding disorder. [308]
- ▸OSA–CSA FVIII discrepancies affect approximately one-third of patients with mild HA and may change diagnosis or treatment classification. [10][307]
- ▸Female terminology should incorporate bleeding history and FVIII level rather than assuming that every female with an **F8** variant is asymptomatic. [6][7][311]
Definition
Hemophilia A (HA) is an inherited bleeding disorder caused by deficiency or dysfunction of coagulation factor VIII (FVIII), encoded by the F8 gene. FVIII functions as a cofactor within the intrinsic tenase complex, supporting activation of factor X and propagation of clot formation; reduced or absent FVIII therefore impairs secondary hemostasis and produces excessive bleeding. [1]C4[306] HA is predominantly X-linked and most clinically apparent in males, although females with pathogenic F8 variants may also have clinically important HA and remain underdiagnosed. [1]C4[6]A1c[7]C4[311]D
A diagnosis of HA is supported by reduced plasma FVIII activity, a pathogenic or likely pathogenic F8 variant, and exclusion of von Willebrand disease or another explanation for low FVIII. The diagnostic threshold identified in the supplied evidence is FVIII activity <40% of normal. [1]C4 Molecular confirmation should use standardized variant nomenclature; the CDC Hemophilia A Mutation Project catalogues F8 variants using Human Genome Variation Society coding-DNA and predicted-protein nomenclature, while also recording traditional mature-protein terminology and associated severity. [312]D
Classification by FVIII activity and bleeding phenotype
HA is classified as mild, moderate, or severe primarily according to baseline FVIII activity. Severe HA is defined in the supplied evidence by residual FVIII activity <1% and is associated with recurrent spontaneous or injury-related bleeding, particularly hemarthroses and muscle hemorrhage; repeated joint or muscle bleeding may occur as often as weekly. [4]B3b[306] Patients with higher residual FVIII activity are generally categorized as nonsevere HA, including mild or moderate disease, but the clinical phenotype may not correspond reliably to the laboratory grade. [10]C4[308]D
The severity label should therefore be interpreted together with personal bleeding history, age, exposure to hemostatic challenges, genotype, and the assay used to measure FVIII. A person classified as having mild or moderate HA may nevertheless experience a severe bleeding disorder; an international working-group approach cited in the evidence considers a single major bleeding event, including an ISTH Bleeding Assessment Tool grade 4 event, sufficient to reclassify an apparently mild or moderate disorder as clinically severe. [308]D Platelet activation and other biologic factors may also modify bleeding expression: increased platelet activation was observed in patients with severe HA, indicating that platelet behavior may contribute to variation in bleeding tendency beyond FVIII activity alone. [4]B3b
Assay-dependent classification
FVIII activity is measured using one-stage clotting assays (OSA) and/or chromogenic assays (CSA). Disagreement between OSA and CSA occurs in approximately one-third of patients with mild HA and can alter both diagnosis and severity assignment. [307] “Discrepant hemophilia A” (DHA) denotes a clinically relevant difference in FVIII activity measured by different assay methodologies in nonsevere HA. [10]C4 Such discrepancies have resulted in previously missed diagnoses and incorrect severity classification, with direct consequences for treatment decisions. [10]C4[307] Accordingly, a discordant result should not be dismissed solely because one assay reports a near-normal or substantially different FVIII activity; interpretation should incorporate bleeding phenotype and, when appropriate, confirmatory testing. [10]C4[307]
Nomenclature for women and girls
The traditional term “hemophilia carrier” can imply that a female has no bleeding disorder. This is inaccurate because females with hemophilia-associated F8 variants may bleed despite normal FVIII activity, and many remain undiagnosed or untreated. [6]A1c[7]C4[311]D The ISTH Scientific and Standardization Committee proposed a nomenclature for hemophilia in women and girls based on two dimensions: personal bleeding history and baseline FVIII activity. [6]A1c This approach distinguishes clinically relevant female states rather than treating all females with an affected male relative or an F8 variant as asymptomatic carriers. [6]A1c
Reproductive genetic counseling should recognize HA as an X-linked condition with potential fetal transmission and should address preconception and postconception carrier screening when the family history or genetic background indicates risk. [304] Genome-sequencing-based preconception screening can evaluate substantially more gene–disorder pairs than conventional targeted testing, but reported variants require pathogenicity assessment and confirmation before clinical reporting. [314]D Genotype–phenotype relationships are useful but imperfect: large numbers of unique F8 mutations have been documented, and mutation databases associate variants with reported HA severity while preserving standardized HGVS descriptions. [312]D
Related terminology and boundaries
HA should be distinguished from hemophilia B, which results from factor IX deficiency; both are inherited disorders of secondary hemostasis, but the deficient factor defines the type. [306][309]D “Hemophilia with inhibitors” describes HA complicated by neutralizing antibodies against replacement FVIII, not a separate inherited hemophilia subtype; inhibitor development has been reported in approximately 29% of patients in one cohort and varies with product source and purity. [8]B2b Physical disability, recurrent hemarthrosis, surgical complications, and rehabilitation needs are consequences or clinical dimensions of HA rather than alternative disease definitions. [2]A1a[305] Similarly, artificial-intelligence tools and viscoelastic testing may support diagnosis, risk stratification, or management, but they do not replace the core definition based on FVIII deficiency or dysfunction, bleeding phenotype, and appropriate laboratory assessment. [9]B2a[310]D
| Domain | Definition or implication |
|---|---|
| Disease type | Hemophilia A: inherited FVIII deficiency or dysfunction; hemophilia B: factor IX deficiency. [306][309]D |
| Diagnostic activity threshold | FVIII activity <40% of normal, with appropriate differential diagnosis. [1]C4 |
| Severe HA | Residual FVIII activity <1%; recurrent spontaneous or trauma-related joint and muscle bleeding may occur. [4]B3b[306] |
| Nonsevere HA | Mild or moderate laboratory categories; clinical bleeding may still be substantial or clinically severe. [10]C4[308]D |
| Assay issue | OSA and CSA may disagree, particularly in mild HA; discrepant results can change diagnosis and management. [10]C4[307] |
| Female nomenclature | Classify according to personal bleeding history and baseline FVIII level rather than carrier status alone. [6]A1c |
2. Pathophysiology & Mechanism
- ▸Hemophilia A results from pathogenic F8 variants causing absent, reduced, or dysfunctional FVIII; mutation type influences residual activity, protein processing, stability, and inhibitor risk. [14][27][37]
- ▸Approximately 30% of children with severe hemophilia A develop neutralizing FVIII inhibitors after replacement, whereas approximately 70% show no detectable antibody response. [14]
- ▸Female carriers may bleed despite normal FVIII activity because of mosaicism, X-chromosome inactivation, and additional genetic modifiers. [315][323]
- ▸Repeated hemarthrosis causes iron-associated inflammation, synovial pathology, and progressive arthropathy; neutrophil-dependent interferonopathy is a proposed contributor. [397][320]
- ▸Acquired hemophilia A is an autoimmune FVIII-inhibitor disorder and is distinct from inherited F8-related hemophilia A. [38][39]
Genetic and molecular basis
Hemophilia A is an X-linked inherited bleeding disorder caused by a pathogenic variant in F8, resulting in absent, reduced, or dysfunctional coagulation factor VIII (FVIII). The degree of residual FVIII activity is strongly related to clinical severity in affected males, although the specific mutation can also influence protein processing, stability, immunogenicity, and treatment response. [14]B2a[37]C4 Severe disease is frequently associated with major structural abnormalities, including intron 22 or intron 1 inversions, whereas missense variants account for nearly all mild or moderate cases but for fewer than 20% of severe cases. [37]C4[316]C Intron 22 inversion is detected in approximately 45% of patients with severe hemophilia A. [325]D
Missense substitutions may disrupt FVIII conformation, intracellular processing, secretion, or stability. The p.Arg1800His variant, for example, produces moderate hemophilia A through defective processing and reduced stability of functional FVIII. [37]C4 Patient-derived endothelial-cell models have also demonstrated mutation-specific intracellular handling: selected high-inhibitor-risk nonsense variants in the FVIII light chain can be retained in the endoplasmic reticulum and undergo proteasomal processing rather than achieving normal secretion. [27]D5 These findings support a mechanistic link between the molecular fate of mutant FVIII and both residual circulating activity and immune recognition. [27]D5[37]C4
Sex, carrier status, and X-chromosome inactivation
Female carriers have one mutant and one apparently normal F8 allele, but FVIII activity is variable because of cellular mosaicism and X-chromosome inactivation (XCI). [315] Skewed XCI can preferentially silence the wild-type allele and produce a hemophilia A phenotype in a heterozygous female; disruptive NKAP variants have been associated with extreme XCI skewing and musculoskeletal manifestations in females carrying an F8 defect. [323]D Consequently, bleeding risk is not confined to carriers with conventionally low FVIII activity: females with apparently normal FVIII levels may still experience abnormal reproductive-tract or other bleeding. [315] A single FVIII threshold that reliably excludes clinically important bleeding in carriers has not been established. [315]
Defective hemostasis and bleeding phenotype
Insufficient functional FVIII compromises coagulation and causes impaired clot formation, producing a bleeding phenotype that ranges from mild provoked bleeding to recurrent spontaneous bleeding, according to residual FVIII activity and other genetic or biological modifiers. [14]B2a[37]C4 Mutation type may also influence manifestations beyond bleeding; genotype-specific differences in frequency-domain postural-control measures have been reported despite comparable radiographic arthropathy and conventional sway parameters in patients with inversion versus non-inversion variants. [316]C
Patients with non-severe hemophilia A can nevertheless develop joint damage. In a multicenter real-world study, joint condition was assessed alongside FVIII levels, F8 mutation, thrombin generation, and age, emphasizing that residual FVIII activity alone does not fully capture long-term musculoskeletal risk. [317]C Nonneutralizing anti-FVIII antibodies have been detected in approximately 13% of people with moderate hemophilia A in a Nordic cohort; their clinical significance remains uncertain. [318]
Hemophilic arthropathy
Repeated hemarthroses initiate a self-perpetuating process of synovial inflammation, hyperplasia, blood-product accumulation, and progressive cartilage and bone damage. Iron deposition and inflammatory signaling are implicated in progression, and joint degeneration may occur despite prophylaxis because current FVIII replacement and FVIII-mimetic therapies provide only partial protection from joint bleeding. [397]D[320]D Experimental studies indicate that joint damage involves innate immune mechanisms: neutrophil-dependent interferonopathy contributes to hemophilic arthropathy, while CX3CR1-positive synovial macrophages accumulate during experimental disease but are not required for acute synovitis. [397]D[42]D5 These observations distinguish the immediate inflammatory response to bleeding from later pathways that sustain chronic synovitis and structural degeneration. [397]D[42]D5
Immune tolerance and FVIII inhibitors
Exogenous FVIII can be recognized as a neoantigen, particularly when endogenous FVIII production is absent or markedly abnormal. Neutralizing anti-FVIII antibodies, termed inhibitors, develop in approximately 30% of children with severe hemophilia A receiving FVIII concentrate; the remaining approximately 70% have no detectable antibody response and may have developed apparent immune tolerance. [14]B2a Inhibitor formation reflects interactions among the F8 mutation, residual endogenous FVIII expression, antigen processing and presentation, and host immune determinants, including HLA variation. [14]B2a[40]B2b[324]D Nonsense mutations show heterogeneous inhibitor risk, potentially because premature-stop-codon readthrough produces trace amounts of full-length FVIII, including wild-type and variant molecules, that may modify immune recognition. [40]B2b Variant location also matters: nonsense mutations in the FVIII light chain have been associated with higher inhibitor risk than comparable heavy-chain variants, consistent with differences in intracellular processing and secretion. [27]D5
Nonfactor prophylaxis reduces routine exposure to FVIII concentrate, whereas FVIII may be reserved for bleeding or perioperative hemostasis; this changing exposure pattern may alter opportunities for immune priming and tolerance, although the relevant mechanisms remain incompletely defined. [14]B2a
Acquired FVIII autoimmunity
Acquired hemophilia A is mechanistically distinct from inherited hemophilia A: it results from autoantibodies that inhibit endogenous FVIII in individuals without the inherited disorder. [38]C4[39]C4 Immune checkpoint inhibitors, especially anti-PD-1 therapy, can trigger this autoimmune complication; in a series of 11 cases, 9 followed anti-PD-1 monotherapy. [38]C4 Acquired FVIII inhibitors have also been reported in association with myeloproliferative disease, including polycythemia vera evolving to myelofibrosis, although the mechanism remains uncertain. [39]C4
| Determinant | Mechanistic consequence | Clinical implication |
|---|---|---|
| Severe F8 structural variant, including intron 22 inversion | Markedly reduced or absent functional FVIII | Severe bleeding phenotype and increased inhibitor concern. [14]B2a[325]D |
| Missense variant | Altered FVIII structure, processing, secretion, or stability | Mild-to-moderate disease is common, but variant-specific effects vary. [37]C4 |
| X-chromosome inactivation in a female carrier | Unequal expression of mutant and wild-type F8 alleles | FVIII activity and bleeding risk are heterogeneous. [315][323]D |
| Repeated joint bleeding | Iron deposition, inflammation, synovial hyperplasia, and immune activation | Progressive hemophilic arthropathy. [397]D[320]D |
| Anti-FVIII antibody | Neutralization of replacement FVIII | Treatment failure and need for inhibitor-directed management. [14]B2a |
3. Epidemiology, Etiology & Risk Factors
- ▸Hemophilia A is an F8-related, predominantly X-linked bleeding disorder affecting males, while female carriers may have clinically important bleeding. [74][331]
- ▸Severe disease carries substantial early-life bleeding risk; in the PedNet cohort, ICH occurred in 2.2% of children with hemophilia and 75% of events occurred before 1 year. [67]
- ▸F8 genotype is a recognized modifier of inhibitor development and may influence immune tolerance induction outcomes. [72]
- ▸Approximately 30% of previously untreated patients with severe hemophilia A developed inhibitors within the first 50 exposure days in the updated PedNet registry analysis. [398]
- ▸IL10 polymorphisms are a potential immune-genetic modifier of inhibitor formation, but the supplied evidence does not establish a standalone clinical predictor. [329]
- ▸Pregnancy and delivery are high-risk periods for hemophilia carriers; severe postpartum hemorrhage is defined as blood loss of at least 1,000 mL. [327]
- ▸Acquired hemophilia A is distinct from congenital HA and is caused by autoantibodies against FVIII, sometimes occurring with autoimmune or inflammatory disease. [330]
Overview and epidemiology
Hemophilia A (HA) is a congenital bleeding disorder caused by reduced or absent factor VIII (FVIII) activity and is inherited predominantly through an X-linked recessive pattern; consequently, affected males constitute the principal clinical population, although females may be heterozygous carriers and can also have clinically relevant bleeding when FVIII activity is reduced. [74]A1a[331]C The measured prevalence of HA varies substantially among regions and health systems, partly reflecting differences in case ascertainment, access to laboratory diagnosis, registry coverage, and survival. A systematic review and meta-analysis specifically evaluated the prevalence of HA among males in Africa because primary studies had reported inconsistent estimates; the supplied abstract confirms the objective and systematic search but does not provide the pooled numerical estimate. [74]A1a
Disease severity is determined primarily by residual FVIII activity and the underlying F8 variant. Severe HA is associated with particularly early and clinically significant bleeding, including intracranial hemorrhage (ICH) during infancy and early childhood. [67]B2b[331]C In the PedNet registry, which included 2,275 children with HA, ICH before prophylaxis occurred in 61 of 2,727 children with hemophilia overall, corresponding to 2.2% and 10 per 1,000 patient-years; 75% of events occurred before 1 year of age. [67]B2b These data support infancy as a high-risk period and suggest that earlier prophylaxis may have preventive potential, although the cited study was observational and focused on ICH before prophylaxis. [67]B2b
Etiology and genetic determinants
HA results from pathogenic variants in the F8 gene, producing quantitative FVIII deficiency or dysfunctional FVIII. [74]A1a[331]C The F8 genotype is also an important determinant of alloimmune inhibitor risk, particularly in patients receiving replacement FVIII. [72]A1a The genotype may influence inhibitor development through the degree to which infused FVIII is recognized as immunologically foreign; however, genotype-based prediction is incomplete, and the 2026 systematic review was designed to evaluate genotype not only as a risk factor for inhibitors but also as a determinant of immune tolerance induction (ITI) success or failure. [72]A1a
Host immune genetics may further modify inhibitor risk. A systematic review and meta-analysis evaluated variants in the anti-inflammatory cytokine gene IL10, because IL-10 regulates immune responses and antibody production; the study specifically assessed associations between IL-10 polymorphisms and inhibitor formation. [329] The available abstract does not report the pooled effect estimates, so IL10 variation should be regarded as a potential modifier rather than a clinically established standalone predictor. [329]
Treatment-related risk factors for inhibitors
Inhibitors are neutralizing antibodies directed against therapeutic FVIII and are a major complication of replacement treatment. [72]A1a[73]A1a[398]C The risk is concentrated early in exposure: the updated PedNet registry analysis describes inhibitor development in approximately 30% of previously untreated patients with severe HA during the first 50 exposure days. [398]C Risk assessment is particularly relevant in previously untreated patients (PUPs), children with severe disease, and patients undergoing initial intensive exposure or repeated treatment for bleeding, surgery, or prophylaxis. [73]A1a[398]C
FVIII product characteristics have been investigated as possible determinants of inhibitor risk, including plasma-derived versus recombinant products and standard-half-life versus extended-half-life recombinant FVIII. [398]C A systematic review of 16 studies involving 1,145 pediatric patients compared standard- and extended-half-life recombinant FVIII in previously treated and untreated children; it assessed efficacy, safety, and inhibitor development, but the supplied abstract does not provide a definitive product-specific inhibitor estimate. [73]A1a Accordingly, product selection alone should not be presented as a reliably independent predictor without considering age, severity, F8 genotype, treatment intensity, and other host factors. [72]A1a[73]A1a[398]C
Female carriers, acquired disease, and changing risk profiles
Female carriers may experience bleeding during pregnancy and delivery, particularly when FVIII activity is reduced. In a prospective Dutch cohort, revised guidance increased the threshold for third-trimester prophylaxis from <50 IU/dL to <80 IU/dL and increased the intrapartum target from ≥100 IU/dL to ≥150 IU/dL because severe postpartum hemorrhage (PPH; ≥1,000 mL) remained a concern. [327] The study evaluated whether this enhanced management reduced severe PPH incidence; its abstract indicates that persistent PPH remained clinically important, emphasizing that carrier status and obstetric factors confer risk even with intensified hemostatic management. [327]
Acquired hemophilia A (AHA) is etiologically distinct from congenital HA and results from autoantibodies against endogenous FVIII. [330]C It may occur in association with autoimmune or inflammatory conditions; a retrospective study of bullous pemphigoid patients investigated AHA and identified lipopolysaccharide-binding protein as a potential FVIII-inhibitory factor in a BP-associated case, although this represents mechanistic and retrospective evidence rather than a general population risk estimate. [330]C
Age, comorbidity, and complications
As people with HA live longer, age-related cardiovascular risk becomes increasingly relevant. In the prospective ADVANCE Japan registry, adults aged ≥40 years with HA were followed for five years to assess arterial thrombotic risk using established cardiovascular risk scores; participants with previous arterial thrombosis were excluded. [62]B2b Older age and conventional comorbidities—including hypertension, diabetes, hyperlipidemia, obesity, prior stroke, or cardiovascular disease—were also specifically evaluated in analyses of people aged ≥50 years receiving emicizumab. [333]
Cumulative joint bleeding contributes to hemophilic arthropathy, with advanced hip and knee disease sometimes requiring arthroplasty; a retrospective study evaluated 64 patients undergoing total knee or hip arthroplasty for end-stage arthropathy. [292]C4 Dental extraction and intracranial bleeding remain clinically important bleeding settings, with postextraction hemorrhage studied in a Japanese multicenter cohort and ICH risk documented in children before prophylaxis. [399][67]B2b These complications reflect disease burden and treatment context rather than separate causes of HA.
| Category | Examples and implications |
|---|---|
| Genetic cause | Pathogenic F8 variants causing reduced or dysfunctional FVIII. [74]A1a[331]C |
| Inhibitor susceptibility | F8 genotype, severe disease, early exposure, and possible IL10 variants. [72]A1a[329][398]C |
| Treatment context | PUP status, first 50 exposure days, FVIII product class, and treatment intensity. [73]A1a[398]C |
| Sex and reproductive factors | Female carrier status, reduced FVIII activity, pregnancy, and delivery. [327] |
| Acquired disease | Autoantibodies to FVIII, including associations with autoimmune or inflammatory disorders. [330]C |
| Age-related factors | Older age and cardiovascular comorbidities increasingly influence thrombotic risk. [62]B2b[333] |
4. Clinical Presentation
- ▸The hallmark presentation of severe congenital hemophilia A is recurrent hemarthrosis and soft-tissue bleeding with risk of progressive joint damage. [340]
- ▸Intracranial hemorrhage is uncommon but life-threatening and occurs more often in children with hemophilia than in the general pediatric population. [331]
- ▸Women and girls can have clinically significant hemophilia A; carrier status does not reliably indicate absence of bleeding. [90][311]
- ▸In one retrospective carrier study, **23% had FVIII activity below 40 IU/dL by one-stage assay**, and chromogenic testing sometimes provided different clinical information. [232]
- ▸Acquired hemophilia A typically presents with new spontaneous or trauma-related ecchymoses, subcutaneous or intramuscular hematomas, mucosal bleeding, and an isolated prolonged aPTT. [96][97][98]
- ▸An isolated prolonged aPTT without bleeding may result from lupus anticoagulant or another non-hemophilic cause and requires laboratory differentiation from a FVIII inhibitor. [96]
Hemophilia A results in a spectrum of bleeding manifestations determined largely by residual factor VIII (FVIII) activity, although assay-related discrepancies and individual variation can complicate clinical risk assessment, particularly in women and girls. [232]C4[311]D The phenotype ranges from minimal or procedure-related bleeding to recurrent spontaneous hemorrhage with progressive joint damage. [339][340]
Congenital hemophilia A
In boys with severe congenital hemophilia A, bleeding commonly begins early in life, particularly after circumcision, venipuncture, surgery, trauma, or other invasive procedures; spontaneous bleeding may also occur. [340] The characteristic pattern is recurrent hemarthrosis and soft-tissue bleeding, with repeated joint hemorrhage causing synovial injury, chronic inflammation, reduced mobility, and hemophilic arthropathy. [340][342]D Knees, ankles, and elbows are clinically important target joints in children with severe disease, and joint damage may develop despite modern prophylaxis or apparently low recent bleeding rates. [342]D[343]D
Early joint disease may be clinically occult. Persistent joint symptoms, reduced range of motion, swelling, warmth, or altered gait should prompt assessment even when routine joint scores and reported bleeding frequency are reassuring. [342]D Magnetic resonance imaging can identify hemosiderin deposition and structural abnormalities before they are evident on routine examination; T2* MRI has been investigated as a sensitive marker of occult joint involvement in children. [342]D MRI studies in boys with severe hemophilia have also evaluated interval changes in the ankles, knees, and elbows during prophylaxis. [343]D
Bleeding can involve skin, subcutaneous tissues, muscles, mucosa, the oral cavity, urinary tract, and central nervous system. [331]C[339] Oral bleeding may follow dental disease, exfoliation, extraction, or other dental procedures, and ranges from minor oral-cavity bleeding to potentially life-threatening hemorrhage. [339] Hematuria is recognized in hemophilia A; upper urinary tract bleeding is uncommon but may present as gross hematuria and can mimic a renal or urothelial tumor on imaging. [130]C4 Intracranial hemorrhage is uncommon but disproportionately more frequent in children with hemophilia than in the general pediatric population and is a life-threatening complication. [331]C New severe headache, vomiting, altered consciousness, focal neurologic findings, or neurologic change after even minor trauma should therefore be treated as possible intracranial bleeding in an affected patient. [331]C
Bleeding severity generally correlates with FVIII activity, but a single one-stage clotting assay may not fully represent bleeding risk. [232]C4 In a retrospective study of hemophilia A carriers, 23% had FVIII activity below 40 IU/dL by one-stage assay, and chromogenic testing identified clinically relevant assay discrepancies in some individuals. [232]C4 Consequently, women and girls with low FVIII levels or bleeding symptoms should not be presumed asymptomatic solely because of carrier status or a borderline routine assay result. [232]C4[311]D
Women and girls
Women and girls may have clinically significant hemophilia A rather than being symptom-free carriers. [90]D5[311]D Reported manifestations include heavy menstrual bleeding, postpartum or surgical bleeding, easy bruising, prolonged bleeding after dental procedures, and bleeding that is disproportionate to measured FVIII activity or has historically been dismissed. [90]D5[311]D Phenotypic expression may vary among carriers, and assessment should integrate personal bleeding history, family history, menstrual and obstetric history, procedural outcomes, and FVIII testing. [232]C4[311]D
Acquired hemophilia A
Acquired hemophilia A (AHA) is an autoimmune disorder caused by inhibitory autoantibodies against FVIII and typically presents with new, spontaneous, or trauma-related bleeding in a person without a prior bleeding history. [338][341][98]C4 The clinical pattern often differs from congenital disease: large ecchymoses, extensive subcutaneous hematomas, intramuscular bleeding, soft-tissue hemorrhage, mucosal bleeding, and bleeding after procedures are prominent, whereas recurrent hemarthrosis is not the defining presentation. [97]C4[98]C4 Severe or persistent bleeding may produce anemia and functional impairment. [97]C4[98]C4
AHA should be considered when significant bleeding is accompanied by an isolated prolonged activated partial thromboplastin time (aPTT), particularly when the platelet count and other routine coagulation findings do not explain the presentation. [338][96]C4[97]C4 The differential diagnosis of isolated prolonged aPTT includes FVIII deficiency, a FVIII inhibitor, lupus anticoagulant, and other intrinsic-pathway abnormalities; mixing studies and specific FVIII activity and inhibitor testing are required to distinguish these entities. [96]C4 Not every patient with an isolated prolonged aPTT is bleeding: lupus anticoagulant or other antiphospholipid antibodies may prolong the aPTT without producing the bleeding phenotype of AHA. [96]C4
AHA has been reported in association with pregnancy, malignancy, autoimmune disease, rheumatoid arthritis, systemic lupus erythematosus, and drug exposure. [95]C4[97]C4[98]C4 In a 22-patient adult cohort, the mean age was 62 years with a range of 22–102 years; suspected associated conditions included pregnancy (27%) and malignancy (23%), and men and women were represented equally. [98]C4 Case reports describe spontaneous leg and muscle hematomas in rheumatoid arthritis and severe bleeding in adalimumab-associated AHA. [97]C4[341] Rituximab-treated cases likewise involved adults with significant bleeding and prolonged aPTT despite initial factor replacement and corticosteroids. [338]
Important diagnostic context
Petechiae, purpura, and ecchymoses after COVID-19 vaccination have been reported in the literature, but these findings are nonspecific and may reflect vascular or platelet-related disorders rather than hemophilia A. [92]C4 In a patient with new bruising or bleeding, the diagnosis should therefore be based on the complete bleeding pattern and coagulation evaluation rather than skin findings alone. [92]C4[96]C4
| Pattern | Typical clinical presentation | Key distinguishing considerations |
|---|---|---|
| Congenital severe disease | Recurrent hemarthrosis, muscle and soft-tissue bleeding, procedure-related bleeding, and possible intracranial hemorrhage | Joint bleeding may cause progressive arthropathy; early damage can be occult on routine examination. [331]C[340][342]D |
| Congenital disease in women and girls | Heavy menstrual, obstetric, dental, surgical, or easy-bruising phenotype | Bleeding risk may be underestimated by carrier status or one-stage FVIII testing alone. [90]D5[232]C4[311]D |
| Acquired hemophilia A | New spontaneous ecchymoses, large subcutaneous or intramuscular hematomas, mucosal or post-procedural bleeding | Usually occurs without a prior personal bleeding history and is associated with an isolated prolonged aPTT. [96]C4[97]C4[98]C4 |
| Atypical urinary presentation | Gross hematuria from urinary tract or renal pelvic hemorrhage | Upper urinary tract bleeding may mimic a tumor on imaging. [130]C4 |
5. Diagnosis & Workup
- ▸Do not exclude clinically important hemophilia A in women or girls because FVIII:C is normal; X-chromosome inactivation and other biological factors make FVIII:C and bleeding phenotype variable.[315][311]
- ▸An isolated prolonged APTT requires differentiation among congenital FVIII deficiency, acquired FVIII inhibitors, antiphospholipid antibodies, and other causes.[96]
- ▸Molecular workup should account for intron 1/22 inversions, sequence variants, copy-number changes, and complex structural variants.[41][400]
- ▸Define the familial F8 variant whenever possible before cascade, prenatal, or preimplantation testing.[126][349]
- ▸Consider hemorrhagic mimics, including renal pelvic hemorrhage masquerading as a tumor, when imaging findings are atypical.[130]
Diagnostic overview
Hemophilia A (HA) is an inherited bleeding disorder caused by deficient or dysfunctional coagulation factor VIII (FVIII) and is usually associated with pathogenic variation in the F8 gene.[348]D Although classically recognized in males, women and girls may have clinically important bleeding and should not be considered unaffected solely because they are female or have a normal FVIII activity (FVIII:C) result.[311]D[315] The diagnostic assessment should therefore integrate bleeding history, family history, laboratory findings, sex and reproductive context, and molecular testing.[311]D[315][346]
Initial clinical and laboratory assessment
Evaluation should begin with characterization of bleeding manifestations, including spontaneous or provoked bleeding, mucosal or reproductive-tract bleeding, postoperative bleeding, hematuria, and bleeding in relatives.[311]D[315][346] In female potential carriers, FVIII:C is variable because of mosaicism related to the second, usually wild-type, F8 allele and X-chromosome inactivation (XCI); therefore, FVIII:C alone does not reliably exclude carrier status or abnormal bleeding risk.[315] A normal FVIII:C should not end the evaluation when the bleeding phenotype or family history is suggestive.[315]
Coagulation testing is central to the workup. An isolated prolonged activated partial thromboplastin time (APTT) may be caused by congenital FVIII deficiency, an acquired FVIII inhibitor, antiphospholipid antibodies, or other laboratory and factor-related conditions; distinguishing these causes requires correlation with bleeding symptoms and targeted follow-up testing.[96]C4 Acquired hemophilia A (AHA) should be considered particularly when a patient has new bleeding and an isolated prolonged APTT without a previously established congenital diagnosis.[96]C4 In patients receiving FVIII replacement, neutralizing inhibitors are diagnosed conventionally with the Nijmegen-modified Bethesda assay, although assay sensitivity and interlaboratory performance may vary.[350]D A paper-strip point-of-care inhibitor test has been developed as a rapid, equipment-free alternative, but it should be regarded as an emerging diagnostic technology rather than a replacement for locally validated laboratory testing.[350]D
Molecular confirmation and carrier testing
Molecular testing confirms the familial diagnosis, establishes the causative variant when possible, and supports cascade testing, counseling, prenatal diagnosis, and reproductive planning.[41]C4[126]B2a Testing strategies should be capable of identifying small sequence variants as well as structural abnormalities. Long-range PCR is useful for detecting F8 intron 1 and intron 22 inversions, while sequencing can identify small deletions and other variants.[41]C4 When routine testing is unrevealing or a structural rearrangement is suspected, copy-number analysis, structural-variant sequencing, genome walking, or long-read whole-genome sequencing may resolve partial or whole-gene deletions, duplications, and complex rearrangements at nucleotide resolution.[400]D These structural variants represent important causes of severe hemophilia and may be missed by limited variant panels.[400]D
Carrier assessment should include genetic testing when the familial variant is known and FVIII:C measurement interpreted cautiously.[315][41]C4 In families without a previously identified variant, comprehensive molecular analysis may be required; a reported carrier-screening workflow combined high-throughput sequencing, long-range PCR, Sanger confirmation, and copy-number or structural-variant methods to characterize complex F8 changes.[41]C4 Linkage or haplotype analysis may assist carrier detection when direct variant identification is unavailable, although polymorphism-based approaches are population- and family-specific.[321]D
Prenatal and reproductive diagnosis
Once the familial F8 variant is defined, genetic counseling should address fetal risk, maternal carrier status, and available reproductive choices.[126]B2a[349]D Prenatal diagnosis has used chorionic-villus sampling or amniocentesis, with methodology varying substantially across regions and studies; a systematic review of 24 studies included 969 pregnancies, of which 78.3% involved hemophilia A carriers.[126]B2a Preimplantation genetic testing for monogenic disease is another option for couples at risk and is performed through multidisciplinary counseling, in-vitro fertilization with intracytoplasmic sperm injection, embryo biopsy, and variant and/or linkage analysis.[349]D
Pregnancy-specific assessment should distinguish inherited HA from acquired hemophilia. Prepartum AHA is rare but may cause maternal hemorrhage, and transplacental inhibitor transfer can produce transiently low neonatal FVIII levels.[347]C Women with inherited bleeding disorders also require coordinated maternal, fetal, neonatal, and hemostatic assessment because pregnancy may be associated with maternal bleeding and adverse neonatal outcomes.[376]
Important diagnostic mimics and associated findings
Hematuria in HA may reflect urinary-tract bleeding rather than malignancy. A renal pelvic hemorrhage can mimic a urothelial tumor on imaging; clinical context, imaging characteristics, and response to FVIII replacement may support hemorrhage and help avoid unnecessary invasive procedures.[130]C4 Atypical neurologic or systemic features should prompt evaluation for coincident disease rather than being attributed automatically to HA. For example, cerebral X-linked adrenoleukodystrophy has been reported with HA in a patient carrying pathogenic variants in both F8 and ABCD1, demonstrating that dual X-linked disorders can occur.[94]C4
As individuals with HA age, the diagnostic and baseline assessment may also include cardiovascular risk characterization. In adults aged ≥40 years without prior arterial thrombosis, the ADVANCE Japan cohort evaluated 5-year arterial-event risk using the Hisayama model, Suita score, and QRISK3, reflecting the increasing relevance of cardiovascular comorbidity in long-term hemophilia care.[62]B2b
| Domain | Practical focus | Evidence |
|---|---|---|
| Clinical phenotype | Bleeding history, family history, reproductive-tract bleeding, hematuria, and unexplained postoperative bleeding | [311]D[315][346] |
| Coagulation laboratory testing | FVIII assessment and investigation of isolated prolonged APTT; consider inhibitor testing when acquired disease or treatment failure is suspected | [96]C4[350]D |
| Molecular testing | Sequence analysis plus targeted inversion, copy-number, structural-variant, or long-read testing when indicated | [41]C4[400]D |
| Female carrier assessment | Combine genetic testing with cautious interpretation of FVIII:C; normal FVIII:C does not exclude bleeding risk | [315][41]C4 |
| Reproductive diagnosis | Genetic counseling followed by prenatal diagnosis or preimplantation genetic testing when appropriate | [126]B2a[349]D |
| Differential diagnosis | Evaluate acquired hemophilia, antiphospholipid antibodies, hemorrhagic renal lesions, and coincident X-linked disease | [96]C4[130]C4[94]C4 |
6. Staging, Risk Stratification & Prognostic Scoring
- ▸Null F8 mutations identified a genetically high-risk group in SIPPET; with pdFVIII, cumulative inhibitor incidence was 31%, whereas no inhibitors occurred among genetically low-risk patients with non-null mutations. [11]
- ▸No single universal bleeding-risk score is currently supported because published studies use heterogeneous predictors and outcomes. [135]
- ▸Joint-risk assessment may incorporate CAJAS, HEAD-US, target-joint history, and functional or imaging findings. [134,356]
- ▸Inhibitor prognosis and ITI planning may incorporate inhibitor titre, early response, mutation status, and other poor-risk features; low-dose ITI and rituximab evidence is mainly cohort-based. [11,133,357,351]
- ▸In older adults, cardiovascular risk scores may estimate arterial-event risk, but hemophilia-specific prospective validation remains limited. [62]
Scope and principles
Risk stratification in hemophilia A should be multidimensional rather than based solely on baseline factor VIII (FVIII) activity. Relevant domains include the F8 genotype, inhibitor risk, bleeding phenotype during prophylaxis, joint status, treatment pharmacokinetics, cardiovascular risk in older adults, and patient-reported or functional outcomes. The available evidence is heterogeneous: a systematic review of bleeding-risk models in people with hemophilia receiving regular prophylaxis found substantial variation in risk factors, outcome definitions, and statistical methods, preventing a unified quantitative synthesis. [135]B2a
Genetic and inhibitor-risk stratification
The strongest treatment-specific evidence comes from the randomized SIPPET analysis of 235 previously untreated patients with severe hemophilia A; 197 had null F8 mutations and were classified as genetically high risk, whereas 38 had non-null mutations and were classified as genetically low risk. [11]A1b Among patients receiving plasma-derived FVIII (pdFVIII), no inhibitors occurred in the genetically low-risk group, while the cumulative inhibitor incidence in the high-risk group was 31%. [11]A1b In recipients of recombinant FVIII (rFVIII), inhibitor risk was not markedly separated between the low- and high-genetic-risk groups, indicating that mutation-based stratification may modify interpretation of product-associated inhibitor risk rather than replace prospective inhibitor surveillance. [11]A1b
Machine-learning approaches may add biological and clinical variables to conventional risk assessment. In the HEMFIL cohort, HemfilNET was developed in previously untreated or minimally treated children with severe or moderately severe hemophilia A, using data and biological samples collected before FVIII exposure and following participants to 75 exposure days without an inhibitor or until inhibitor development. [141]B2b This model is investigational and should be regarded as an adjunct to, not a substitute for, serial inhibitor testing and clinical assessment. [141]B2b A 2025 systematic review likewise concluded that artificial intelligence and predictive analytics are being explored for diagnosis, risk stratification, and personalized management of bleeding disorders, but emphasized the complexity and heterogeneity of these disorders. [9]B2a
Bleeding, joint, and functional-risk assessment
For patients on regular prophylaxis, bleeding risk should be reassessed using clinical history, breakthrough-bleeding patterns, treatment adherence and exposure, joint history, and other patient-level variables; however, current evidence does not support a single validated universal bleeding-risk score because of heterogeneity across studies. [135]B2a Joint damage is an important prognostic outcome. The Colorado Adult Joint Assessment Scale (CAJAS) evaluates swelling, muscle atrophy, axial deformity, crepitus, range of motion, contracture, instability, strength, and gait across six joints, and has been studied for validity and reliability in adults with moderate-to-severe hemophilia A. [134]B2b
In non-severe hemophilia A, a multicenter artificial-intelligence study used age, target-joint history, thrombin-generation capacity, one-stage and chromogenic FVIII results, and their assay ratio to predict joint damage defined as a HEAD-US score >0. [356] This approach remains a prediction model requiring external validation and should not replace standardized clinical and imaging assessment. [356] Thrombin-generation testing may provide additional information about global hemostatic status, but its applicability to routine daily practice remains an area of evaluation, particularly because conventional FVIII monitoring has limitations for some FVIII-related and non-factor therapies. [355]
Treatment-response and pharmacokinetic prognostication
Individual FVIII pharmacokinetics vary substantially. In a real-world cohort of 85 people with severe hemophilia A receiving rFVIII-Fc, the median observed half-life in the model-development population was 20.75 hours, with a range of 8.25–41.5 hours; clinical prediction models were developed from 50 profiles and externally evaluated in 35 additional profiles. [354] Such models may support individualized dosing and target selection, but predicted half-life should be confirmed or clinically contextualized through pharmacokinetic assessment and bleeding outcomes. [354]
For patients with inhibitors, prognostic factors can guide immune-tolerance induction (ITI) strategy. In a Chinese pediatric cohort with high-titer inhibitors, low-dose ITI used pdFVIII/von Willebrand factor at 50 FVIII IU/kg every other day; immunosuppression was selected according to inhibitor titre and response, including escalation when titres were ≥40 Bethesda units (BU) or when ITI-alone was ineffective. [357] In another cohort, low-dose ITI combined with one to three courses of rituximab was evaluated in 76 children with high-titer inhibitors, with outcomes categorized by inhibitor negativity and the speed of response; transcriptomic analyses were exploratory and included patients with failure or rapid success. [133]B2b A 2026 single-center retrospective study further evaluated low-dose ITI with a single rituximab dose, but its design and setting limit generalizability. [351]C
Aging and acquired hemophilia A
In aging adults with hemophilia, arterial thrombotic risk should be assessed separately from bleeding and inhibitor risk. In the prospective ADVANCE Japan cohort, adults aged ≥40 years without prior arterial thrombosis were followed for five years, and the Hisayama model, Suita score, and QRISK3 were compared for arterial-event prediction; prospective hemophilia-specific validation remains limited. [62]B2b
Acquired hemophilia A is a distinct autoimmune disorder and should not be staged with congenital hemophilia A scores. In a Dutch cohort of 143 patients, treatment outcomes were evaluated using multivariable logistic and Cox regression. [142]B3b In a long-term observational study of 41 patients, all recurrences occurred within 1 year of initial remission; initial FVIII activity <1 IU/dL and failure to achieve complete remission were significant predictors of recurrence. [360]C
Practical interpretation
Use genotype to identify increased inhibitor susceptibility, clinical bleeding and joint tools to quantify disease burden, pharmacokinetic models to individualize replacement, and validated cardiovascular scores when appropriate in older adults. AI-derived scores and novel biomarkers should be treated as emerging tools until independently validated. [9]B2a[135]B2a[141]B2b[356]
| Domain | Assessable indicators | Evidence and limitation |
|---|---|---|
| Inhibitor susceptibility | F8 null versus non-null mutation; FVIII product exposure; serial inhibitor testing | SIPPET supports genetic risk stratification, but rFVIII-treated groups showed less separation by genotype. [11]A1b |
| Bleeding phenotype | Breakthrough bleeds, joint history, prophylaxis context, adherence and exposure | Systematic-review evidence is heterogeneous and does not establish one universal score. [135]B2a |
| Joint and function | CAJAS, HEAD-US, target-joint history, range of motion, gait, strength | Validated or investigational tools can quantify damage and predict risk, but AI models require further validation. [134]B2b[356] |
| Treatment personalization | rFVIII-Fc half-life and pharmacokinetic profile | Real-world half-life ranged from 8.25 to 41.5 hours in one development cohort. [354] |
| Aging-related thrombosis | Hisayama, Suita, or QRISK3 estimates | Scores were evaluated in adults aged ≥40 years in ADVANCE Japan; hemophilia-specific data remain limited. [62]B2b |
| Acquired hemophilia A recurrence | Initial FVIII activity and achievement of complete remission | FVIII activity <1 IU/dL and failure to achieve complete remission predicted recurrence in one cohort. [360]C |
7. Acute & Emergency Management
- ▸Contact the hemophilia treatment centre urgently for major bleeding, trauma, neurologic symptoms, unusual bleeding, or uncertain inhibitor status.[148][386][394]
- ▸Do not delay specialist-directed hemostatic treatment for suspected life-threatening bleeding while awaiting definitive imaging or laboratory confirmation.[148][394]
- ▸Emicizumab is prophylactic and does not treat an established acute bleed; inhibitor patients require specialist-guided bypassing therapy.[144]
- ▸Head trauma in a child with hemophilia warrants a low threshold for urgent treatment, neurologic observation, and neuroimaging.[393]
- ▸Consider acquired hemophilia A when new spontaneous hematomas occur with isolated prolonged aPTT and low FVIII activity.[97]
- ▸Women, girls, and carriers may have clinically significant bleeding and require symptom-based emergency assessment.[150][311]
Immediate priorities
Acute bleeding in hemophilia A is a time-critical problem. Emergency clinicians should identify the patient’s hemophilia diagnosis, baseline severity, inhibitor status, current prophylaxis—including emicizumab—and usual hemostatic plan, while simultaneously assessing airway, breathing, circulation, neurologic status, bleeding site, and hemodynamic stability.[148]D5[394]D Prompt communication with the patient’s hemophilia treatment centre, hematologist, hospital pharmacy, and nursing team is recommended because coordinated inter- and intra-centre care is a central consensus objective in hemophilia management.[386] Delays may be particularly consequential for severe bleeding, including intracranial, retroperitoneal, thoracic, abdominal or pelvic bleeding and large or deep muscle hematomas.[394]D
Treat suspected serious bleeding empirically according to the patient-specific emergency plan and involve the hemophilia centre urgently; diagnostic confirmation should not delay hemostatic treatment when the clinical probability of a major bleed is high.[148]D5[394]D Obtain appropriate laboratory testing and imaging, but interpret coagulation assays in the context of the treatment being used, because emicizumab alters conventional coagulation testing and does not itself treat an established acute bleed.[144]C4 Hospital pharmacy and specialist nursing involvement can improve treatment coordination, medication access, adherence, and drug-related outcomes.[386][388]
Hemostatic treatment and emicizumab
For patients not receiving emicizumab, acute treatment generally requires the patient’s prescribed FVIII replacement strategy, selected according to bleed location, severity, FVIII inhibitor status, and the local hemophilia-centre protocol.[148]D5[394]D The available references do not provide a universal FVIII dose or target level; therefore, emergency departments should use the patient’s written plan or consult the treating centre rather than apply an unsourced fixed regimen.[148]D5[386]
Emicizumab is a prophylactic agent that partially mimics FVIII activity, but it prevents rather than treats acute bleeding.[144]C4 Patients receiving emicizumab without inhibitors may still require concomitant FVIII for breakthrough bleeding; real-world data specifically evaluated concomitant FVIII use and healthcare utilization after emicizumab initiation.[392]D In patients with FVIII inhibitors, emergency treatment is more complex because exogenous FVIII may be ineffective; specialist-guided bypassing therapy is required.[144]C4 The references do not establish a single universally preferred bypassing regimen or dose for every emergency.[144]C4
Emicizumab prophylaxis has been associated with fewer emergency-department visits and hospitalizations overall, with a statistically significant reduction in both outcomes in children; the reduction was not statistically significant in adults in one retrospective study.[149]B3b This population-level finding must not be used to dismiss a new bleed or trauma in an individual patient. Pharmacokinetic-guided prophylaxis may improve individualized FVIII exposure and was studied in relation to bleeding and healthcare-resource outcomes, but it does not replace emergency treatment of an active major bleed.[391]
Head trauma and neurologic symptoms
Head trauma in a child with hemophilia warrants a low threshold for immediate hemophilia-centre consultation, urgent hemostatic treatment, serial neurologic assessment, and neuroimaging according to the clinical scenario.[393]D Intracranial hemorrhage is among the most serious potential consequences of hemophilia-associated trauma, and a pediatric emergency algorithm has been proposed because evidence specific to hemophilia is limited and clinicians face substantial uncertainty.[393]D New headache, vomiting, seizure, altered consciousness, focal neurologic deficit, or progressive symptoms should be treated as an emergency; imaging decisions should be individualized rather than based solely on general-population head-trauma rules.[393]D[394]D
Major, unusual, and site-specific bleeding
Large muscle or soft-tissue hematomas, retroperitoneal bleeding, hemothorax, hemoperitoneum, and expanding abdominal or pelvic bleeding require resuscitation, urgent imaging, specialist hemostatic therapy, and surgical, interventional-radiology, or critical-care input when indicated.[394]D A reported corpus-luteum hemorrhage in a patient with acquired FVIII deficiency was successfully managed conservatively with blood products and factor-concentrate support, avoiding surgery; this illustrates that gynecologic hemorrhage may be life-threatening and requires early hematology and gynecology involvement.[146]C4
Women and girls with hemophilia or carrier status may experience clinically important bleeding rather than being asymptomatic; emergency assessment should therefore be based on bleeding phenotype and current symptoms, not sex or carrier label.[150]B3b[311]D Real-world data show that carriers may have mild-to-severe bleeding events and differing healthcare utilization from noncarrier controls.[150]B3b Pregnancy, delivery, and the postpartum period require particular vigilance: a reported postpartum patient with acquired hemophilia A developed hemorrhagic shock and an extensive abdominal-wall hematoma after cesarean delivery and required resuscitation, embolization, hemostatic therapy, immune-complex removal, and immunosuppression.[396]C
Acquired hemophilia and diagnostic pitfalls
New spontaneous bruising, deep hematomas, or muscle bleeding with an isolated prolonged aPTT should raise concern for acquired hemophilia A, particularly when the bleeding pattern is new or atypical.[97]C4 A case associated with rheumatoid arthritis showed anemia, normal platelets, prolonged aPTT, very low FVIII activity, normal FIX, and imaging-confirmed muscle hematoma.[97]C4 This presentation differs from congenital hemophilia and requires urgent hematology consultation for hemostatic treatment and inhibitor eradication; management should not be delayed while attributing bleeding to trauma or medication alone.[97]C4[396]C
Cardiovascular emergencies and competing thrombosis
Acute myocardial infarction in hemophilia requires simultaneous management of ischemia and bleeding risk. A case of inferior STEMI in an elderly patient was treated with emergency drug-coated-balloon angioplasty supported by FVIII replacement; dual antiplatelet therapy was stopped after 3 weeks, with no reported recurrent thrombotic or hemorrhagic event during 1 year of follow-up.[389]C This is case-level evidence, not a general antithrombotic protocol; decisions about PCI, antiplatelet therapy, anticoagulation, and FVIII support must be individualized with cardiology and hemophilia specialists.[389]C
Other urgent complications and care coordination
Severe muscle pain, weakness, dark urine, or unexplained marked creatine-kinase elevation in a patient receiving emicizumab should prompt evaluation for rhabdomyolysis, including renal injury, electrolyte disturbance, and disseminated intravascular coagulation.[390]C This association is based on a case report and does not establish causality or a standard emicizumab-discontinuation strategy.[390]C Patients may encounter barriers to timely care and may report “invisible” or unrecognized bleeds, supporting clear emergency plans, patient education, and direct access to the hemophilia centre.[145]C4 Recurrent bleeding and joint disorders are associated with increased disease burden and healthcare-resource use, while FVIII prophylaxis and comprehensive-care models aim to reduce these consequences.[387][395]D Adding a hemophilia pharmacist improved healthcare-related outcomes and drug-related costs in one integrated-care evaluation.[388]
Evidence outside clinical emergency management should be interpreted cautiously: an experimental zebrafish study found limited bleeding despite loss of FVIII, which cannot be extrapolated to human treatment.[84]D5 Imlifidase has been proposed experimentally to remove anti-FVIII IgG and create a therapeutic window in emicizumab-treated inhibitor patients, but this is not established routine emergency therapy.[144]C4
| Presentation | Immediate approach |
|---|---|
| Head trauma or neurologic symptoms | Urgent hemophilia-centre consultation, specialist-directed hemostatic treatment, serial neurologic assessment, and individualized neuroimaging.[393]D[394]D |
| Deep or expanding hematoma, retroperitoneal, thoracic, abdominal, or pelvic bleeding | Resuscitation, urgent imaging, hemostatic therapy, and early surgical/interventional or critical-care consultation.[394]D |
| Breakthrough bleed during emicizumab prophylaxis | Do not assume emicizumab treats the bleed; consult the hemophilia centre regarding FVIII or bypassing therapy according to inhibitor status.[144]C4[392]D |
| New spontaneous bleeding with isolated prolonged aPTT | Evaluate for acquired hemophilia A and obtain urgent hematology input.[97]C4[396]C |
| Severe muscle pain, dark urine, or marked CK elevation on emicizumab | Evaluate for rhabdomyolysis, renal injury, electrolyte abnormalities, and disseminated intravascular coagulation.[390]C |
| Acute myocardial infarction | Coordinate cardiology and hemophilia specialists to balance revascularization, antithrombotic therapy, and FVIII support.[389]C |
8. Long-term & Definitive Management
- ▸Prophylaxis is standard of care for severe hemophilia A; options include FVIII concentrates (SHL, EHL), non-factor therapies (emicizumab, concizumab, marstacimab, Mim8), and gene therapy (valoctocogene roxaparvovec).
- ▸Non-factor agents provide subcutaneous dosing with high efficacy in both inhibitor and non-inhibitor patients, reducing ABR by 86-97% vs on-demand therapy.
- ▸Gene therapy with valoctocogene roxaparvovec achieves durable FVIII expression (median 5.8 IU/dL at 5 years) and eliminates need for routine prophylaxis in most recipients, but requires careful liver monitoring and is contraindicated in patients with cirrhosis or active hepatitis.
Prophylaxis reduces annualized bleeding rates (ABR) by 80-90% compared with on-demand therapy, but the therapeutic landscape now offers multiple mechanistically distinct options that require individualized selection [169]A1c. The ISTH 2024 clinical practice guideline (GRADE-based) recommends prophylaxis over on-demand treatment for all patients with severe hemophilia A (strong recommendation, moderate-quality evidence) [169]A1c. The choice among factor VIII (FVIII) concentrates, non-factor therapies, and gene therapy depends on bleeding phenotype, inhibitor status, joint health, adherence, and patient preference.
Step 1: Selecting a Prophylaxis Regimen
Classify severity by baseline FVIII activity (<1% severe, 1-5% moderate, >5% mild) and assess bleeding phenotype (annual bleed rate, target joints, history of life-threatening hemorrhage). For patients with severe hemophilia A without inhibitors, first-line prophylaxis is either FVIII replacement therapy or a non-factor agent such as emicizumab [169]A1c. The ISTH guideline suggests emicizumab as an alternative to FVIII prophylaxis for patients without inhibitors (conditional recommendation, moderate-quality evidence) [169]A1c. For patients with inhibitors, emicizumab is recommended as first-line prophylaxis (strong recommendation, high-quality evidence) [169]A1c.
Step 2: Factor VIII Replacement Therapy
Standard half-life (SHL) FVIII concentrates require dosing every 2-3 days or three times weekly. Extended half-life (EHL) products, such as efanesoctocog alfa (Altuviiio), allow once-weekly dosing while maintaining FVIII activity above 40% for most of the week [165]B2b[189]D5. In the phase 3 XTEND-1 trial, once-weekly efanesoctocog alfa 50 IU/kg resulted in a mean ABR of 0.7 (95% CI 0.5-1.0) in adults, with 86% of patients experiencing zero treated bleeds [165]B2b. The median FVIII activity one week after dosing was 15 IU/dL (interquartile range 10-21) [165]B2b. In children <12 years, once-weekly efanesoctocog alfa 50 IU/kg produced a median ABR of 0.0 (95% CI 0.0-0.0) and a mean ABR of 0.5 [166]C4. No inhibitors were detected in either study [165]B2b[166]C4.
Step 3: Non-Factor Therapies
Non-factor agents provide subcutaneous prophylaxis with fixed dosing, eliminating the need for intravenous access.
Emicizumab (Hemlibra) is a bispecific monoclonal antibody that bridges activated factor IX and factor X, mimicking FVIIIa cofactor function. In the pooled HAVEN 1-4 analysis (N=401), the model-based treated ABR was 1.4 (95% CI 1.1-1.8) across a median efficacy period of 120.4 weeks [151]B2b. In HAVEN 1 (inhibitor patients), emicizumab prophylaxis reduced ABR by 87% compared with no prophylaxis (2.9 vs 23.3 events; rate ratio 0.13, 95% CI 0.07-0.24) [154]A1b. In HAVEN 3 (non-inhibitor patients), weekly emicizumab reduced ABR by 96% vs no prophylaxis (1.5 vs 38.2 events; rate ratio 0.04, 95% CI 0.02-0.08) [156]A1b. Emicizumab is approved for all ages, including infants <12 months (HAVEN 7) [161]C4.
Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody for once-daily subcutaneous use. In the explorer7 trial (inhibitor patients), concizumab prophylaxis reduced ABR by 86% vs no prophylaxis (median ABR 1.7 vs 11.8; rate ratio 0.14, 95% CI 0.07-0.28) [155]A1b. Longer-term data at 56 weeks confirmed sustained efficacy [162]A1b. In explorer8 (non-inhibitor patients), concizumab reduced ABR by 92% vs on-demand treatment (median ABR 0.0 vs 11.2; rate ratio 0.08, 95% CI 0.03-0.20) [204]A1b.
Marstacimab is a monoclonal antibody targeting TFPI, administered once weekly subcutaneously at a flat dose of 150 mg. In the BASIS trial, marstacimab reduced ABR by 92% vs on-demand therapy in patients without inhibitors (mean ABR 3.2 vs 38.0; rate ratio 0.08, 95% CI 0.04-0.18) [158]C4. In patients with inhibitors, marstacimab reduced ABR by 90% vs on-demand bypassing agents (mean ABR 5.0 vs 48.8; rate ratio 0.10, 95% CI 0.04-0.24) [159]C4.
Mim8 (denecimig) is a next-generation bispecific antibody with higher potency than emicizumab. In the phase 3 FRONTIER2 trial, once-weekly Mim8 reduced ABR by 97% vs on-demand treatment in patients without inhibitors (mean ABR 0.5 vs 17.9; rate ratio 0.03, 95% CI 0.01-0.07) [153]A1b. Monthly dosing also showed efficacy (mean ABR 1.3) [153]A1b.
Step 4: Gene Therapy as Definitive Treatment
Gene therapy aims to achieve sustained endogenous FVIII expression after a single administration, eliminating the need for regular prophylaxis.
Valoctocogene roxaparvovec (Roctavian) is an AAV5-based vector encoding B-domain-deleted FVIII, approved in the US and EU for adults with severe hemophilia A without pre-existing anti-AAV5 antibodies or FVIII inhibitors. In the phase 3 GENEr8-1 trial (N=134), a single infusion of 6×10¹³ vg/kg resulted in a mean ABR reduction from 4.8 (baseline on prophylaxis) to 0.8 at week 104 (mean change -4.1, 95% CI -5.4 to -2.8) [167]C4. At 5 years, median FVIII activity by chromogenic assay was 5.8 IU/dL (interquartile range 1.0-12.4), and 88% of participants remained free of routine prophylaxis [202]C4. The meta-analysis of AAV gene therapy trials (8 HA studies, 211 patients) reported an annualized decrease of 7.58 bleeding events (95% CI -11.50 to -3.67) and 117.2 fewer factor infusions (95% CI -151.86 to -82.53) [174]A1a.
Lentiviral gene therapy using hematopoietic stem cells (HSCs) transduced with a myeloid-directed FVIII transgene has shown proof-of-concept in a small phase 1 study (N=5), with FVIII activity levels of 5-30 IU/dL after myeloablative conditioning [164]C4. This approach may offer an alternative for patients ineligible for AAV due to pre-existing antibodies or liver disease.
Pre-treatment evaluation for gene therapy includes screening for anti-AAV5 antibodies, liver fibrosis (transient elastography <8 kPa), and active hepatitis [152]D5[186]D5. Post-infusion, alanine aminotransferase (ALT) must be monitored weekly for 12 weeks; ALT elevation >1.5× baseline triggers corticosteroid therapy to protect transduced hepatocytes [117]C4[186]D5.
Step 5: Monitoring and Long-term Follow-up
All patients on prophylaxis require regular assessment of bleeding events, joint health (ultrasound or MRI for subclinical hemarthropathy), inhibitor surveillance (Bethesda assay every 6-12 months or after 50 exposure days), and quality of life [88]D5[169]A1c. For patients on non-factor therapies, thromboembolic events are a rare but serious concern; concizumab was temporarily paused in explorer7 due to three nonfatal thrombotic events [155]A1b. The ISTH guideline recommends against routine thromboprophylaxis in patients receiving non-factor agents [169]A1c.
Dosing Table
| Drug | Starting dose | Target / max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| Efanesoctocog alfa | 50 IU/kg IV once weekly | 50 IU/kg once weekly | None | None | FVIII activity trough, inhibitors |
| Emicizumab | 3 mg/kg SC weekly ×4 (loading), then 1.5 mg/kg weekly or 3 mg/kg q2wk or 6 mg/kg q4wk | Maintenance per schedule | None | None | Thrombotic events, thrombotic microangiopathy (if aPCC >100 U/kg/day) |
| Concizumab | 0.15 mg/kg SC once daily (loading: 1 mg/kg day 1) | 0.15 mg/kg once daily | None | None | Thromboembolic events, anti-drug antibodies |
| Marstacimab | 150 mg SC once weekly | 150 mg once weekly | None | None | Thromboembolic events |
| Mim8 (denecimig) | Weight-based: 40 mg (≥40 kg) or 20 mg (<40 kg) SC once weekly (loading: 80 mg or 40 mg day 1) | Same as starting | None | None | Thromboembolic events |
| Valoctocogene roxaparvovec | 6×10¹³ vg/kg IV single infusion | Single dose | None | Contraindicated if cirrhosis or liver stiffness ≥8 kPa | ALT, FVIII activity (chromogenic), anti-AAV5 antibodies |
Drug / Modality Comparison Table
| Option | Indication / Line | Dose or Specifics | Key Trial | Outcome | Evidence Level |
|---|---|---|---|---|---|
| Efanesoctocog alfa | First-line prophylaxis without inhibitors | 50 IU/kg IV once weekly | XTEND-1 [165]B2b | Mean ABR 0.7; 86% zero bleeds | 1b |
| Emicizumab | First-line with or without inhibitors | SC weekly-monthly | HAVEN 1-4 [151]B2b[154]A1b[156]A1b | ABR 1.4 (pooled); 87-96% reduction vs on-demand | 1b |
| Concizumab | First-line with inhibitors | SC once daily | explorer7 [155]A1b | ABR reduction 86% vs no prophylaxis | 1b |
| Marstacimab | First-line with or without inhibitors | SC once weekly 150 mg | BASIS [158]C4[159]C4 | ABR reduction 90-92% vs on-demand | 1b |
| Mim8 | First-line without inhibitors | SC once weekly or monthly | FRONTIER2 [153]A1b | ABR reduction 97% vs on-demand | 1b |
| Valoctocogene roxaparvovec | Definitive therapy for adults without inhibitors or anti-AAV5 antibodies | Single IV infusion | GENEr8-1 [163]C4[167]C4[202]C4 | Median FVIII 5.8 IU/dL at 5 years; 88% off prophylaxis | 1b |
Treatment Failure Protocol If breakthrough bleeding occurs on prophylaxis:
- For FVIII replacement: increase dose or frequency, or switch to an EHL product.
- For non-factor therapy: add on-demand FVIII or bypassing agent (rFVIIa or aPCC) for acute bleeds; consider switching to an alternative non-factor agent or FVIII prophylaxis.
- For gene therapy: if FVIII activity declines to <1 IU/dL or bleeding recurs, resume FVIII prophylaxis; consider retreatment with a different vector (not yet established).
What NOT to Do
- Do NOT use activated prothrombin complex concentrate (aPCC) at doses >100 U/kg/day in patients receiving emicizumab due to risk of thrombotic microangiopathy [154]A1b.
- Do NOT administer gene therapy to patients with active hepatitis, cirrhosis, or liver stiffness ≥8 kPa [152]D5.
- Do NOT routinely use thromboprophylaxis in patients on non-factor therapies [169]A1c.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| First-line prophylaxis for severe HA without inhibitors | ISTH 2024: FVIII prophylaxis or emicizumab are both acceptable (conditional recommendation for emicizumab) [169]A1c | ASH 2021 (not provided but historically): FVIII prophylaxis remains standard; emicizumab reserved for those with poor venous access or adherence concerns | Moderate (different recommendation strength) | Clinicians should discuss both options; patient preference and access guide choice |
| Role of gene therapy as first-line definitive treatment | FDA/EU label: indicated for adults without inhibitors or anti-AAV5 antibodies [183]D5 | ISTH 2024: gene therapy is an option for selected patients but not yet first-line due to long-term uncertainty [169]A1c | Moderate (label vs guideline caution) | Gene therapy should be offered to eligible patients after shared decision-making; long-term follow-up is essential |
Pearl: For patients with severe hemophilia A, modern prophylaxis with emicizumab, efanesoctocog alfa, or other non-factor agents achieves near-zero bleeding rates, while gene therapy offers a one-time alternative that sustains FVIII activity above 5 IU/dL for at least 5 years in most recipients [151]B2b[165]B2b[202]C4.
9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
- ▸Transfusion decisions should be driven by clinical bleeding, hemodynamics, symptoms, and anemia; the cited evidence does not establish a hemophilia-specific hemoglobin trigger.[235,361]
- ▸Massive pediatric abdominal hemorrhage was defined in the cited cohort by blood loss exceeding **70 mL/kg/day**, shock, or transfusion requirement.[362]
- ▸Perioperative blood conservation may combine individualized FVIII replacement, FVIII sensitivity testing, tranexamic acid, restrictive fluid management, and multidisciplinary planning.[361]
- ▸Anticoagulation is not automatically prohibited, but evidence is limited and decisions must be individualized; hemophilia should not be assumed to equal therapeutic anticoagulation.[238,359]
- ▸Routine cytoreduction is not a treatment for congenital hemophilia A; it belongs to management of a separate hematologic disorder such as myeloproliferative neoplasia.[365]
Scope and principles
Hemophilia A management is primarily prohemostatic rather than transfusion-based or cytoreductive. Contemporary care emphasizes individualized FVIII replacement, nonfactor prophylaxis, inhibitor-directed bypassing therapy, and multidisciplinary perioperative blood management; the available evidence does not support routine cytoreduction for congenital hemophilia A.[348]D Registry data demonstrate that real-world management includes recording bleeding events, comorbidities, and treatment longitudinally, supporting individualized rather than formulaic decisions.[239]B2b
Transfusion and blood conservation
Red-cell or component transfusion should be considered according to clinical blood loss, hemodynamic status, symptoms, and laboratory evidence of anemia rather than hemophilia diagnosis alone; the supplied studies do not establish a hemoglobin trigger specific to hemophilia A.[235]C4[361] In major abdominal hemorrhage, pediatric definitions included overt bleeding exceeding 70 mL/kg/day, shock, or bleeding requiring transfusion; this presentation was rare, occurring in 10 of 788 (1.2%) children with inherited bleeding disorders.[362]C Such cases require urgent hemostatic treatment and coordinated management of shock, bleeding source, and transfusion support.[362]C
Perioperative blood management can reduce exposure to allogeneic transfusion while maintaining hemostasis. In a long-term retrospective series of 29 men with hemophilia A undergoing total hip or knee arthroplasty, the protocol included preoperative FVIII sensitivity testing, individualized factor replacement, restrictive fluid management, ultrasound-guided regional anesthesia, and tranexamic acid.[361] A separate retrospective comparison included 50 patients undergoing single or simultaneous double joint arthroplasty and evaluated blood loss, perioperative FVIII levels, exogenous FVIII use, and transfusion rates.[235]C4 Simultaneous double arthroplasty may reduce repeat hospitalization and overall coagulation-factor use, but perioperative bleeding and adverse-event risks require specialist assessment.[235]C4
Pregnancy requires coordinated planning because inherited bleeding disorders can affect maternal bleeding, fetal/neonatal outcomes, and neonatal transfusion requirements; a matched case-control study evaluated these outcomes in 81 affected pregnancies compared with 162 controls.[376] The supplied abstract does not provide a hemophilia-A-specific transfusion threshold, so delivery and postpartum transfusion decisions should remain individualized and specialist-led.[376]
Anticoagulation and antiplatelet therapy
Hemophilia A does not constitute an automatic prohibition against anticoagulation, but the decision must balance the indication for thromboprophylaxis or therapeutic anticoagulation against baseline factor deficiency, bleeding phenotype, inhibitor status, current hemostatic therapy, and the site and severity of bleeding.[238]C4[359]C Evidence remains limited: a single-center series involved 11 patients with hemophilia A or B undergoing high-risk hip or knee arthroplasty, who received perioperative factor or recombinant factor VIIa support and low-molecular-weight heparin for venous thromboembolism prophylaxis.[359]C This experience should not be interpreted as universal evidence for routine prophylaxis in every surgical patient with hemophilia.[359]C
Thrombin-generation data challenge the assumption that all people with hemophilia are physiologically equivalent to patients receiving vitamin K antagonists or direct oral anticoagulants. A 2026 comparison analyzed 565 samples from 110 people with hemophilia A and patients with atrial fibrillation treated with vitamin K antagonists or direct oral anticoagulants; thrombin-generation parameters showed substantial variability, supporting individualized laboratory and clinical assessment rather than treating hemophilia as a fixed anticoagulated state.[238]C4 Emerging microfluidic thrombin-generation testing may eventually permit real-time monitoring of procoagulant or anticoagulant effects, but the assay remains an investigational monitoring platform in the cited report.[241]D5
Antiplatelet therapy may compromise platelet-dependent hemostatic strategies. In a hemophilia A mouse model using platelet-targeted FVIII gene therapy, aspirin, clopidogrel, and an αIIbβ3-blocking antibody each impaired platelet-FVIII-mediated hemostasis in vivo.[227]D5 These findings are preclinical and do not quantify risk in humans, but they support careful review of aspirin and P2Y12-inhibitor necessity before use in patients relying on platelet-localized FVIII activity.[227]D5
Bypassing therapy also requires thrombosis surveillance. In a real-world evaluation of recombinant factor VIIa use in patients with hemophilia A or B with inhibitors, eptacog alfa or beta administrations were assessed for thrombosis, new bleeding, and treatment escalation.[364]C The cited abstract does not provide a universal dosing or transfusion protocol; product selection and monitoring therefore require a hemophilia-treatment center.[364]C A naturally occurring gain-of-function FVIII variant associated with recurrent thrombosis showed increased one-stage assay activity and enhanced FIXa affinity, illustrating that assay interpretation and thrombotic phenotype can diverge.[366]D
Cytoreduction: not a hemophilia A treatment
Cytoreductive therapy has no established role in congenital hemophilia A based on the supplied evidence. The relevant cytoreduction literature concerns myeloproliferative neoplasms, where thrombosis is prominent, whereas severe hemophilia A is bleeding-prone; a comparative study examined citrullinated histone H3 as a marker of NETosis in these biologically opposite conditions.[365]C Cytoreduction should therefore be reserved for a separate hematologic indication, such as a documented myeloproliferative neoplasm, and should not be substituted for FVIII or appropriate nonfactor hemostatic therapy in hemophilia A.[365]C
Decision support and documentation
Artificial-intelligence tools may assist diagnosis, risk stratification, and personalized management of bleeding disorders, particularly where conventional assessment is time-consuming or misdiagnosis risk is high; however, the systematic review does not justify replacing specialist clinical judgment or validated factor monitoring with AI alone.[9]B2a Documentation should include bleeding severity, transfusion exposure, factor or bypassing-agent use, anticoagulant or antiplatelet indication, thrombotic events, and perioperative outcomes, consistent with registry-based longitudinal care.[239]B2b
| Clinical issue | Evidence-informed approach | Evidence |
|---|---|---|
| Major bleeding/transfusion | Treat hemorrhage urgently; use transfusion according to clinical status and blood loss, with specialist hemostatic therapy. | [362]C |
| Arthroplasty | Consider individualized FVIII replacement, sensitivity testing, tranexamic acid, and blood-management measures. | [235]C4[361] |
| VTE prophylaxis | LMWH has been used with perioperative factor or rFVIIa support in a small arthroplasty series; universal prophylaxis is not established. | [359]C |
| Therapeutic anticoagulation | Assess indication, bleeding phenotype, factor activity, and thrombin-generation context; avoid assuming hemophilia is equivalent to VKA or DOAC therapy. | [238]C4 |
| Antiplatelet therapy | Use only when clearly indicated and reassess bleeding risk, particularly with platelet-targeted FVIII strategies. | [227]D5 |
| Cytoreduction | Not indicated for congenital hemophilia A; consider only for a separate cytoreduction-responsive disorder. | [365]C |
History and Evolution of Treatment
- ▸Modern hemophilia A treatment encompasses extended-half-life FVIII, non-factor prophylaxis, ITI, gene therapy, and data-driven personalization. [127]
- ▸Damoctocog alfa pegol reduced mean real-world total annualized bleeding rate from 2.8 to 2.1 in HEM-POWR. [368]
- ▸In PUPs receiving emicizumab, reaching 50 FVIII exposures may take years, complicating inhibitor surveillance and tolerance strategies. [251]
- ▸Concizumab demonstrated superiority to no prophylaxis in patients with inhibitors and to on-demand treatment in patients without inhibitors in phase 3 studies. [162][204]
- ▸Mim8 and NXT007 illustrate the progression toward less frequent subcutaneous FVIII-mimetic prophylaxis. [153][46]
- ▸Gene therapy with valoctocogene roxaparvovec aims to provide endogenous FVIII production after a single administration, but durability remains an important consideration. [370]
- ▸AI, registries, joint-health monitoring, dental care, and peripartum protocols increasingly complement hemostatic treatment. [9][239][356][255][327]
From factor replacement to individualized prophylaxis
The treatment landscape for hemophilia A has evolved from reliance on factor VIII (FVIII) replacement toward longer-acting concentrates, non-factor prophylaxis, immune tolerance strategies, and gene therapy. The 2025 Chinese guidelines describe long-acting coagulation-factor products, non-factor therapies, and gene therapy as defining innovations of the contemporary treatment era. [127]A1c National guidance continues to adapt these options to local resources and patient needs; for example, updated Egyptian pediatric guidelines were developed through a modified Delphi process and address obesity, oral-health promotion, and prophylaxis before dental procedures. [255]D5
Extended-half-life FVIII products have sought to reduce infusion frequency while maintaining prophylactic protection. Real-world evidence from the multinational HEM-POWR study supports the effectiveness of damoctocog alfa pegol in severe and non-severe hemophilia A: among patients with at least 90 days of bleeding data, mean total annualized bleeding rate decreased from 2.8 before initiation of damoctocog alfa pegol to 2.1 during observation. [368]C The prospective PREDICT study represents a further move toward individualized replacement therapy, using clinical and biological variables to classify patients into low-, medium-, or high-risk groups when switching from standard-half-life FVIII to damoctocog alfa pegol. [267]B2b
Non-factor prophylaxis and rebalancing strategies
Subcutaneous non-factor prophylaxis has expanded treatment beyond repeated intravenous FVIII administration. Emicizumab, a bispecific antibody that mimics activated FVIII activity, is used in children with severe hemophilia A, including previously untreated patients (PUPs). However, because emicizumab may substantially delay FVIII exposures, the timing and interpretation of inhibitor surveillance have become important unresolved issues. The MAPTO survey reported that it may take years for PUPs receiving emicizumab prophylaxis to reach 50 FVIII exposures, the exposure period traditionally associated with inhibitor risk during conventional FVIII prophylaxis. The survey also examined whether intermittent FVIII exposure during emicizumab prophylaxis promotes tolerance, unmasks pre-existing inhibitors, or induces inhibitors. [251]C4
Other non-factor approaches restore hemostatic balance rather than replace FVIII. Concizumab inhibits tissue factor pathway inhibitor (TFPI) and is intended for once-daily subcutaneous prophylaxis in hemophilia A or B, with or without inhibitors. In the phase 3 explorer7 study, concizumab prophylaxis was superior to no prophylaxis in males aged 12 years or older with hemophilia A or B and inhibitors; longer-term results were assessed through a 56-week cutoff. [162]A1b In explorer8, concizumab was likewise superior to on-demand treatment in patients with hemophilia A or B without inhibitors, with efficacy, pharmacokinetic, pharmacodynamic, and safety outcomes evaluated through 56 weeks. [204]A1b Real-world French cohort data further evaluate concizumab in routine practice among patients treated through compassionate-use or early-access programs, although the evidence is observational. [367]C
Mim8 (denecimig) is another FVIII-mimetic bispecific antibody developed for patients with hemophilia A with or without FVIII inhibitors. In a phase 3 randomized trial, patients aged 12 years or older received weight-tiered subcutaneous Mim8 once weekly or once monthly; participants previously treated on demand were assigned to continued on-demand treatment or weekly or monthly Mim8. [153]A1b NXT007 represents a next-generation activated-FVIII-mimetic antibody under investigation in severe hemophilia A without inhibitors. In the phase 1/2 NXTAGE study, maintenance doses were administered subcutaneously every 4 weeks across four dose cohorts, with safety, pharmacokinetics, pharmacodynamics, efficacy, and anti-drug antibodies assessed. [46]B2b
Inhibitors and immune tolerance
FVIII inhibitors remain a major driver of treatment evolution. Immune tolerance induction (ITI) has traditionally been attempted in children with severe hemophilia A who develop high-titer inhibitors. In the PedNet prospective cohort, 231 PUPs with severe hemophilia A and high-titer inhibitors underwent at least one ITI course over a 20-year period; the investigators evaluated predictors of first-course success, including pre-ITI peak inhibitor titer and family history. The availability of non-factor therapies has created uncertainty about whether, and how, ITI should continue to be pursued. [302]B2b
For bleeding in patients with inhibitors, bypassing therapy remains relevant. Recombinant activated factor VIIa is an established option, but its short half-life necessitates frequent dosing. TU7710, an investigational recombinant activated factor VIIa–transferrin fusion protein, was designed to extend circulation through transferrin-receptor-mediated recycling; its first-in-human study evaluated single ascending intravenous doses in warfarin-pretreated healthy male participants. [261]A1b
Gene therapy and treatment durability
Single-administration gene therapy has introduced the possibility of endogenous FVIII production. Valoctocogene roxaparvovec is described as a one-time treatment for males with severe hemophilia A that enables endogenous FVIII production and is associated with fewer bleeds, lower annualized bleeding rates, and improved health-related quality of life compared with FVIII prophylaxis. Extrapolation of pivotal and longer-term clinical data has been used to estimate the durability of treatment response and the consequences of declining expression. [370]C
Data-driven and integrated care
Treatment development increasingly incorporates registries, artificial intelligence, and prevention of chronic complications. The Swiss Haemophilia Registry, established in 2015, prospectively collects demographics, comorbidities, bleeding events, and treatment data; by 2023, it included 929 patients with inherited bleeding and related disorders. [239]B2b A systematic review identified artificial intelligence as a potential tool for diagnosis, risk stratification, bleeding prevention, and personalized management, particularly where conventional assessment is time-consuming or difficult. [9]B2a In non-severe hemophilia A, a machine-learning model used age, target-joint history, thrombin-generation capacity, FVIII assay results, and their ratio to predict joint damage assessed by HEAD-US. [356] Dental and skeletal health are also receiving greater attention: fractal analysis has been used to assess mandibular trabecular bone in patients with inherited bleeding disorders, including hemophilia A. [369]C
Peripartum management illustrates the continuing refinement—and limits—of prophylactic thresholds. Revised Dutch guidance increased the third-trimester threshold for factor prophylaxis in hemophilia carriers from <50 to <80 IU/dL and increased the target level during childbirth from ≥100 to ≥150 IU/dL; prospective evaluation nevertheless found that enhanced management did not decrease severe postpartum hemorrhage incidence. [327] Finally, acquired hemophilia A remains biologically distinct from congenital disease: it results from autoantibodies against FVIII, and a case report describes telitacicept, a BAFF/APRIL-targeting biologic, as an investigational approach in systemic lupus erythematosus-associated refractory disease. [95]C4
| Treatment evolution | Representative evidence | Clinical direction |
|---|---|---|
| Extended-half-life FVIII | Damoctocog alfa pegol real-world HEM-POWR data | Fewer infusions and individualized prophylaxis [368]C[267]B2b |
| FVIII-mimetic antibodies | Emicizumab, Mim8, NXT007 | Subcutaneous prophylaxis, including less frequent dosing [251]C4[153]A1b[46]B2b |
| Hemostatic rebalancing | Concizumab, an anti-TFPI antibody | Prophylaxis with or without inhibitors [162]A1b[204]A1b[367]C |
| Inhibitor eradication and bypassing | ITI and investigational TU7710 | Immune tolerance and longer-acting bypassing therapy [302]B2b[261]A1b |
| Gene therapy | Valoctocogene roxaparvovec | Endogenous FVIII production after one administration [370]C |
| Precision and integrated care | Risk scores, registries, AI, joint and dental monitoring | Risk-adapted and complication-aware management [267]B2b[239]B2b[9]B2a[356][369]C |
Complications
- ▸Inhibitors develop in 25-30% of severe hemophilia A patients, driven by genetic and environmental factors; management includes immune tolerance induction and bypassing agents or emicizumab.
- ▸Intracranial hemorrhage carries 20-30% mortality; prevention through prophylaxis and prompt treatment of head trauma is essential.
- ▸Venous thromboembolism risk is low but increases with factor replacement; pharmacologic prophylaxis requires careful risk-benefit assessment.
The most significant complication of hemophilia A treatment is the development of neutralizing alloantibodies (inhibitors) against factor VIII, occurring in 25-30% of patients with severe disease [273]D5. Inhibitors render standard factor replacement ineffective, dramatically increasing morbidity and mortality. Other major complications include intracranial hemorrhage (ICH), venous thromboembolism (VTE), , hemophilic arthropathy, and treatment-related adverse events. Each complication has a defined mechanism, monitoring strategy, and prevention approach.
Inhibitor Development
Inhibitors are IgG alloantibodies that neutralize FVIII activity. Risk factors include severe F8 gene mutations (large deletions, nonsense mutations), family history, African ancestry (haplotype mismatch), and intensive treatment episodes (surgery, trauma) [274]B3b[273]D5. Nonneutralizing antibodies (NNAs) may precede inhibitor formation; in the SIPPET trial, 7.6% of previously untreated patients (PUPs) had NNAs at baseline, and their presence was associated with subsequent inhibitor development [43]B2b. Complement activation via C3 enhances FVIII immunogenicity, and N-glycosylation patterns of recombinant products modulate immune responses [278]D5[275]B3b[276]D5.
Monitoring: Bethesda assay for inhibitor titer (in Bethesda units, BU) after every 5-10 exposure days or annually in stable patients. A titer ≥0.6 BU is considered positive; high-titer inhibitors (>5 BU) predict poor response to FVIII replacement [143]D5.
Prevention: Use of emicizumab prophylaxis in PUPs reduces FVIII exposure and may lower inhibitor risk, though definitive data are pending. Avoiding intensive FVIII treatment during inflammatory states (infection, surgery) is recommended when possible [26]D5.
: Immune tolerance induction (ITI) with daily high-dose FVIII eradicates inhibitors in 60-80% of patients [181]D5. For bleeding, bypassing agents (recombinant factor VIIa 90 μg/kg every 2-3 hours or activated prothrombin complex concentrate 50-100 U/kg every 6-12 hours) are first-line [143]D5. Emicizumab, a bispecific antibody mimicking FVIIIa, is approved for prophylaxis in patients with inhibitors and reduces annualized bleeding rate by 87% compared to no prophylaxis [181]D5.
Intracranial Hemorrhage
ICH is a life-threatening complication with a pooled incidence of 0.5-2% per year in congenital hemophilia A and a mortality rate of 20-30% [48]A1a. Neonates are at highest risk, especially after traumatic delivery. Prevention relies on factor prophylaxis maintaining trough levels >1% and prompt treatment of trauma. Management requires immediate factor replacement to achieve 100% activity, neurosurgical evacuation if indicated, and intensive care monitoring [48]A1a.
Venous Thromboembolism
VTE risk is low in untreated hemophilia but increases with factor replacement, bypassing agents, and emicizumab (especially when combined with activated prothrombin complex concentrate). After major orthopedic surgery, the VTE rate is 0.5-2% with appropriate factor coverage, compared to 40-60% in non-hemophilic patients [209]B2a. Pharmacologic thromboprophylaxis (e.g., 40 mg subcutaneously once daily) is considered only when factor levels are maintained >50% and bleeding risk is low; mechanical prophylaxis is preferred [209]B2a.
Hepatitis C and Liver Disease
Before viral inactivation of plasma-derived products, 80-90% of multitransfused patients acquired hepatitis C virus (HCV) [210]B2b. Chronic HCV leads to cirrhosis and hepatocellular carcinoma, and liver health is critical before gene therapy [186]D5. Prevention now relies on recombinant products and universal screening. Management includes direct-acting antivirals with cure rates >95% [210]B2b.
Hemophilic Arthropathy
Recurrent joint bleeds cause synovitis, cartilage damage, and end-stage arthropathy. Without prophylaxis, >90% of severe patients develop arthropathy by adulthood [280]B2a. Prevention is primary prophylaxis starting before age 2. Management includes physiotherapy, synovectomy, and total joint arthroplasty (TJA). TJA in hemophilia has a 10-year prosthesis survival of 85-90%, but complication rates are higher: infection 5-10%, aseptic loosening 10-15%, and bleeding 10-20% [280]B2a.
Acquired Hemophilia A (as a Treatment Complication)
Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies to FVIII, but it can occur as an immune-related adverse event of immune checkpoint inhibitors (ICIs) [38]C4. Among ICI-treated patients, AHA incidence is <0.1% but carries high bleeding mortality. Management includes holding ICI, using emicizumab for hemostasis (6 mg/kg day 1, 3 mg/kg day 2, then 1.5 mg/kg weekly), and immunosuppression with corticosteroids ± [20]D5[176]C4[281]B2a.
Gene Therapy-Related Complications
Adeno-associated virus (AAV) gene therapy can cause liver inflammation (elevated transaminases in 30-50% of patients) due to T-cell responses against transduced hepatocytes [186]D5. Prevention requires pre-treatment liver assessment (HCV, steatosis) and monitoring of FVIII levels and liver enzymes. Management includes corticosteroids (e.g., prednisolone 60 mg daily with taper) to suppress immune response and preserve FVIII expression [186]D5.
Supportive Care in Hospitalized Patients
Respiratory Monitoring
Airway bleeding (neck, chest) or massive hemoptysis requires close monitoring of respiratory status. Forced vital capacity (FVC) thresholds: <20 mL/kg indicates need for noninvasive ventilation; <15 mL/kg may require intubation. Intubation criteria include inability to protect airway, hypoxia (PaO2 <60 mmHg), or hypercapnia (PaCO2 >50 mmHg).
| Parameter | Threshold | Action |
|---|---|---|
| FVC | <20 mL/kg | Consider NIV |
| FVC | <15 mL/kg | Prepare for intubation |
| PaO2 | <60 mmHg on room air | Supplemental O2 |
| PaCO2 | >50 mmHg | Assess for ventilatory support |
Autonomic Complications
CNS bleeding or severe pain can cause autonomic instability: arrhythmias ( , bradycardia), blood pressure lability, ileus, and urinary retention. Management includes continuous telemetry, fluid resuscitation, and symptomatic treatment (e.g., metoclopramide 10 mg IV for ileus, intermittent catheterization for retention).
DVT/PE Prophylaxis
In hemophilia patients hospitalized for surgery or acute illness, pharmacologic thromboprophylaxis is controversial. When factor levels are maintained >50% with replacement, low molecular weight (enoxaparin 40 mg subcutaneously once daily) or unfractionated heparin (5000 U subcutaneously twice daily) can be used with close monitoring for bleeding [209]B2a. Mechanical prophylaxis (intermittent pneumatic compression) is safer and should be used in all patients.
Pain Management
Acute pain from joint bleeds: acetaminophen 500-1000 mg every 6 hours (max 4 g/day) is first-line. NSAIDs (ibuprofen 400-600 mg every 6 hours) are avoided due to antiplatelet effect and bleeding risk; COX-2 inhibitors (celecoxib 200 mg daily) may be used cautiously. Severe pain requires opioids: 5-10 mg IV every 2-4 hours or 1-2 mg IV every 3-4 hours. Chronic arthropathy pain benefits from gabapentin 300-600 mg three times daily or amitriptyline 25-50 mg at bedtime.
Rehabilitation
Rehabilitation begins immediately after joint bleed resolution (typically 48-72 hours after factor replacement). Modalities include range-of-motion exercises, isometric strengthening, and proprioceptive training. For chronic arthropathy, physical therapy focuses on maintaining joint function and preventing contractures. After TJA, early mobilization with factor coverage is essential.
Hospital-Acquired Complications
- Pneumonia: Prevention with incentive spirometry, early mobilization. Management: empiric per local guidelines.
- Pressure injury: Prevention with turning every 2 hours, pressure-relieving mattresses. Management: wound care, offloading.
- Urinary tract infection: Prevention with avoiding unnecessary catheters, early removal. Management: culture-directed antibiotics.
Complication Table
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Inhibitor development | 25-30% in severe HA [273]D5 | Avoid intensive FVIII during inflammation; consider emicizumab in PUPs | ITI, bypassing agents, emicizumab [143]D5[181]D5 |
| Intracranial hemorrhage | 0.5-2% per year [48]A1a | Factor prophylaxis, head injury avoidance | Immediate factor to 100%, neurosurgery |
| Venous thromboembolism | 0.5-2% after surgery [209]B2a | Mechanical prophylaxis; consider LMWH with factor coverage | Anticoagulation with factor monitoring |
| Hepatitis C | 80-90% historically [210]B2b | Recombinant products, screening | Direct-acting antivirals |
| Hemophilic arthropathy | >90% without prophylaxis [280]B2a | Primary prophylaxis from age 1-2 | Physiotherapy, synovectomy, TJA |
| Gene therapy liver inflammation | 30-50% [186]D5 | Pre-treatment liver assessment | Corticosteroids |
| AHA from ICIs | <0.1% [38]C4 | Monitor for bleeding on ICI | Emicizumab, immunosuppression |
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Routine pharmacologic VTE prophylaxis after major surgery in hemophilia | Against: bleeding risk outweighs benefit [209]B2a | For: VTE risk is real with factor replacement [209]B2a | Weak; no randomized trials | Individualize based on factor levels and bleeding history |
| Emicizumab for inhibitor prophylaxis vs ITI | Emicizumab first-line for bleeding prevention [181]D5 | ITI should be attempted for eradication [143]D5 | Moderate; both are valid | Emicizumab reduces bleeding while ITI is ongoing |
Pearl: Inhibitor development remains the most consequential complication of hemophilia A treatment, occurring in one-quarter of severe patients; early detection via Bethesda monitoring and prompt use of bypassing agents or emicizumab are critical to reduce morbidity and mortality [273]D5[181]D5.
11. Prognosis & Natural History
- ▸Severe hemophilia A has a lifelong risk of recurrent joint and soft-tissue bleeding, with progressive arthropathy if joint bleeding is not prevented. [340]
- ▸ABR comparisons require standardized bleed definitions, exposure periods, and statistical methods. [405]
- ▸Early prophylaxis and newer non-factor therapies aim to reduce bleeding and preserve joint health, but individual treatment needs remain variable. [334][340][267]
- ▸FVIII inhibitors substantially complicate prognosis; F8 genotype may help predict ITI outcomes, but individual prediction remains limited. [72][407]
- ▸Acquired hemophilia A has distinct survival and infection risks related to autoantibodies and immunosuppression. [170][291][337]
- ▸Arthroplasty can improve function in end-stage arthropathy but requires long-term surveillance for bleeding, infection, and prosthesis complications. [280][371][292]
Overall trajectory
The prognosis of hemophilia A is heterogeneous and depends on bleeding phenotype, joint involvement, inhibitor status, treatment access, adherence, comorbidity, and the quality of longitudinal monitoring. In severe congenital disease, recurrent joint and soft-tissue bleeding is the defining clinical problem and may produce progressive hemophilic arthropathy; early prophylaxis is intended to prevent joint damage before it becomes established. [340] Bleeding outcomes should be interpreted cautiously because clinical trials, registries, and observational studies have used inconsistent definitions of bleeding, variable observation periods, and different statistical methods for annualized bleeding rate (ABR). [405]
ABR and annual joint bleeding rate remain important measures of treatment effectiveness, but comparisons between studies require attention to the precise bleed definition, treatment exposure, observation duration, and analytic method. [405] Contemporary monitoring increasingly incorporates clinical bleeding, joint status, physical function, and patient-reported outcomes rather than relying on ABR alone; a Delphi-based monitoring tool was developed for this multidimensional reassessment, although its validation was consensus-based rather than clinical validation in patient cohorts. [352]C
Effect of preventive treatment
Replacement prophylaxis remains a major determinant of long-term outcome in children with severe hemophilia A. A 2025 Cochrane review specifically examined previously untreated or minimally treated children without proven joint damage because early prophylaxis may prevent progressive joint injury; the review emphasizes recurrent hemarthroses and soft-tissue bleeding as the disease hallmark but does not establish a single universally optimal regimen. [340] A separate Cochrane review evaluated non-factor therapies, including emicizumab, concizumab, marstacimab, and fitusiran, against factor prophylaxis, bypassing therapy, placebo, or no prophylaxis for bleeding and bleeding-related outcomes. [334]
Emicizumab has expanded prophylactic options for people with severe hemophilia A with or without inhibitors. Real-world work has evaluated bleeding rates in children and adults without inhibitors and examined their relationship with plasma emicizumab concentrations, reflecting ongoing uncertainty about whether conventional weight-based dosing is excessive for some patients. [404]C In adults with severe hemophilia A, the RESOLVE observational study followed patients for at least 2 years after switching from replacement therapy to emicizumab and assessed ABR, annualized joint bleeding rate, Hemophilia Joint Health Score, and HEAD-US findings, including hypertrophic synovium. [373] Denecimig (Mim8), another subcutaneous FVIII-mimetic prophylactic therapy, was studied in children aged 1–11 years for 52 weeks, with weekly dosing during the first 26 weeks and caregiver-selected weekly or monthly dosing during the second 26 weeks; outcomes included treated bleeds, adverse events, injection-site reactions, antidenecimig antibodies, and caregiver-reported outcomes. [406]
Individual prophylaxis requirements remain variable. The PREDICT study evaluated a risk score incorporating phenotypic and biologic variables to guide selection of prophylaxis when switching from standard-half-life FVIII to damoctocog alfa pegol, supporting risk-adapted rather than uniform treatment selection. [267]B2b
Inhibitors and immune tolerance
Development of neutralizing FVIII alloantibodies is a major adverse prognostic event because it complicates replacement therapy and may increase treatment burden. A systematic review and meta-analysis evaluated whether F8 genotype predicts immune tolerance induction (ITI) success or failure in people with hemophilia A and inhibitors; the analysis reflects the continuing need to identify determinants of an outcome that remains difficult to predict individually. [72]A1a In a retrospective cohort of 34 children with severe hemophilia A, inhibitors, and large F8 deletions, isolated A1-domain deletions were specifically investigated against nonisolated deletions, with exploratory assessment of residual F8 mRNA and protein; the report’s principal premise was that isolated A1-domain deletions may have more favorable ITI outcomes than other large deletions. [407]C
Acquired hemophilia A
Acquired hemophilia A has a different natural history from congenital hemophilia and is caused by neutralizing FVIII autoantibodies. [170]B2b In the GTH-AHA-EMI follow-up, 47 patients treated with emicizumab with postponed immunosuppression were followed for 2 years and compared with a propensity-score-matched cohort of 101 patients receiving immediate immunosuppression; outcomes included overall survival, infection- and bleeding-related mortality, and complete remission. [170]B2b The study was motivated by the substantial infection risk associated with immunosuppressive therapy, which is a leading cause of death in acquired hemophilia. [170]B2b
A real-world case series described five patients treated with emicizumab and combined these observations with a systematic review and patient-level analysis, reflecting increasing interest in early emicizumab to reduce bleeding and treatment-related hospitalization. [372]C In a systematic review of autoimmune bullous disease combined with acquired hemophilia A, 80 patients were identified, with analysis of clinical manifestations, treatment strategies, and survival outcomes. [291]C4 Rituximab, used in acquired hemophilia and other autoimmune hematologic disorders, can cause B-cell depletion, hypogammaglobulinemia, and increased infection risk; a multicenter retrospective study evaluated infections in patients receiving rituximab. [337]C
Musculoskeletal and surgical outcomes
When end-stage arthropathy develops, total knee or hip arthroplasty may improve pain and function but remains associated with perioperative bleeding, infection, bone-health concerns, and prosthesis complications. [280]B2a A retrospective study of 70 patients and 108 knees evaluated prophylactic versus on-demand factor replacement after primary total knee arthroplasty, with a mean follow-up of 9.7 years (range 5–22 years) and assessment of patient-reported outcomes and prosthesis survival. [371] Another retrospective series evaluated 42 knee and 30 hip arthroplasties performed between 2014 and 2024, measuring range of motion, functional scores, pain, activities of daily living, satisfaction, and radiographic outcomes. [292]C4 A systematic review of 14 retrospective cohort studies assessed prosthesis survival and complications after total hip arthroplasty in hemophilic patients. [280]B2a
Major bleeding, psychosocial burden, and special populations
Massive gastrointestinal, intraperitoneal, or pelvic hemorrhage is uncommon but potentially life-threatening. In a pediatric inherited-bleeding-disorder cohort of 788 patients, 10 (1.2%) developed massive abdominal hemorrhage, defined by major blood loss, shock, transfusion, or imaging-confirmed intraperitoneal or pelvic bleeding. [362]C Chronic pain, recurrent joint hemorrhage, limb impairment, anxiety, depression, and stigma remain important dimensions of long-term disease burden, as shown in a Chinese cross-sectional study of a predominantly male hemophilia population. [375] Pregnancy outcomes in women with inherited bleeding disorders have also been studied in a matched case-control cohort of 81 pregnancies versus 162 controls, with assessment of maternal, fetal, and neonatal outcomes, although these findings apply to inherited bleeding disorders broadly rather than exclusively to hemophilia A. [376]
| Domain | Prognostic relevance | Evidence |
|---|---|---|
| Bleeding phenotype | Recurrent joint and soft-tissue bleeding drives progressive joint damage; ABR interpretation varies by methodology. | [340][405] |
| Prophylaxis | Early factor prophylaxis and non-factor therapies are intended to prevent bleeding and preserve joints. | [334][340] |
| Inhibitors | FVIII alloantibodies complicate treatment; genotype may influence ITI outcome. | [72]A1a[407]C |
| Established arthropathy | Arthroplasty may improve pain and function but carries long-term prosthesis and perioperative risks. | [280]B2a[371][292]C4 |
| Acquired disease | Survival is influenced by bleeding, remission, infection, and immunosuppression-related complications. | [170]B2b[291]C4[337]C |
| Psychosocial health | Pain, disability, anxiety, depression, and stigma contribute to long-term burden. | [375] |
12. Special Populations & Prevention
- ▸During emicizumab prophylaxis in previously untreated children, the timing and effect of additional FVIII exposure remain uncertain, including whether exposure promotes tolerance, unmasks, or induces inhibitors. [251]
- ▸Pregnancy planning should recognize the revised Dutch thresholds of <80 IU/dL for third-trimester prophylaxis and ≥150 IU/dL as the childbirth peak target; severe PPH remained a concern despite intensified management. [327]
- ▸PND and technically enhanced F8 variant detection are important components of reproductive and family prevention strategies. [126][380]
- ▸Older adults with hemophilia require individualized arterial-thrombosis prevention that balances cardiovascular risk with bleeding risk. [62]
Children receiving emicizumab
Emicizumab has expanded prophylaxis for children with hemophilia A (HA), including those with and without FVIII inhibitors. In a prospective 12-month real-world cohort from a low- and middle-income setting, 72 children younger than 18 years received emicizumab; 70 had severe HA and 2 had moderate HA with a severe bleeding phenotype, and the cohort included both inhibitor-positive and inhibitor-negative patients. Outcomes included annualized bleeding rate (ABR), joint health using HJHS 2.1, and functional capacity using the Functional Independence Score in Hemophilia. [301]C4 A separate 12-month real-world study in northeastern India evaluated 40 children with moderate-to-severe HA, including children with inhibitors, and assessed bleeding, joint health, safety, and patient-reported outcomes. [379]
Long-term registry evidence from Canada included 710 people with HA who received at least one dose of emicizumab between 2018 and 2023; 539 (75.9%) had more than one year of exposure. The study compared intra-patient ABRs before and after emicizumab using negative-binomial regression and evaluated safety and effectiveness. [378] In young children without inhibitors, a real-world self-controlled study compared 12 months of standard-dose FVIII prophylaxis with 12 months after transition to emicizumab, assessing overall, treated, joint, and spontaneous ABRs, zero-bleeding proportions, and direct annual prophylaxis costs; most patients received reduced-dose maintenance regimens in the emicizumab period. [381] Plasma emicizumab concentration and its relationship with bleeding rates remain an area of real-world investigation in children and adults with severe HA without inhibitors. [404]C
Inhibitor prevention and surveillance
In previously untreated patients (PUPs), emicizumab prophylaxis may substantially prolong the time required to reach 50 FVIII exposure days, the exposure benchmark traditionally associated with the period of inhibitor risk during conventional FVIII prophylaxis. The clinical effect of intermittent or additional FVIII exposure during emicizumab prophylaxis remains uncertain: it may promote tolerance, unmask an existing inhibitor, or induce an inhibitor. [251]C4 The international MAPTO survey therefore examined practices and perceptions among hemophilia health-care providers regarding concomitant FVIII use and inhibitor surveillance in children with severe HA receiving emicizumab. [251]C4
Immune tolerance induction (ITI) remains relevant for children with FVIII inhibitors. In an observational study of 121 pediatric patients with HA and inhibitors, low-dose ITI used approximately 50 IU/kg FVIII every other day; rituximab was added for patients with higher-risk clinical features. Maternal microchimerism was assessed by droplet digital PCR, and 101 patients were evaluable; 18 were maternal-microchimerism positive and 70 negative, while 88 completed ITI. [402] Maternal microchimerism was investigated as a potential predictor of ITI success and as a possible protective factor against inhibitor development, but these observational findings do not establish a treatment recommendation. [402]
Pregnancy, childbirth, and neonatal prevention
Pregnant hemophilia carriers require coordinated hematology, obstetric, anesthesia, and neonatal planning. Dutch guidance increased the third-trimester prophylaxis threshold from <50 IU/dL to <80 IU/dL and the target peak factor level during childbirth from ≥100 IU/dL to ≥150 IU/dL because severe postpartum hemorrhage (PPH), defined as ≥1000 mL, remained a concern. A prospective Dutch study conducted from 2018 to 2024 evaluated whether the revised strategy reduced severe PPH incidence; its stated objective was to assess outcomes after implementation, and enhanced peripartum hemostatic management did not decrease severe PPH incidence. [327]
A matched case-control study from Iran evaluated 81 pregnancies among women with inherited bleeding disorders against 162 control pregnancies and examined fetal or neonatal mortality, neonatal intensive-care admission, intrauterine growth restriction, neonatal transfusion, and postpartum bleeding outcomes. [376] Decisions about neuraxial analgesia require individualized assessment because clinicians remain concerned about spinal or epidural hematoma in pregnant individuals with inherited bleeding disorders and high-quality evidence is limited. A retrospective tertiary-center study described anesthetic practices, laboratory findings, antenatal recommendations, and outcomes for deliveries managed by a regional bleeding-disorders program. [383]C
Prenatal diagnosis (PND) remains an important prevention and reproductive-planning tool for families affected by HA or hemophilia B. A systematic review of 24 studies published from 2005 through September 2025 included 969 pregnancies; 78.3% (759) involved hemophilia A carriers and 16.3% (158) hemophilia B carriers, while amniocentesis accounted for 45.8% of reported procedures. The review identified substantial global heterogeneity in PND methods and practices. [126]B2a Expanded carrier screening using next-generation sequencing may miss technically challenging variants, including F8 inversions, single-exon copy-number variants, and other complex changes; an optimized multiplex long-distance PCR/amplicon-sequencing assay was developed to improve detection in expanded carrier screening. [380]
Older adults and systems-based prevention
As life expectancy increases, arterial thrombotic disease becomes an important issue in adults with hemophilia. In the prospective ADVANCE Japan cohort, adults aged ≥40 years without previous arterial thrombosis were followed for five years, and the Hisayama model, Suita score, and QRISK3 were evaluated for estimating arterial-event risk. Risk scores may support primary-prevention discussions, but arterial-event management must balance thrombosis risk against hemophilia-related bleeding risk. [62]B2b
Interfacility collaboration can reduce disparities between specialist hemophilia treatment centers and local medical facilities. In Japan, approximately 6000 people with hemophilia are cared for across about 1000 clinics or hospitals; a retrospective claims-database study assessed whether the Japan Hemophilia Network Committee, established in 2018, was facilitating collaboration between expert and non-expert facilities. [382] AI and machine-learning methods are being investigated for prevention, diagnosis, risk stratification, and personalized management of bleeding disorders, particularly where conventional assessment is time-consuming or access to specialist expertise is limited. [9]B2a
Prevention also requires rapid recognition of unusual bleeding. A pediatric cohort found massive gastrointestinal, intraperitoneal, or pelvic hemorrhage to be rare but potentially life-threatening in inherited bleeding disorders; massive gastrointestinal bleeding was defined as blood loss >70 mL/kg/day, shock, or transfusion, while intraperitoneal and pelvic hemorrhage required imaging confirmation. [362]C Laboratory capacity is important in resource-constrained settings: a study evaluated whether inhibitor-screening assay results could predict Bethesda titers and reduce reliance on the more resource-intensive classical or modified Nijmegen-Bethesda assay. [403] Cross-mixing tests can help distinguish prolonged aPTT etiologies; in one retrospective series, lupus anticoagulant accounted for most cases, whereas inhibitor-pattern results were associated with bleeding and acquired hemophilia A. [303]C4
| Population or setting | Evidence-informed priority |
|---|---|
| PUPs receiving emicizumab | Clarify FVIII exposure strategy and monitor for inhibitors; 50 FVIII exposure days may take years to reach. [251]C4 |
| Pregnant carriers | Coordinate factor assessment and peripartum planning; Dutch thresholds were <80 IU/dL for prophylaxis and ≥150 IU/dL peak target at childbirth. [327] |
| Adults aged ≥40 years | Consider validated cardiovascular risk scores while accounting for bleeding risk. [62]B2b |
| Resource-limited services | Strengthen inhibitor testing, specialist collaboration, and diagnostic referral pathways. [382][403] |
| Clinical concern | Definition or threshold |
|---|---|
| Severe postpartum hemorrhage | ≥1000 mL. [327] |
| Massive gastrointestinal hemorrhage in children | >70 mL/kg/day, shock, or transfusion. [362]C |
| Massive intraperitoneal or pelvic hemorrhage | Imaging confirmation required in the cited pediatric study. [362]C |
References
- [1]
Kurian CJ, Drelich DA, Rizk S. “Successful liver transplant from a hemophilia A donor with no development of hemophilia A in recipient.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 31997485 ↗
L4CASE_REPORTCited in: 1. Definition, Classification & Nomenclature, 2. Pathophysiology & Mechanism - [2]
Elshennawy S, Zahreldin AA, Mortada H et al.. “The Efficacy of Physical Therapy Modalities in Patients With Hemophilia: A Systematic Review of Randomized Controlled Trials With Meta-analysis.” Archives of physical medicine and rehabilitation (2022). PMID: 35868453 ↗
L1SR_MA_RCTCited in: 1. Definition, Classification & Nomenclature - [3]
Hermans C, Chowdary P, Konkle BA et al.. “A revised classification of FVIII concentrates: rationale and novel metrics.” Blood advances (2026). PMID: 41678963 ↗
L5OTHERCited in: 1. Definition, Classification & Nomenclature - [4]
van Bladel ER, Roest M, de Groot PG et al.. “Up-regulation of platelet activation in hemophilia A.” Haematologica (2011). PMID: 21422116 ↗
L3OTHERCited in: 1. Definition, Classification & Nomenclature, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [5]
Testa MF, Lombardi S, Bernardi F et al.. “Translational readthrough at F8 nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association.” Haematologica (2023). PMID: 35924581 ↗
L5OTHERCited in: 1. Definition, Classification & Nomenclature - [6]
van Galen KPM, d'Oiron R, James P et al.. “A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34327828 ↗
L1OTHERCited in: 1. Definition, Classification & Nomenclature, 5. Diagnosis & Workup, History and Evolution of Treatment - [7]
Rawal A, Kidchob C, Ou J et al.. “Application of machine learning approaches for predicting hemophilia A severity.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38718927 ↗
L4OTHERCited in: 1. Definition, Classification & Nomenclature, 6. Staging, Risk Stratification & Prognostic Scoring - [8]
Mancuso ME, Mannucci PM, Rocino A et al.. “Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.” Journal of thrombosis and haemostasis : JTH (2012). PMID: 22452823 ↗
L2OTHERCited in: 1. Definition, Classification & Nomenclature - [9]
Mohamed FRR, Aldabbagh Z, Kalou W et al.. “The use of artificial intelligence in the prevention and management of bleeding disorders: a systematic review.” Frontiers in medicine (2025). PMID: 41140650 ↗
L2SR_OBSCited in: 1. Definition, Classification & Nomenclature, 5. Diagnosis & Workup, 6. Staging, Risk Stratification & Prognostic Scoring, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 10. Complications, 12. Special Populations & Prevention - [10]
Al-Huniti A, Sharathkumar A, Krantz M et al.. “Discrepant Hemophilia A: An Underdiagnosed Disease Entity.” American journal of clinical pathology (2020). PMID: 32232366 ↗
L4REVIEW_NARRATIVECited in: 1. Definition, Classification & Nomenclature - [11]
Rosendaal FR, Palla R, Garagiola I et al.. “Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis.” Blood (2017). PMID: 28768627 ↗
L1RCTCited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 6. Staging, Risk Stratification & Prognostic Scoring, History and Evolution of Treatment - [12]
Astermark J, Oldenburg J, Carlson J et al.. “Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.” Blood (2006). PMID: 16926287 ↗
L3TRIAL_NONRANDOMCited in: 2. Pathophysiology & Mechanism - [13]
Gouw SC, van den Berg HM, Oldenburg J et al.. “F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.” Blood (2012). PMID: 22282501 ↗
L2SR_OBSCited in: 2. Pathophysiology & Mechanism, 11. Prognosis & Natural History - [14]
van Stam LE, Lacroix-Desmazes S, Fijnvandraat K et al.. “Tolerance to factor VIII in the era of nonfactor therapies: immunologic perspectives and a systematic review of the literature.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 39800259 ↗
L2SR_OBSCited in: 2. Pathophysiology & Mechanism, 12. Special Populations & Prevention - [15]
El-Maarri O, Singer H, Klein C et al.. “Lack of F8 mRNA: a novel mechanism leading to hemophilia A.” Blood (2005). PMID: 16339403 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism - [16]
Astermark J. “FVIII inhibitors: pathogenesis and avoidance.” Blood (2015). PMID: 25712994 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management - [17]
Gunasekera D, Ettinger RA, Nakaya Fletcher S et al.. “Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.” Blood (2015). PMID: 25617427 ↗
L3OTHERCited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors - [18]
Peyvandi F, Kunicki T, Lillicrap D. “Genetic sequence analysis of inherited bleeding diseases.” Blood (2013). PMID: 24124085 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup, 6. Staging, Risk Stratification & Prognostic Scoring, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [19]
Hawerkamp HC, Yeow A, Byrne CM et al.. “The interleukin-33 receptor (ST2) is a novel therapeutic target to attenuate the progression of hemophilic arthropathy.” Blood (2025). PMID: 40680269 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [20]
Ellsworth P, Chen SL, Jones LA et al.. “Acquired hemophilia A: a narrative review and management approach in the emicizumab era.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39536818 ↗
L5CASE_REPORTCited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup, 8. Long-term & Definitive Management, 10. Complications, 11. Prognosis & Natural History - [21]
Yada K, Nogami K, Takeyama M et al.. “Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26278069 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism - [22]
Nakajima Y, Oda A, Baatartsogt N et al.. “The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential.” Blood advances (2024). PMID: 38820442 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [23]
Dutta D, Gunasekera D, Ragni MV et al.. “Accurate, simple, and inexpensive assays to diagnose F8 gene inversion mutations in hemophilia A patients and carriers.” Blood advances (2016). PMID: 29296938 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [24]
Kis-Toth K, Rajani GM, Simpson A et al.. “Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization.” Blood advances (2018). PMID: 30396910 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [25]
Kim HJ, Kim DK, Yoo KY et al.. “Heterogeneous lengths of copy number mutations in human coagulopathy revealed by genome-wide high-density SNP array.” Haematologica (2011). PMID: 21993689 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism - [26]
Varthaman A, Lacroix-Desmazes S. “Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?” Haematologica (2018). PMID: 30514798 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 10. Complications - [27]
Singer H, Chawla P, Czogalla-Nitsche KJ et al.. “Divergent processing of FVIII light chain variants: secretory potential versus proteasomal retention.” Haematologica (2025). PMID: 41307134 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [28]
Casaña P, Cabrera N, Cid AR et al.. “Severe and moderate hemophilia A: identification of 38 new genetic alterations.” Haematologica (2008). PMID: 18403393 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 12. Special Populations & Prevention - [29]
Margaglione M, Castaman G, Morfini M et al.. “The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype.” Haematologica (2008). PMID: 18387975 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism, 12. Special Populations & Prevention - [30]
Hart DP, Uzun N, Skelton S et al.. “Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A.” Haematologica (2018). PMID: 30266735 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [31]
Donadon I, McVey JH, Garagiola I et al.. “Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity.” Haematologica (2017). PMID: 29170251 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [32]
David D, Ventura C, Moreira I et al.. “The spectrum of mutations and molecular pathogenesis of hemophilia A in 181 Portuguese patients.” Haematologica (2006). PMID: 16769589 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism - [33]
Seidizadeh O, Peyvandi F, Mannucci PM. “Von Willebrand disease type 2N: An update.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 33497541 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup, 8. Long-term & Definitive Management - [34]
Kumar S, Schroeder JA, Shi Q. “Platelet-targeted gene therapy induces immune tolerance in hemophilia and beyond.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37558132 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [35]
Furukawa S, Baatartsogt N, Kawamura T et al.. “The factor (F)VIII K1693N mutation (FVIII-Nara) in a patient with moderate hemophilia A confers resistance to thrombin-catalyzed cleavage at Arg1689 involving P4' position.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40374115 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [36]
Pavlova A, Brondke H, Müsebeck J et al.. “Molecular mechanisms underlying hemophilia A phenotype in seven females.” Journal of thrombosis and haemostasis : JTH (2009). PMID: 19302446 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism - [37]
Wang H, Tian J, Zhang M et al.. “The p. Arg1800His Mutation of Factor VIII Results in Moderate Hemophilia A Due to Defective Processing and Stability of Functional Protein.” Cell biology international (2026). PMID: 42132504 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism - [38]
Wolff L, Ertl C, Heinzerling L et al.. “Acquired hemophilia due to immune checkpoint inhibitors: a case series introducing emicizumab treatment.” The oncologist (2025). PMID: 40828901 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism, 10. Complications - [39]
Prabhu RS, V S SR, S N R. “Large intramuscular hematoma due to acquired Factor VIII inhibitors in post Polycythemia Vera-Myelofibrosis.” Clinical hematology international (2025). PMID: 40636934 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism - [40]
Testa MF, Pinotti M, Branchini A et al.. “Immunogenic implications of translational readthrough modulate the association of F8 nonsense mutations with inhibitors in Hemophilia A.” Molecular medicine (Cambridge, Mass.) (2026). PMID: 42374266 ↗
L2OTHERCited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management - [41]
Sun H, Mei L, He X et al.. “Genetic analysis of F8 mutations in five hemophilia a carriers.” Frontiers in medicine (2026). PMID: 42221123 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism - [42]
Lawrence AG, Murangi T, Chevalier A et al.. “CX3CR1+ synovial macrophages accumulate in the joint during experimental hemophilic arthropathy but are not required for acute synovitis.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42128059 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [43]
Cannavò A, Valsecchi C, Garagiola I et al.. “Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A.” Blood (2016). PMID: 28034891 ↗
L2RCTCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, 10. Complications, 12. Special Populations & Prevention - [44]
Peyvandi F, Mannucci PM, Garagiola I et al.. “A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.” The New England journal of medicine (2016). PMID: 27223147 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [45]
Manco-Johnson MJ, Abshire TC, Shapiro AD et al.. “Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.” The New England journal of medicine (2007). PMID: 17687129 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, 11. Prognosis & Natural History - [46]
Nogami K, You CW, Park YS et al.. “NXTAGE: a phase 1/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors.” Blood (2026). PMID: 41643195 ↗
L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [47]
Königs C, Ozelo MC, Dunn A et al.. “First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results.” Blood (2022). PMID: 35421219 ↗
L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, 12. Special Populations & Prevention - [48]
Zwagemaker AF, Gouw SC, Jansen JS et al.. “Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis.” Blood (2021). PMID: 34411236 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Complications, 11. Prognosis & Natural History - [49]
Pipe SW, Lissitchkov T, Georgiev P et al.. “Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B.” Blood advances (2025). PMID: 39642315 ↗
L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors - [50]
Male C, Königs C, Dey S et al.. “The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.” Blood advances (2023). PMID: 35858373 ↗
L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, 12. Special Populations & Prevention - [51]
Sambe T, Miwa T, Yoneyama K et al.. “A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40554054 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [52]
Gringeri A, Lundin B, von Mackensen S et al.. “A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study).” Journal of thrombosis and haemostasis : JTH (2011). PMID: 21255253 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 4. Clinical Presentation - [53]
Van Der Valk P, Makris M, Fischer K et al.. “Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study.” Blood advances (2022). PMID: 34879394 ↗
L2COHORTCited in: 3. Epidemiology, Etiology & Risk Factors - [54]
Xi M, Makris M, Marcucci M et al.. “Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.” Journal of thrombosis and haemostasis : JTH (2013). PMID: 23802542 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Complications - [55]
Hassan S, Cannavò A, Gouw SC et al.. “Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29665204 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors - [56]
Iorio A, Halimeh S, Holzhauer S et al.. “Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.” Journal of thrombosis and haemostasis : JTH (2010). PMID: 20345722 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors - [57]
Kempton CL, Payne AB. “HLA-DRB1-factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study.” Blood advances (2018). PMID: 30037801 ↗
L3CASE_CONTROLCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Complications - [58]
Abdi A, Eckhardt CL, van Velzen AS et al.. “Treatment-related risk factors for inhibitor development in non-severe hemophilia A after 50 cumulative exposure days: A case-control study.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34107158 ↗
L3CASE_CONTROLCited in: 3. Epidemiology, Etiology & Risk Factors - [59]
Scott DW, Pratt KP, Miao CH. “Progress toward inducing immunologic tolerance to factor VIII.” Blood (2013). PMID: 23502223 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors - [60]
Gouw SC, van der Bom JG, Ljung R et al.. “Factor VIII products and inhibitor development in severe hemophilia A.” The New England journal of medicine (2013). PMID: 23323899 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Prognosis & Natural History - [61]
Viel KR, Ameri A, Abshire TC et al.. “Inhibitors of factor VIII in black patients with hemophilia.” The New England journal of medicine (2009). PMID: 19369668 ↗
L3OTHERCited in: 3. Epidemiology, Etiology & Risk Factors - [62]
Nagao A, Sawada A, Kanematsu T et al.. “Cardiovascular risk scores estimate arterial thrombotic risk in aging adults with hemophilia in the ADVANCE Japan cohort.” Blood advances (2026). PMID: 42335204 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 6. Staging, Risk Stratification & Prognostic Scoring - [63]
Lundgren TS, Denning G, Stowell SR et al.. “Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice.” Blood advances (2022). PMID: 35286375 ↗
L5OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 6. Staging, Risk Stratification & Prognostic Scoring - [64]
Li E, Li Z, Wang J et al.. “Single-cell sequencing on PBMCs from patients with HA and HB with inhibitors reveals different immune responses to FVIII and FIX.” Blood advances (2025). PMID: 40402102 ↗
L4OTHERCited in: 3. Epidemiology, Etiology & Risk Factors - [65]
Wang P, Zhou R, Xue F et al.. “Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferiority trial.” American journal of hematology (2023). PMID: 37851608 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors - [66]
Gringeri A, Mannucci PM, Gringeri M et al.. “Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A.” Haematologica (2025). PMID: 40176766 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors - [67]
Andersson NG, De Kovel M, Castaman G et al.. “Intracranial hemorrhage before start of prophylaxis in children with hemophilia: incidence, timing, and potential for prevention.” Haematologica (2024). PMID: 39605212 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup, 12. Special Populations & Prevention - [68]
Oldenburg J, Lacroix-Desmazes S, Lillicrap D. “Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.” Haematologica (2015). PMID: 25638804 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors - [69]
Georgescu MT, Moorehead PC, van Velzen AS et al.. “Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms.” Haematologica (2018). PMID: 29674503 ↗
L5OTHERCited in: 3. Epidemiology, Etiology & Risk Factors - [70]
Bowyer AE, Van Veen JJ, Goodeve AC et al.. “Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A.” Haematologica (2013). PMID: 23812942 ↗
L4OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup - [71]
Calvez T, Chambost H, d'Oiron R et al.. “Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.” Haematologica (2017). PMID: 29025913 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors - [72]
Barbosa JO, Barbosa IO, Souza RP et al.. “F8 Genotype and Immune Tolerance Induction Outcome in People with Hemophilia A and Inhibitors: A Systematic Review and Meta-Analysis.” Thrombosis and haemostasis (2026). PMID: 42140226 ↗
L1TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Prognosis & Natural History - [73]
Feng X, Zhou X, Sun J et al.. “Efficacy and Safety of Recombinant Factor VIII in Previously Untreated and Previously Treated Children with Hemophilia A: A Systematic Review.” Advances in therapy (2025). PMID: 40048104 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors - [74]
Debela MB, Bekele K, Zenbaba D. “The prevalence of Hemophilia A in males in Africa: evidence from a systematic review and meta-analysis.” BMC public health (2024). PMID: 39334048 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors - [75]
Huth-Kühne A, Baudo F, Collins P et al.. “International recommendations on the diagnosis and treatment of patients with acquired hemophilia A.” Haematologica (2009). PMID: 19336751 ↗
L1GUIDELINECited in: 4. Clinical Presentation, 5. Diagnosis & Workup, 8. Long-term & Definitive Management, History and Evolution of Treatment - [76]
Warren BB, Thornhill D, Stein J et al.. “Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study.” Blood advances (2020). PMID: 32492157 ↗
L2RCTCited in: 4. Clinical Presentation, History and Evolution of Treatment, 11. Prognosis & Natural History - [77]
Denis CV, Susen S, Lenting PJ. “von Willebrand disease: what does the future hold?” Blood (2021). PMID: 33662989 ↗
L5OTHERCited in: 4. Clinical Presentation, 5. Diagnosis & Workup - [78]
Haxaire C, Hakobyan N, Pannellini T et al.. “Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway.” Blood (2018). PMID: 29776906 ↗
L5OTHERCited in: 4. Clinical Presentation - [79]
Muto A, Yoshihashi K, Takeda M et al.. “Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.” Blood (2014). PMID: 25274508 ↗
L5OTHERCited in: 4. Clinical Presentation - [80]
Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH et al.. “Bleeding in carriers of hemophilia.” Blood (2006). PMID: 16551972 ↗
L4OTHERCited in: 4. Clinical Presentation, History and Evolution of Treatment - [81]
Menegatti M, Peyvandi F. “Treatment of rare factor deficiencies other than hemophilia.” Blood (2018). PMID: 30559262 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation - [82]
Liu W, Liu J, Xue F et al.. “Anti-CD38 antibody for refractory acquired hemophilia A.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 36940802 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation - [83]
Radwi M, Farsi S. “A case report of acquired hemophilia following COVID-19 vaccine.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 33783953 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation - [84]
Raghunath A, Richter CE, Griffin MS et al.. “Loss of factor VIII in zebrafish rebalances antithrombin deficiency but has a limited bleeding diathesis.” Blood advances (2025). PMID: 40085950 ↗
L5OTHERCited in: 4. Clinical Presentation, 7. Acute & Emergency Management, 11. Prognosis & Natural History - [85]
Weitzmann MN, Roser-Page S, Vikulina T et al.. “Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice.” Blood advances (2019). PMID: 30700417 ↗
L5OTHERCited in: 4. Clinical Presentation - [86]
La Mura V, Bitto N, Capelli C et al.. “Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy.” Blood advances (2023). PMID: 37505111 ↗
L2OTHERCited in: 4. Clinical Presentation - [87]
Stagaard R, Ley CD, Almholt K et al.. “Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.” Blood advances (2018). PMID: 30459211 ↗
L5OTHERCited in: 4. Clinical Presentation - [88]
Gualtierotti R, Solimeno LP, Peyvandi F. “Hemophilic arthropathy: Current knowledge and future perspectives.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34197690 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis & Workup, 8. Long-term & Definitive Management, History and Evolution of Treatment - [89]
Baas L, van der Graaf R, van Hoorn ES et al.. “The ethics of gene therapy for hemophilia: a narrative review.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 36696181 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation - [90]
Chaigneau M, Bowman M, Wilton P et al.. “The history of women and hemophilia: a narrative review of evolving beliefs and testing practices.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39675566 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, History and Evolution of Treatment - [91]
Cao W, Trask AR, Bignotti AI et al.. “Coagulation factor VIII regulates von Willebrand factor homeostasis invivo.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37726033 ↗
L4OTHERCited in: 4. Clinical Presentation - [92]
Kalantari Y, Mirahmadi SMS, Alilou S et al.. “A Systematic Review of Vascular Injuries: A Review of Petechiae, Purpura, and Ecchymosis in Critical Situations Following COVID-19 Vaccination.” Health science reports (2025). PMID: 40083673 ↗
L4SR_OBSCited in: 4. Clinical Presentation - [93]
Poyraz Isleyen T, Tarakci E, Leblebici G et al.. “Comparison of Efficiency of Closed Kinetic Chain Exercises Versus Proprioceptive Exercises in Improving Balance and Gait in People With Hemophilia: Protocol for a Randomized Controlled Trial.” JMIR research protocols (2025). PMID: 40273449 ↗
L5TRIAL_NONRANDOMCited in: 4. Clinical Presentation - [94]
Terrone G, Fecarotta S, Lorello P et al.. “Cerebral X-Linked Adrenoleukodystrophy Associated with Hemophilia A: a case report.” Hormone research in paediatrics (2026). PMID: 42328992 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 5. Diagnosis & Workup, 8. Long-term & Definitive Management - [95]
Liu X, Li W. “Case Report: Telitacicept in the treatment of systemic lupus erythematosus complicated by acquired hemophilia A.” Frontiers in immunology (2026). PMID: 41909654 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 8. Long-term & Definitive Management - [96]
Liu L, Guo D. “Case Report: Differential diagnosis and clinical management of isolated prolonged activated partial thromboplastin time.” Frontiers in immunology (2026). PMID: 41869337 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 5. Diagnosis & Workup - [97]
Gioia C, Paroli M, Morace V et al.. “Acquired Hemophilia Associated with Rheumatoid Arthritis: A Case Report and Review of the Literature.” International journal of molecular sciences (2025). PMID: 40332156 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 7. Acute & Emergency Management, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [98]
Waldman Radinsky L, Sivan M, Lubetsky A et al.. “Acquired Hemophilia-A Case Series and Review.” Journal of clinical medicine (2025). PMID: 40095589 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation - [99]
Sood SL, Cheng D, Ragni M et al.. “A cross-sectional analysis of cardiovascular disease in the hemophilia population.” Blood advances (2018). PMID: 29895623 ↗
L2TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup, History and Evolution of Treatment - [100]
Punt MC, Aalders TH, Bloemenkamp KWM et al.. “The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 32271985 ↗
L5SR_OBSCited in: 5. Diagnosis & Workup, 12. Special Populations & Prevention - [101]
Follenzi A, Raut S, Merlin S et al.. “Role of bone marrow transplantation for correcting hemophilia A in mice.” Blood (2012). PMID: 22368271 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [102]
Holstein K, Liu X, Smith A et al.. “Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study.” Blood (2020). PMID: 32268359 ↗
L2OTHERCited in: 5. Diagnosis & Workup - [103]
Yadav N, Kanjirakkuzhiyil S, Kumar S et al.. “The therapeutic effect of bone marrow-derived liver cells in the phenotypic correction of murine hemophilia A.” Blood (2009). PMID: 19752394 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [104]
Ide LM, Gangadharan B, Chiang KY et al.. “Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens.” Blood (2007). PMID: 17569821 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [105]
Collins P, Baudo F, Knoebl P et al.. “Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2).” Blood (2012). PMID: 22517903 ↗
L2OTHERCited in: 5. Diagnosis & Workup - [106]
Sherman A, Su J, Lin S et al.. “Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells.” Blood (2014). PMID: 24825864 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [107]
Gangadharan B, Parker ET, Ide LM et al.. “High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells.” Blood (2006). PMID: 16449528 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [108]
Johnsen JM, MacKinnon HJ. “JTH in Clinic - Obstetric bleeding: VWD and other inherited bleeding disorders.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35621921 ↗
L5CASE_REPORTCited in: 5. Diagnosis & Workup - [109]
Mingot-Castellano ME, Pardos-Gea J, Haya S et al.. “Management of acquired hemophilia A: results from the Spanish registry.” Blood advances (2021). PMID: 34521101 ↗
L2OTHERCited in: 5. Diagnosis & Workup - [110]
Poston JN, Bryan C, von Drygalski A et al.. “Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort.” Blood advances (2024). PMID: 39361769 ↗
L2OTHERCited in: 5. Diagnosis & Workup, 8. Long-term & Definitive Management, 11. Prognosis & Natural History - [111]
Han JH, Dupervil B, Mahajerin A et al.. “Clinical and treatment characteristics of infants and toddlers less than 2 years of age with hemophilia.” Blood advances (2024). PMID: 38547443 ↗
L2OTHERCited in: 5. Diagnosis & Workup, History and Evolution of Treatment, 12. Special Populations & Prevention - [112]
Hiramoto T, Inaba H, Baatartsogt N et al.. “Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A.” Blood advances (2023). PMID: 37792826 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [113]
Lyde RB, Ahn HS, Vo KK et al.. “Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.” Blood advances (2019). PMID: 31036722 ↗
L5OTHERCited in: 5. Diagnosis & Workup, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [114]
Oleshko O, Vollack-Hesse N, Tiede A et al.. “von Willebrand factor modulates immune complexes and the recall response against factor VIII in a murine hemophilia A model.” Blood advances (2023). PMID: 37756521 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [115]
Elnaggar M, Al-Mohannadi A, Hasan W et al.. “CD14+/CD31+ monocytes expanded by UM171 correct hemophilia A in zebrafish upon lentiviral gene transfer of factor VIII.” Blood advances (2023). PMID: 36477543 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [116]
Shi Q, Mattson JG, Fahs SA et al.. “The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.” Blood advances (2020). PMID: 31899798 ↗
L5OTHERCited in: 5. Diagnosis & Workup, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [117]
La Mura V, Bitto N, Ciavarella A et al.. “Biopsy-proven immune-mediated hepatitis after valoctocogene roxaparvovec.” Haematologica (2026). PMID: 42389809 ↗
L4OTHERCited in: 5. Diagnosis & Workup, 8. Long-term & Definitive Management - [118]
Tiede A, Collins P, Knoebl P et al.. “International recommendations on the diagnosis and treatment of acquired hemophilia A.” Haematologica (2020). PMID: 32381574 ↗
L1OTHERCited in: 5. Diagnosis & Workup, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Prognosis & Natural History, 12. Special Populations & Prevention - [119]
Castaman G, Goodeve A, Eikenboom J. “Principles of care for the diagnosis and treatment of von Willebrand disease.” Haematologica (2013). PMID: 23633542 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup, 8. Long-term & Definitive Management - [120]
Dasgupta S, Navarrete AM, André S et al.. “Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation.” Haematologica (2008). PMID: 18166789 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [121]
Merlin S, Akula S, Cottonaro A et al.. “Therapeutic potential of fetal liver cell transplantation in hemophilia A mice.” Haematologica (2023). PMID: 36700401 ↗
L5OTHERCited in: 5. Diagnosis & Workup, 8. Long-term & Definitive Management, 12. Special Populations & Prevention - [122]
Chen Y, Xue F, Kumar S et al.. “FVIII-containing platelets modulate immune responses and attenuate inhibitor development in hemophilia A mice.” Haematologica (2026). PMID: 41676910 ↗
L5OTHERCited in: 5. Diagnosis & Workup, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [123]
Boender J, Kruip MJ, Leebeek FW. “A diagnostic approach to mild bleeding disorders.” Journal of thrombosis and haemostasis : JTH (2016). PMID: 27208505 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment - [124]
Lim MY, Ardila J, Castaman G et al.. “Diagnosis and management of hemophilia A and B.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41967712 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup - [125]
Collins PW. “Treatment of acquired hemophilia A.” Journal of thrombosis and haemostasis : JTH (2007). PMID: 17461924 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup - [126]
Safdari SM, Bakhtiyaridovvombaigi M, Damerchiloo F et al.. “Two decades of prenatal diagnosis in hemophilia A and B: a systematic review of global trends and current practices.” Thrombosis journal (2026). PMID: 41742268 ↗
L2SR_OBSCited in: 5. Diagnosis & Workup, 6. Staging, Risk Stratification & Prognostic Scoring, 12. Special Populations & Prevention - [127]
. “[Chinese guidelines on the treatment of hemophilia (2025)].” Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2025). PMID: 41087175 ↗
L1GUIDELINECited in: 5. Diagnosis & Workup, History and Evolution of Treatment - [128]
Hölz J, Nobile C, Holzapfel J et al.. “Cardiac surgery in an infant hemophilia B carrier with moderate hemophilia: a case report.” Frontiers in cardiovascular medicine (2026). PMID: 41929463 ↗
L4CASE_REPORTCited in: 5. Diagnosis & Workup - [129]
Pshenichnikova O, Salomashkina V, Yastrubinetskaya O et al.. “A Rare Case of Mild Hemophilia A in a Female with Mosaic Monosomy X and a De Novo F8 Variant.” International journal of molecular sciences (2025). PMID: 41465324 ↗
L4CASE_REPORTCited in: 5. Diagnosis & Workup - [130]
Turkkan E, Yapici O, Alaygut D. “A rare but misleading cause of hematuria in hemophilia A: renal pelvic hemorrhage mimicking tumor.” Pediatric nephrology (Berlin, Germany) (2026). PMID: 42370986 ↗
L4OTHERCited in: 5. Diagnosis & Workup, 8. Long-term & Definitive Management - [131]
Tiede A, Hofbauer CJ, Werwitzke S et al.. “Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study.” Blood (2016). PMID: 26912467 ↗
L2TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 11. Prognosis & Natural History - [132]
Krudysz-Amblo J, Parhami-Seren B, Butenas S et al.. “Quantitation of anti-factor VIII antibodies in human plasma.” Blood (2009). PMID: 19144987 ↗
L5TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [133]
Li Z, Tang Y, Chen Z et al.. “Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40286913 ↗
L2TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 11. Prognosis & Natural History - [134]
Funk SM, Engelen S, Benjamin K et al.. “Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderate-severe hemophilia A.” Journal of thrombosis and haemostasis : JTH (2019). PMID: 31557391 ↗
L2TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [135]
Germini F, Noronha N, Abraham Philip B et al.. “Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literature.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35395700 ↗
L2SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [136]
Tiede A, Klamroth R, Scharf RE et al.. “Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.” Blood (2014). PMID: 25525118 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [137]
Goedhart TMHJ, Bukkems LH, Zwaan CM et al.. “Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice.” Blood advances (2021). PMID: 34496017 ↗
L5REVIEW_NARRATIVECited in: 6. Staging, Risk Stratification & Prognostic Scoring, 12. Special Populations & Prevention - [138]
Soldà G, Asselta R. “Applying artificial intelligence to uncover the genetic landscape of coagulation factors.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 39798926 ↗
L5REVIEW_NARRATIVECited in: 6. Staging, Risk Stratification & Prognostic Scoring - [139]
van Balen EC, Haverman L, Hassan S et al.. “Validation of PROMIS Profile-29 in adults with hemophilia in the Netherlands.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34245088 ↗
L4OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [140]
Schulman S, Eelde A, Holmström M et al.. “Validation of a composite score for clinical severity of hemophilia.” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18466317 ↗
L4OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [141]
Jardim LL, Schieber TA, Santana MP et al.. “Prediction of inhibitor development in previously untreated and minimally treated children with severe and moderately severe hemophilia A using a machine-learning network.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38810700 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [142]
Schep SJ, van Dijk WEM, Beckers EAM et al.. “Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study.” American journal of hematology (2020). PMID: 32974947 ↗
L3COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [143]
Kempton CL, White GC. “How we treat a hemophilia A patient with a factor VIII inhibitor.” Blood (2008). PMID: 18820129 ↗
L5REVIEW_NARRATIVECited in: 7. Acute & Emergency Management, 10. Complications - [144]
Bou-Jaoudeh M, Mimoun A, Delignat S et al.. “Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37473843 ↗
L4OTHERCited in: 7. Acute & Emergency Management - [145]
Arya S, Siad FM, Wilton P et al.. “Invisible bleeds: Lived experiences and barriers to care for men with hemophilia.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34689399 ↗
L4OTHERCited in: 7. Acute & Emergency Management - [146]
Xie X, Jiang S. “Corpus luteum hemorrhage with acquired hemophilia A: a case report and literature review.” BMC women's health (2022). PMID: 36221134 ↗
L4CASE_REPORTCited in: 7. Acute & Emergency Management - [147]
Yoon CW, Park HK, Rha JH. “A case report and experience of endovascular treatment for a patient with hemophilia who had a hyperacute ischemic stroke.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2020). PMID: 32389557 ↗
L4CASE_REPORTCited in: 7. Acute & Emergency Management - [148]
Horn EH, Forsyth K, Gooding R et al.. “Management of haemophilia and heritable bleeding disorders in the ED.” Emergency medicine journal : EMJ (2025). PMID: 40579048 ↗
L5REVIEW_NARRATIVECited in: 7. Acute & Emergency Management - [149]
Geller D, Budnik I, Barhod T et al.. “The Impact of Emicizumab Prophylaxis on Hospitalizations and Emergency Department Visits Among Hemophilia A Patients Is Age Related.” Pediatric blood & cancer (2024). PMID: 39582123 ↗
L3OTHERCited in: 7. Acute & Emergency Management - [150]
Xing S, Batt K, Kuharic M et al.. “Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.” Journal of managed care & specialty pharmacy (2023). PMID: 37276033 ↗
L3OTHERCited in: 7. Acute & Emergency Management - [151]
Callaghan MU, Negrier C, Paz-Priel I et al.. “Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.” Blood (2021). PMID: 33512413 ↗
L2RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Special Populations & Prevention - [152]
La Mura V, Cardinale V, De Cristofaro R et al.. “Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice.” Blood advances (2024). PMID: 39226466 ↗
L5GUIDELINECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [153]
Mancuso ME, Chan AKC, Shanmukhaiah C et al.. “Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.” The New England journal of medicine (2026). PMID: 42054679 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [154]
Oldenburg J, Mahlangu JN, Kim B et al.. “Emicizumab Prophylaxis in Hemophilia A with Inhibitors.” The New England journal of medicine (2017). PMID: 28691557 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [155]
Matsushita T, Shapiro A, Abraham A et al.. “Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.” The New England journal of medicine (2023). PMID: 37646676 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [156]
Mahlangu J, Oldenburg J, Paz-Priel I et al.. “Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.” The New England journal of medicine (2018). PMID: 30157389 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [157]
Pasi KJ, Rangarajan S, Georgiev P et al.. “Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.” The New England journal of medicine (2017). PMID: 28691885 ↗
L4RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [158]
Matino D, Palladino A, Taylor CT et al.. “Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial.” Blood (2025). PMID: 40608864 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [159]
Matino D, Acharya SS, Taylor CT et al.. “Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.” Blood (2026). PMID: 41351884 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [160]
Young G, Liesner R, Chang T et al.. “A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.” Blood (2019). PMID: 31697801 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [161]
Pipe SW, Collins P, Dhalluin C et al.. “Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.” Blood (2024). PMID: 38127586 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [162]
Mahlangu J, Boban A, Bruzelius M et al.. “Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.” Blood advances (2026). PMID: 41499759 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [163]
Ozelo MC, Mahlangu J, Pasi KJ et al.. “Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.” The New England journal of medicine (2022). PMID: 35294811 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [164]
Srivastava A, Abraham A, Aboobacker F et al.. “Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A.” The New England journal of medicine (2024). PMID: 39655790 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [165]
von Drygalski A, Chowdary P, Kulkarni R et al.. “Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.” The New England journal of medicine (2023). PMID: 36720133 ↗
L2TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 12. Special Populations & Prevention - [166]
Malec L, Peyvandi F, Chan AKC et al.. “Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.” The New England journal of medicine (2024). PMID: 39018533 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 12. Special Populations & Prevention - [167]
Mahlangu J, Kaczmarek R, von Drygalski A et al.. “Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.” The New England journal of medicine (2023). PMID: 36812433 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [168]
George LA, Monahan PE, Eyster ME et al.. “Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.” The New England journal of medicine (2021). PMID: 34788507 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [169]
Rezende SM, Neumann I, Angchaisuksiri P et al.. “International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39043543 ↗
L1GUIDELINECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [170]
Schimansky IM, Dobbelstein C, Klamroth R et al.. “Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A.” Blood advances (2025). PMID: 40795229 ↗
L2TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 10. Complications, 11. Prognosis & Natural History - [171]
Lissitchkov T, Willemze A, Katragadda S et al.. “Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.” Blood advances (2022). PMID: 34794179 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [172]
Agarwal S, Sandza K, Obrochta Moss K et al.. “Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A.” Blood advances (2024). PMID: 39024543 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [173]
Lentz SR, Chowdary P, Gil L et al.. “FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 38142846 ↗
L2RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [174]
Deshpande SR, Joseph K, Tong J et al.. “Adeno-associated virus-based gene therapy for hemophilia A and B: a systematic review and meta-analysis.” Blood advances (2024). PMID: 39374576 ↗
L1SR_OBSCited in: 8. Long-term & Definitive Management - [175]
Madan B, Ozelo MC, Raheja P et al.. “Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38614387 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [176]
Shima M, Amano K, Ogawa Y et al.. “A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 36696195 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 10. Complications - [177]
Samelson-Jones BJ, Doshi BS, George LA. “Coagulation factor VIII: biological basis of emerging hemophilia A therapies.” Blood (2024). PMID: 39088776 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management - [178]
Weyand AC, Pipe SW. “New therapies for hemophilia.” Blood (2018). PMID: 30559264 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management - [179]
Franchini M, Lippi G. “Acquired factor VIII inhibitors.” Blood (2008). PMID: 18463353 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 11. Prognosis & Natural History - [180]
Perrin GQ, Herzog RW, Markusic DM. “Update on clinical gene therapy for hemophilia.” Blood (2018). PMID: 30559260 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Complications - [181]
Kempton CL, Meeks SL. “Toward optimal therapy for inhibitors in hemophilia.” Blood (2014). PMID: 25428222 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Complications - [182]
Callaghan MU, Sidonio R, Pipe SW. “Novel therapeutics for hemophilia and other bleeding disorders.” Blood (2018). PMID: 29769259 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management - [183]
Samelson-Jones BJ, Small JC, George LA. “Roctavian gene therapy for hemophilia A.” Blood advances (2024). PMID: 38991118 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [184]
Johnsen JM, Fletcher SN, Huston H et al.. “Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative.” Blood advances (2017). PMID: 29296726 ↗
L4OTHERCited in: 8. Long-term & Definitive Management - [185]
George LA. “Hemophilia gene therapy comes of age.” Blood advances (2017). PMID: 29296912 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management - [186]
Ragni MV, Mead H, de Jong YP et al.. “Optimizing liver health before and after gene therapy for hemophilia A.” Blood advances (2024). PMID: 38843379 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Complications, 12. Special Populations & Prevention - [187]
Machin N, Ragni MV, Smith KJ. “Gene therapy in hemophilia A: a cost-effectiveness analysis.” Blood advances (2018). PMID: 30042145 ↗
L2OTHERCited in: 8. Long-term & Definitive Management - [188]
Mannucci PM. “Hemophilia therapy: the future has begun.” Haematologica (2020). PMID: 32060150 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management - [189]
Dargaud Y, Leuci A, Ruiz AR et al.. “Efanesoctocog alfa: the renaissance of Factor VIII replacement therapy.” Haematologica (2024). PMID: 38356459 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management - [190]
Sefiane T, McCluskey G, Clavel M et al.. “Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice.” Haematologica (2025). PMID: 40176760 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [191]
Miranda M, Hansen BE, Wehbi B et al.. “FVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4.” Haematologica (2024). PMID: 39665218 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [192]
Loomans JI, Kruip MJHA, Carcao M et al.. “Desmopressin in moderate hemophilia A patients: a treatment worth considering.” Haematologica (2018). PMID: 29305412 ↗
L3OTHERCited in: 8. Long-term & Definitive Management - [193]
Ringler E, Iannazzo SO, Herzig J et al.. “Complement protein C3a enhances adaptive immune responses towards FVIII products.” Haematologica (2023). PMID: 36727395 ↗
L5OTHERCited in: 8. Long-term & Definitive Management, 10. Complications - [194]
Martorell L, Cortina V, Parra R et al.. “Variable readthrough responsiveness of nonsense mutations in hemophilia A.” Haematologica (2020). PMID: 31197069 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [195]
Chaves DG, Velloso-Rodrigues C, Moreau V et al.. “Reactivity profile of anti-factor VIII antibodies with designed synthetic peptides mimicking epitopes of the C2 and a1 domains.” British journal of haematology (2008). PMID: 18422780 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [196]
van Helden PM, van den Berg HM, Gouw SC et al.. “IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.” British journal of haematology (2008). PMID: 18510679 ↗
L2OTHERCited in: 8. Long-term & Definitive Management - [197]
Lyde R, Sabatino D, Sullivan SK et al.. “Platelet-delivered therapeutics.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26149015 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [198]
Franchini M, Favaloro EJ, Lippi G. “Mild hemophilia A.” Journal of thrombosis and haemostasis : JTH (2009). PMID: 19995408 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Prognosis & Natural History - [199]
Teranishi-Ikawa Y, Soeda T, Koga H et al.. “A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37940048 ↗
L5OTHERCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [200]
Johnsen JM, Fletcher SN, Dove A et al.. “Results of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35770352 ↗
L4OTHERCited in: 8. Long-term & Definitive Management - [201]
Valentino LA, Kaczmarek R, Pierce GF et al.. “Hemophilia gene therapy: first, do no harm.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37353081 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [202]
Leavitt AD, Mahlangu J, Raheja P et al.. “Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.” Research and practice in thrombosis and haemostasis (2026). PMID: 42064204 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [203]
Sternberg AR, Watson CT, Davidson RJ et al.. “One-stage Assay Factor VIII Activity Reflects AAV-Derived Factor VIII-Enhanced Thrombin Activation and Predicts Phenotype.” Blood (2026). PMID: 42371804 ↗
L4OTHERCited in: 8. Long-term & Definitive Management - [204]
Young G, Angchaisuksiri P, Apte SJ et al.. “Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.” Blood advances (2026). PMID: 42341325 ↗
L1OTHERCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [205]
Matino D, Acharya SS, Taylor CT et al.. “A plain language summary of the BASIS study looking at people living with severe hemophilia A or B with inhibitors and being treated with marstacimab.” Therapeutic advances in hematology (2026). PMID: 42311704 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [206]
Fouda RT, Argueta DA, Goel Y et al.. “Characterization of a mouse model to study mechanisms of hemophilia A pain.” Blood advances (2026). PMID: 42295153 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [207]
Minno GD, Spadarella G, Borchiellini A et al.. “Italian Patients Journey for Gene Therapy in Haemophilia A.” Haemophilia : the official journal of the World Federation of Hemophilia (2026). PMID: 42290228 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [208]
Foley JH, Petersen KU, Rea CJ et al.. “Solulin increases clot stability in whole blood from humans and dogs with hemophilia.” Blood (2012). PMID: 22234684 ↗
L5TRIAL_NONRANDOMCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [209]
Santagata D, Abenante A, Squizzato A et al.. “Rates of venous thromboembolism and use of thromboprophylaxis after major orthopedic surgery in patients with congenital hemophilia A or B: a systematic review.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38215910 ↗
L2SR_OBSCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 10. Complications, 11. Prognosis & Natural History, 12. Special Populations & Prevention - [210]
Federici AB, Santagostino E, Rumi MG et al.. “The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study.” Haematologica (2006). PMID: 16585016 ↗
L2COHORTCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 10. Complications, 11. Prognosis & Natural History - [211]
Martin K, Key NS. “How I treat patients with inherited bleeding disorders who need anticoagulant therapy.” Blood (2016). PMID: 27106121 ↗
L5REVIEW_NARRATIVECited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [212]
Jiang M, Yang F, Jiang Y et al.. “Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.” Blood (2023). PMID: 37294924 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [213]
Aymonnier K, Kawecki C, Venisse L et al.. “Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.” Blood (2019). PMID: 31383642 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [214]
Chen Y, Schroeder JA, Chen J et al.. “The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.” Blood (2015). PMID: 26668132 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [215]
Ragni MV. “Platelet VIII pack evades immune detection.” Blood (2016). PMID: 26965921 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [216]
Greene TK, Wang C, Hirsch JD et al.. “In vivo efficacy of platelet-delivered, high specific activity factor VIII variants.” Blood (2010). PMID: 20852129 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [217]
Neyman M, Gewirtz J, Poncz M. “Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots.” Blood (2008). PMID: 18559671 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [218]
Shi Q, Kuether EL, Chen Y et al.. “Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.” Blood (2013). PMID: 24269957 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [219]
Rivas-Pollmar MI, Álvarez-Román MT, Butta-Coll NV et al.. “Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 32526092 ↗
L4CASE_REPORTCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 10. Complications - [220]
Gao C, Schroeder JA, Xue F et al.. “Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.” Blood advances (2019). PMID: 31515232 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [221]
Haribhai D, Luo X, Chen J et al.. “TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice.” Blood advances (2016). PMID: 28164173 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [222]
Locke M, Albiez J, Receveur N et al.. “Next-generation FVIIIa-mimetic bispecific antibody NXT007: evaluation in preclinical models of hemostasis and thrombosis.” Blood advances (2026). PMID: 41269788 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [223]
Joo JH, Wang X, Singh S et al.. “Intraosseous delivery of platelet-targeted factor VIII lentiviral vector in humanized NBSGW mice.” Blood advances (2022). PMID: 35849710 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [224]
Wang X, Fu RY, Li C et al.. “Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.” Blood advances (2020). PMID: 33216891 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [225]
Zhang E, Virk ZM, Rodriguez-Lopez J et al.. “Hereditary hemorrhagic telangiectasia may be the most morbid inherited bleeding disorder in women.” Blood advances (2024). PMID: 38593443 ↗
L2OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [226]
Childers KC, Peters SC, Lollar P et al.. “SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa.” Blood advances (2022). PMID: 35255502 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [227]
Yu H, Schroeder JA, Mattson JG et al.. “Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mice.” Blood advances (2026). PMID: 41529228 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [228]
Abache T, Fontayne A, Grenier D et al.. “A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A.” Haematologica (2020). PMID: 33054058 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [229]
Swieringa F, Kuijpers MJ, Lamers MM et al.. “Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow.” Haematologica (2015). PMID: 25769543 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [230]
Eladnani RP, Schaeper U, Diab R et al.. “Enhancing hemostasis potency in hemophilia with a small interfering ribonucleic acid targeting protein S.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40154791 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [231]
Jewell MP, Ashour Z, Baird CH et al.. “Concizumab improves clot formation in hemophilia A under flow.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38815755 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [232]
Desage S, Lienhart A, Janbain M et al.. “Discrepancy between one-stage clotting and chromogenic factor VIII activity in women with hemophilia A and hemophilia A carriers: a retrospective clinical study.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40056988 ↗
L4OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [233]
Chen Y, Li J, Schroeder JA et al.. “Evaluating clinically translatable conditioning for platelet gene therapy in murine hemophilia A with inhibitors.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39127324 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [234]
Childers KC, Peters SC, Spiegel PC. “Structural insights into blood coagulation factor VIII: Procoagulant complexes, membrane binding, and antibody inhibition.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35722946 ↗
L5REVIEW_NARRATIVECited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [235]
Ju Y, Jiang W, Liu H et al.. “Perioperative Hematological Outcomes of Simultaneous Double Total Joint Arthroplasty for Hemophilic Arthritis of the Hip and Knee: A Retrospective Study.” The Journal of arthroplasty (2024). PMID: 39622424 ↗
L4COHORTCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [236]
Zhang Q, Zhao L, Riva N et al.. “Incidence of deep venous thrombosis in patients with hemophilia undergoing bilateral simultaneous total knee arthroplasty: a retrospective cohort study.” BMC musculoskeletal disorders (2024). PMID: 38658972 ↗
L2COHORTCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [237]
Pacheco Zavala E, Vargas Oliva C, Santibañez Bedolla KE et al.. “Adult People with Hemophilia A Have Low Annualized Bleeding Rate, However the Arthropathy Remains a Burden: A Retrospective Cohort Study.” Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion (2024). PMID: 39011249 ↗
L4COHORTCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [238]
Kraemmer D, Ay C, Rejtő J et al.. “Comparison of People with Hemophilia A and Patients with Nonvalvular Atrial Fibrillation on Oral Anticoagulation by Thrombin Generation.” Thrombosis and haemostasis (2026). PMID: 42190734 ↗
L4OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [239]
Bosch A, Alberio L, Fontana P et al.. “The Swiss Haemophilia Registry-Report From the First 8 Years.” Haemophilia : the official journal of the World Federation of Hemophilia (2026). PMID: 42012793 ↗
L2OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [240]
Sidonio RF, Corrales-Medina FF, Johnsen JM et al.. “Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?” Therapeutic advances in hematology (2026). PMID: 41947822 ↗
L5REVIEW_NARRATIVECited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [241]
Steeghs TJ, van Engelshoven L, Coolen NMM et al.. “A chemiluminescent microfluidic thrombin generation assay for real-time monitoring in patient plasma.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41692093 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [242]
Kumar R, Dunn AL, Schneiderman JE et al.. “Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial.” Blood (2022). PMID: 35839450 ↗
L1RCTCited in: History and Evolution of Treatment - [243]
Klamroth R, Windyga J, Radulescu V et al.. “Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study.” Blood (2021). PMID: 33150384 ↗
L1RCTCited in: History and Evolution of Treatment - [244]
Shapiro AD, Angchaisuksiri P, Astermark J et al.. “Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.” Blood (2019). PMID: 31444162 ↗
L2RCTCited in: History and Evolution of Treatment, 12. Special Populations & Prevention - [245]
Mahlangu J, Powell JS, Ragni MV et al.. “Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.” Blood (2013). PMID: 24227821 ↗
L1RCTCited in: History and Evolution of Treatment - [246]
Leissinger C, Gringeri A, Antmen B et al.. “Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.” The New England journal of medicine (2011). PMID: 22047559 ↗
L1RCTCited in: History and Evolution of Treatment, 11. Prognosis & Natural History - [247]
Konkle BA, Stasyshyn O, Chowdary P et al.. “Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.” Blood (2015). PMID: 26157075 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [248]
Lusher JM, Arkin S, Abildgaard CF et al.. “Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.” The New England journal of medicine (1993). PMID: 8421474 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [249]
Di Minno MND, Calcaterra IL, Baldacci E et al.. “Intensive FVIII replacement in hemophilia patients with hypertrophic synovium: a randomized study.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39476971 ↗
L1RCTCited in: History and Evolution of Treatment, 11. Prognosis & Natural History - [250]
High KA. “The gene therapy journey for hemophilia: are we there yet?” Blood (2012). PMID: 22829631 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [251]
van Stam LE, Daisy Horstman BJ, Angchaisuksiri P et al.. “The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41643940 ↗
L4GUIDELINECited in: History and Evolution of Treatment, 12. Special Populations & Prevention - [252]
Srivaths L, Larson J, Fijnvandraat K et al.. “Chromogenic vs one-stage assay to diagnose women and girls with hemophilia A-mapping global approaches and assessing challenges: communication from the SSCs of the ISTH.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40374114 ↗
L4GUIDELINECited in: History and Evolution of Treatment, 12. Special Populations & Prevention - [253]
Alcedo Andrade PE, Mannucci PM, Kessler CM. “Emicizumab: the hemophilia A game-changer.” Haematologica (2024). PMID: 37916312 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [254]
Batty P, Lillicrap D. “Adeno-associated viral vector integration: implications for long-term efficacy and safety.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39097231 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, 11. Prognosis & Natural History - [255]
Mokhtar G, El-Beshlawy A, Alfy ME et al.. “Updated Egyptian national guidelines for management of hemophilia A in children & adolescents.” Annals of hematology (2025). PMID: 41065813 ↗
L5GUIDELINECited in: History and Evolution of Treatment - [256]
de Biasi R, Miraglia E, Mastrullo L et al.. “Kaposi's sarcoma as clinical manifestation of the acquired immunodeficiency syndrome in a hemophilic patient.” Haematologica (1989). PMID: 2511103 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [257]
Krumb E, Lambert C, Van Damme A et al.. “Proactive systematic hemophilia carrier screening: a step toward gender equity in hemophilia care.” Blood advances (2024). PMID: 39167764 ↗
L2OTHERCited in: History and Evolution of Treatment, 12. Special Populations & Prevention - [258]
Schweiger H, Rejtő J, Hofbauer CJ et al.. “Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors.” Blood advances (2022). PMID: 34847225 ↗
L3OTHERCited in: History and Evolution of Treatment, 10. Complications - [259]
Agosti P, Siboni SM, Scardo S et al.. “Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A.” Blood advances (2023). PMID: 37871302 ↗
L3OTHERCited in: History and Evolution of Treatment - [260]
Merlin S, Famà R, Borroni E et al.. “FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.” Blood advances (2019). PMID: 30862611 ↗
L2OTHERCited in: History and Evolution of Treatment - [261]
Kim B, Song J, Kang J et al.. “A first-in-human study assessing the safety, pharmacokinetics, and pharmacodynamics of TU7710, a recombinant factor VIIa-transferrin fusion protein, in warfarin-pretreated healthy male participants.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41651288 ↗
L1RCTCited in: History and Evolution of Treatment - [262]
Tiede A, Abdul Karim F, Jiménez-Yuste V et al.. “Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model.” Haematologica (2021). PMID: 32327501 ↗
L2OTHERCited in: History and Evolution of Treatment - [263]
Astermark J, Oldenburg J, Escobar M et al.. “The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A.” Haematologica (2005). PMID: 15996930 ↗
L3OTHERCited in: History and Evolution of Treatment - [264]
Abrantes JA, Solms A, Garmann D et al.. “Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients.” Haematologica (2019). PMID: 31371418 ↗
L2OTHERCited in: History and Evolution of Treatment - [265]
Melchiorre D, Linari S, Manetti M et al.. “Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A.” Haematologica (2015). PMID: 26494839 ↗
L3OTHERCited in: History and Evolution of Treatment - [266]
Lorenzo JI, Moscardó F, López-Aldeguer J et al.. “Progression to acquired immunodeficiency syndrome in 94 human immunodeficiency virus-positive hemophiliacs with long-term follow-up.” Haematologica (2001). PMID: 11357820 ↗
L2OTHERCited in: History and Evolution of Treatment - [267]
Quon DV, Escobar M, Boggio L et al.. “A New Risk-Based Scoring Approach to Individualize Prophylaxis in Patients with Hemophilia A: Results from the PREDICT Study.” Advances in therapy (2026). PMID: 41886249 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment, 11. Prognosis & Natural History - [268]
Makkar M, Dhinakaran MS, Shukla P et al.. “Effectiveness of myofascial therapy (MFT) along with traditional physiotherapy and intermittent prophylaxis on short-term improvement of joint health in hemophilic arthropathy: a randomized control trial.” Expert review of hematology (2025). PMID: 40249018 ↗
L1RCTCited in: History and Evolution of Treatment - [269]
Carcao M, Schiavulli M, Kulkarni R et al.. “A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial.” Blood advances (2024). PMID: 38266154 ↗
L1TRIAL_NONRANDOMCited in: 10. Complications - [270]
Carlson AL, Althouse J, Ahmed N et al.. “Acquired hemophilia A following SARS-CoV-2 infection and vaccination: clinical summary and insights.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 41110512 ↗
L1SR_OBSCited in: 10. Complications - [271]
Hay CRM, Nissen F, Pipe SW. “Mortality in congenital hemophilia A - a systematic literature review.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 33331043 ↗
L1SR_OBSCited in: 10. Complications, 11. Prognosis & Natural History - [272]
Muczynski V, Christophe OD, Tanner L et al.. “Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody.” Blood (2025). PMID: 40983037 ↗
L2OTHERCited in: 10. Complications - [273]
Lai J, Hough C, Tarrant J et al.. “Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.” Blood (2017). PMID: 28432221 ↗
L5REVIEW_NARRATIVECited in: 10. Complications - [274]
Pratt KP, Gunasekera D, Vir P et al.. “Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?” Blood advances (2023). PMID: 36459498 ↗
L3OTHERCited in: 10. Complications - [275]
Vander Kooi A, Wang S, Fan MN et al.. “Influence of N-glycosylation in the A and C domains on the immunogenicity of factor VIII.” Blood advances (2022). PMID: 35511725 ↗
L3OTHERCited in: 10. Complications - [276]
Lai JD, Swystun LL, Cartier D et al.. “N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice.” Haematologica (2018). PMID: 30002126 ↗
L5OTHERCited in: 10. Complications - [277]
Peyron I, Hartholt RB, Pedró-Cos L et al.. “Comparative profiling of HLA-DR and HLA-DQ associated factor VIII peptides presented by monocyte-derived dendritic cells.” Haematologica (2017). PMID: 29025906 ↗
L5OTHERCited in: 10. Complications - [278]
Rayes J, Ing M, Delignat S et al.. “Complement C3 is a novel modulator of the anti-factor VIII immune response.” Haematologica (2017). PMID: 29146705 ↗
L5OTHERCited in: 10. Complications - [279]
Famà R, Borroni E, Merlin S et al.. “Deciphering the Ets-1/2-mediated transcriptional regulation of F8 gene identifies a minimal F8 promoter for hemophilia A gene therapy.” Haematologica (2021). PMID: 32467137 ↗
L5OTHERCited in: 10. Complications - [280]
Chen L, Lin S, Zhou W et al.. “Prosthesis survival situation and complications following total hip arthroplasty in hemophilic patients: a systematic review.” BMC musculoskeletal disorders (2025). PMID: 40634963 ↗
L2SR_OBSCited in: 10. Complications - [281]
Rungjirajittranon T, Suwanawiboon B, Nakkinkun Y et al.. “First-line immunosuppressive therapies for acquired hemophilia A: A 25-year cohort experience and network meta-analysis.” Thrombosis research (2024). PMID: 38970991 ↗
L2SR_OBSCited in: 10. Complications - [282]
Sun C, Yu J, Sun J et al.. “Case Report: Coexisting cold agglutinin disease and acquired hemophilia A: a rituximab-responsive dual autoimmune disorder.” Frontiers in medicine (2025). PMID: 41179883 ↗
L4CASE_REPORTCited in: 10. Complications - [283]
Laan S, Del Castillo Alferez J, Cannegieter S et al.. “DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis.” Blood (2025). PMID: 39854691 ↗
L1SR_OBSCited in: 11. Prognosis & Natural History, 12. Special Populations & Prevention - [284]
Tagariello G, Iorio A, Santagostino E et al.. “Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders.” Blood (2009). PMID: 19357395 ↗
L2SR_OBSCited in: 11. Prognosis & Natural History - [285]
Kraemmer D, Königsbrügge O, Moik F et al.. “Pharmacokinetic-guided versus standard prophylaxis in hemophilia: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37739039 ↗
L2SR_OBSCited in: 11. Prognosis & Natural History, 12. Special Populations & Prevention - [286]
Leebeek FWG, Miesbach W. “Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues.” Blood (2021). PMID: 34232980 ↗
L5REVIEW_NARRATIVECited in: 11. Prognosis & Natural History - [287]
Glaeser-Khan S, Ito S, Sra M et al.. “Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis.” Blood advances (2025). PMID: 40795232 ↗
L2OTHERCited in: 11. Prognosis & Natural History - [288]
Lim MY, Cheng D, Recht M et al.. “Inhibitors and mortality in persons with nonsevere hemophilia A in the United States.” Blood advances (2020). PMID: 33007074 ↗
L2OTHERCited in: 11. Prognosis & Natural History - [289]
Hassan S, Baselli G, Mollica L et al.. “Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort.” Blood advances (2024). PMID: 38593222 ↗
L2OTHERCited in: 11. Prognosis & Natural History - [290]
Fischer K, Pouw ME, Lewandowski D et al.. “A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.” Haematologica (2011). PMID: 21273268 ↗
L2OTHERCited in: 11. Prognosis & Natural History - [291]
Zou M, Zhan K, Feng X et al.. “Autoimmune Bullous Disease Combined With Acquired Hemophilia A: A Systematic Review and Case Analysis.” The Journal of dermatology (2025). PMID: 40325518 ↗
L4SR_OBSCited in: 11. Prognosis & Natural History - [292]
BaHeTe A, Shao Y, Kang P. “Clinical outcomes of total hip and knee arthroplasty for end-stage hemophilic arthropathy in patients with hemophilia: a retrospective study.” Journal of orthopaedic surgery and research (2025). PMID: 40420097 ↗
L4COHORTCited in: 11. Prognosis & Natural History - [293]
Swystun LL, Ogiwara K, Rawley O et al.. “Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.” Blood (2019). PMID: 31350267 ↗
L2TRIAL_NONRANDOMCited in: 12. Special Populations & Prevention - [294]
Escobar M, Lassila R, Bekdache C et al.. “Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39571935 ↗
L1GUIDELINECited in: 12. Special Populations & Prevention - [295]
Malec L, Mathias M, Dunn AL et al.. “Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40701256 ↗
L2TRIAL_NONRANDOMCited in: 12. Special Populations & Prevention - [296]
Leebeek FWG, Duvekot J, Kruip MJHA. “How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease.” Blood (2020). PMID: 32797211 ↗
L5CASE_REPORTCited in: 12. Special Populations & Prevention - [297]
Shapiro AD. “Concizumab: a novel anti-TFPI therapeutic for hemophilia.” Blood advances (2021). PMID: 33570646 ↗
L5OTHERCited in: 12. Special Populations & Prevention - [298]
Oleshko O, Werwitzke S, Klingberg A et al.. “Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study.” Blood advances (2023). PMID: 35947142 ↗
L3OTHERCited in: 12. Special Populations & Prevention - [299]
Kurnik K, Kreuz W, Horneff S et al.. “Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys.” Haematologica (2007). PMID: 17606451 ↗
L2OTHERCited in: 12. Special Populations & Prevention - [300]
Russick J, Delignat S, Milanov P et al.. “Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA.” Haematologica (2019). PMID: 31289204 ↗
L5OTHERCited in: 12. Special Populations & Prevention - [301]
Sherief LM, Elagamy O, Darwish A et al.. “Emicizumab prophylaxis beyond clinical trials: a multicenter, prospective real-world study of pediatric hemophilia patients with and without inhibitors.” European journal of pediatrics (2026). PMID: 41964698 ↗
L4TRIAL_NONRANDOMCited in: 12. Special Populations & Prevention - [302]
Carcao M, Königs C, Andersson NG et al.. “Predictors of immune tolerance induction success in 231 children with severe hemophilia A with high-titer inhibitors - lessons learned from the PedNet prospective cohort study.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40706963 ↗
L2COHORTCited in: 12. Special Populations & Prevention - [303]
Suita N, Kanemaru A, Komori N et al.. “Role of cross-mixing tests in differentiating etiologies of prolonged aPTT: a single-center retrospective study.” International journal of hematology (2026). PMID: 42204127 ↗
L4COHORTCited in: 12. Special Populations & Prevention - [304]
Wilson RD, De Bie I, Armour CM et al.. “Joint SOGC-CCMG Opinion for Reproductive Genetic Carrier Screening: An Update for All Canadian Providers of Maternity and Reproductive Healthcare in the Era of Direct-to-Consumer Testing.” Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC (2016). PMID: 27638987 ↗
L1bCited in: 1. Definition, Classification & Nomenclature - [305]
Rosas S, Buller LT, Plate J et al.. “Total Knee Arthroplasty among Medicare Beneficiaries with Hemophilia A and B Is Associated with Increased Complications and Higher Costs.” The journal of knee surgery (2019). PMID: 31499568 ↗
L3bCited in: 1. Definition, Classification & Nomenclature - [306]
Omura K, Tsuchiya S. “The Patient Experience of Hemophilia and Human Immunodeficiency Virus: A Systematic Review of Qualitative Evidence.” JBI library of systematic reviews (2012). PMID: 27820530 ↗
L1aCited in: 1. Definition, Classification & Nomenclature - [307]
Al Moosawi M, Nicolson H, Wong SKW et al.. “Treatment changes in hemophilia A with chromogenic factor VIII assay implementation.” Research and practice in thrombosis and haemostasis (2023). PMID: 37063773 ↗
L3bCited in: 1. Definition, Classification & Nomenclature - [308]
Rodeghiero F, Ghiotto L, Pontalto L et al.. “Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype.” HemaSphere (2025). PMID: 40134524 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [309]
Dushimova Z, Pashimov M, Kaibullayeva J et al.. “Therapeutic advances in hemophilia: from molecular innovation to patient-centered global care.” Frontiers in medicine (2025). PMID: 41080961 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [310]
Ramiz S, Hartmann J, Young G et al.. “Clinical utility of viscoelastic testing (TEG and ROTEM analyzers) in the management of old and new therapies for hemophilia.” American journal of hematology (2018). PMID: 30328141 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [311]
Hirniak S, Samuel C, Aditi F et al.. “Symptoms, Diagnosis, and Treatment for Women and Girls With Hemophilia: A Narrative Review.” Haemophilia : the official journal of the World Federation of Hemophilia (2026). PMID: 42438295 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [312]
Payne AB, Miller CH, Kelly FM et al.. “The CDC Hemophilia A Mutation Project (CHAMP) mutation list: a new online resource.” Human mutation (2012). PMID: 23280990 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [313]
Alexander WA, Jensen I, Hathway J et al.. “Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements.” Journal of managed care & specialty pharmacy (2022). PMID: 35343812 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [314]
Punj S, Akkari Y, Huang J et al.. “Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory.” American journal of human genetics (2018). PMID: 29754767 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [315]
Cygan PH, Weidman EA, Wang X et al.. “Integrative modeling to improve bleeding risk prediction in adult female hemophilia A carriers.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41679506 ↗
L3bCited in: 2. Pathophysiology & Mechanism - [316]
Huang YC, Wang WL, Lin HY et al.. “Genotype-Specific Postural Control Deficits in Hemophilia A: Insights from Center of Pressure Analysis Beyond Radiographic Arthropathy.” International journal of molecular sciences (2026). PMID: 41828546 ↗
L4Cited in: 2. Pathophysiology & Mechanism - [317]
Marco-Rico A, Calvo-Villas JM, López-Jaime FJ et al.. “Real-World Evidence on Joint Condition in Non-Severe Hemophilia A Patients: A Multicenter Study.” Journal of blood medicine (2025). PMID: 40417706 ↗
L4Cited in: 2. Pathophysiology & Mechanism - [318]
Måseide RJ, Berntorp E, Astermark J et al.. “Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study).” Research and practice in thrombosis and haemostasis (2024). PMID: 39807249 ↗
L3bCited in: 2. Pathophysiology & Mechanism - [319]
Lin SY, Chen M, Chang SP et al.. “Non-Inversion Variants in Sporadic Hemophilia A Rarely Recur.” International journal of molecular sciences (2026). PMID: 42123421 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [320]
Zhou Y, Shen Y, Yao SX et al.. “Pioglitazone and metformin attenuate hemophilic arthropathy progression via peroxisome proliferator-activated receptor signaling pathway activation.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42107709 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [321]
Hemaliya C, Singh AK, Bharti A et al.. “Molecular Characterization of Factor VIII Gene Variants in Hemophilia A: A Genotype-Haplotype Study from Eastern and Northern-Central India.” Nanotheranostics (2026). PMID: 42099969 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [322]
Kao YT, Yen CC, Ro-Lin Chang G et al.. “Non-viral gene therapy for hemophilia A: long-term outcomes of minicircle FVIII delivery in a mouse model.” Frontiers in pharmacology (2026). PMID: 42038313 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [323]
Avishai E, Dardik R, Rubinstein L et al.. “Deleterious NKAP Mutations Are Associated with Musculoskeletal Abnormalities in Hemizygous Males and Skewed X Chromosome Inactivation in Heterozygous Females.” International journal of molecular sciences (2026). PMID: 41828556 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [324]
Contente S, Ahmed AE, Konkle BA et al.. “Human leukocyte antigen alleles associated with inhibitor development in severe hemophilia A: analysis of the "My Life, Our Future" hemophilia A cohort.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41644240 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [325]
Manderstedt E, Lind-Halldén C, Halldén C et al.. “Noncarrier mothers of hemophilia A patients with Intron 22 inversions often have other rearrangements.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41500367 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [326]
Liu Z, Srivastava V, Hussain A et al.. “Ribosomal read through as an alternative therapy for patients with hemophilia with nonsense mutations.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 41083003 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [327]
de Vaan A, Kruip MJHA, Eikenboom J et al.. “Enhanced peripartum hemostatic management does not decrease postpartum hemorrhage incidence in hemophilia carriers: the Pregnancy and Inherited Bleeding Disorders study.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41796747 ↗
L2bCited in: 3. Epidemiology, Etiology & Risk Factors - [328]
Mahlangu J, Matino D, Benítez Hidalgo O et al.. “Management of breakthrough bleeds and surgical procedures in participants with hemophilia A or B without inhibitors receiving marstacimab prophylaxis in the phase 3 BASIS study.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42107711 ↗
L2bCited in: 3. Epidemiology, Etiology & Risk Factors - [329]
da Conceição Bezerra AF, Batista-Rodrigues YK, Rezende SM et al.. “The role of interleukin-10 gene variants in inhibitor development in hemophilia: A meta-analysis.” Thrombosis research (2025). PMID: 40815904 ↗
L2aCited in: 3. Epidemiology, Etiology & Risk Factors - [330]
Ma S, Sun Y, Zhou W et al.. “Lipopolysaccharide-binding protein functions as factor VIII inhibitor in bullous pemphigoid associated with acquired hemophilia A.” Archives of dermatological research (2025). PMID: 40095178 ↗
L4Cited in: 3. Epidemiology, Etiology & Risk Factors - [331]
Ay Tuncel D, Şaşmaz Hİ, Antmen B. “Outcome and Predisposing Factors for Intracranial Hemorrhage in Turkish Children with Hemophilia.” Journal of clinical medicine (2025). PMID: 39941359 ↗
L4Cited in: 3. Epidemiology, Etiology & Risk Factors - [332]
Mrakotsky C, Walsh KS, Buranahirun Burns C et al.. “The eTHINK Study: Cognitive and Behavioral Outcomes in Children with Hemophilia.” The Journal of pediatrics (2024). PMID: 38734133 ↗
L3bCited in: 3. Epidemiology, Etiology & Risk Factors - [333]
Jiménez-Yuste V, Oldenburg J, Tzeng E et al.. “Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.” Research and practice in thrombosis and haemostasis (2024). PMID: 38783987 ↗
L2bCited in: 3. Epidemiology, Etiology & Risk Factors - [334]
Olasupo OO, Noronha N, Lowe MS et al.. “Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.” The Cochrane database of systematic reviews (2026). PMID: 41873813 ↗
L1aCited in: 3. Epidemiology, Etiology & Risk Factors - [335]
Olasupo OO, Noronha N, Lowe MS et al.. “Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.” The Cochrane database of systematic reviews (2024). PMID: 38411279 ↗
L1aCited in: 3. Epidemiology, Etiology & Risk Factors - [336]
Bordbar M, Beigipour R, Tahami M et al.. “Skeletal complications in patients with hemophilia: a single-center experience.” Journal of orthopaedic surgery and research (2023). PMID: 38017431 ↗
L4Cited in: 3. Epidemiology, Etiology & Risk Factors - [337]
Perrone S, Tomasello R, Raso S et al.. “Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma.” Annals of hematology (2026). PMID: 42105103 ↗
L4Cited in: 3. Epidemiology, Etiology & Risk Factors - [338]
Abumahfouz MAM, Al-Sadi A, Alshurafa A et al.. “Successful eradication of acquired factor VIII inhibitors with rituximab: a report of two cases.” Hematology (Amsterdam, Netherlands) (2024). PMID: 39526835 ↗
L1bCited in: 4. Clinical Presentation - [339]
Kumar M, Badagabettu S, Pai KM et al.. “Evidence-based dental management strategies for individuals with congenital hemophilia: a systematic review.” BMC oral health (2026). PMID: 41618283 ↗
L1aCited in: 4. Clinical Presentation - [340]
Razmpoosh E, Olasupo OO, Bhatt M et al.. “Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously untreated or minimally treated children with hemophilia A or B.” The Cochrane database of systematic reviews (2025). PMID: 40838439 ↗
L1aCited in: 4. Clinical Presentation - [341]
Ceglédi A, Bátai Á, Dolgos J et al.. “Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol.” Pathology oncology research : POR (2024). PMID: 38846411 ↗
L3bCited in: 4. Clinical Presentation - [342]
Garcia J, Hussain T, Dillenbeck J et al.. “T2* Magnetic Resonance Imaging Uncovers Hemosiderin Burden in Pediatric Hemophilia: A Call for Sensitive Imaging Biomarkers.” Pediatric blood & cancer (2026). PMID: 42496612 ↗
L5Cited in: 4. Clinical Presentation - [343]
Zhang N, Carcao M, Ignas DM et al.. “Comparison of Magnetic Resonance Imaging Scales for Assessment of Interval Changes of Arthropathy in Boys with Severe Hemophilia.” Journal of clinical medicine (2025). PMID: 40649172 ↗
L5Cited in: 4. Clinical Presentation - [344]
Lee JS, Schuldt R, Xia Z et al.. “Real-world adherence to and persistence with emicizumab in people with hemophilia A using a national claims database.” Journal of managed care & specialty pharmacy (2026). PMID: 41636686 ↗
L3bCited in: 5. Diagnosis & Workup - [345]
Hilberg T, Schmidt A, Strauss AC et al.. “Pain diagnostics in people with hemophilia - pain pressure thresholds and influence of age and joint status.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 41197804 ↗
L3bCited in: 5. Diagnosis & Workup - [346]
El-Ghamrawy M, Abdelhady M, Zahran SMF et al.. “Characterization of Inherited Bleeding Disorders in Egyptian Children in a Tertiary Care Center: A 10 Years Experience.” Journal of blood medicine (2026). PMID: 42039087 ↗
L3bCited in: 5. Diagnosis & Workup - [347]
Hochart A, Wibaut B, Terriou L et al.. “Prepartum Acquired Hemophilia A: Managing a Double Challenge for Mother and Child.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42431314 ↗
L4Cited in: 5. Diagnosis & Workup - [348]
Seidizadeh O, Peyvandi F, Mannucci PM. “Hemophilia A and von Willebrand disease: parallel therapeutic advances in the most common inherited bleeding disorders.” Haematologica (2026). PMID: 42489058 ↗
L5Cited in: 5. Diagnosis & Workup - [349]
Mortarino M, Garagiola I, Nicotra V et al.. “Preimplantation Genetic Testing for Families at Risk of Haemophilia: Ten-Year Single-Centre Experience.” Haemophilia : the official journal of the World Federation of Hemophilia (2026). PMID: 42415645 ↗
L5Cited in: 5. Diagnosis & Workup - [350]
Kharat S, Jivani F, Patil K et al.. “A rapid point-of-care test for the diagnosis of factor VIII inhibitors in hemophilia A patients.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42019567 ↗
L5Cited in: 5. Diagnosis & Workup - [351]
Yin S, Mu H, Yang W et al.. “Outcomes of low-dose immune tolerance induction with single-dose rituximab in severe hemophilia A: a single-center retrospective experience.” Frontiers in immunology (2026). PMID: 42148133 ↗
L4Cited in: 6. Staging, Risk Stratification & Prognostic Scoring - [352]
Molinari AC, Baldacci E, Barillari G et al.. “Integrating Clinical, Functional, and Patient-Reported Outcomes in Haemophilia Care: A Delphi-Based Consensus on a New Monitoring Tool.” Journal of clinical medicine (2026). PMID: 41976833 ↗
L4Cited in: 6. Staging, Risk Stratification & Prognostic Scoring - [353]
Shi M, Ma Y, Peng X et al.. “Clinical validation and application of targeted long-range polymerase chain reaction and long-read sequencing-based analysis for hemophilia: experience from a hemophilia treatment center in China.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39260745 ↗
L4Cited in: 6. Staging, Risk Stratification & Prognostic Scoring - [354]
Chang CY, Chiou SS, Weng TF et al.. “Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A.” Journal of clinical medicine (2023). PMID: 36983209 ↗
L3bCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [355]
Bernardo Á, Caro A, Martínez-Carballeira D et al.. “Applicability of the Thrombin Generation Test to Evaluate the Hemostatic Status of Hemophilia A Patients in Daily Clinical Practice.” Journal of clinical medicine (2022). PMID: 35743412 ↗
L3bCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [356]
Marco-Rico A, Calvo-Villas JM, Lopez-Jaime FJ et al.. “Joint Damage Prediction in Non-Severe Hemophilia A with Artificial Intelligence.” Journal of blood medicine (2026). PMID: 41883838 ↗
L2bCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [357]
Li Z, Chen Z, Liu G et al.. “Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.” Research and practice in thrombosis and haemostasis (2021). PMID: 34278191 ↗
L2bCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [358]
Fedewa SA, Buckner TW, Parks SG et al.. “Racial and Ethnic Differences in Distress, Depression, and Quality of Life in people with hemophilia.” Journal of racial and ethnic health disparities (2023). PMID: 37133726 ↗
L3bCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [359]
Badulescu OV, Sirbu PD, Ciocoiu M et al.. “Venous Thromboembolism Prophylaxis in Hemophilic Patients Undergoing Total Hip or Knee Arthroplasty: Insights from a Single-Center Experience.” Medicina (Kaunas, Lithuania) (2025). PMID: 40282860 ↗
L4Cited in: 6. Staging, Risk Stratification & Prognostic Scoring - [360]
Reich L, Gatzke F, Rauchfuss S et al.. “Prognostic factors for recurrence in acquired hemophilia A-results from a long-term observational study.” Research and practice in thrombosis and haemostasis (2025). PMID: 40177223 ↗
L4Cited in: 6. Staging, Risk Stratification & Prognostic Scoring - [361]
Peng M, Li S, Wu X et al.. “Perioperative blood management and clinical outcomes in patients with hemophilia undergoing total joint arthroplasty: Our long-term results.” Joint diseases and related surgery (2026). PMID: 42542909 ↗
L3bCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [362]
Radhakrishnan N, Singh A, Pandharipande A et al.. “Managing massive gastrointestinal and abdominal haemorrhage in inherited bleeding disorders: experience from a pediatric cohort.” International journal of hematology (2026). PMID: 41746495 ↗
L4Cited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [363]
Chang IW, Truman M, Yee C et al.. “Characteristics and posttransplant outcomes of patients with congenital and acquired von Willebrand disease and hemophilia A and with renal transplants.” Research and practice in thrombosis and haemostasis (2025). PMID: 41509549 ↗
L4Cited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [364]
George AR, Sylvester KW, Kanaan DM et al.. “Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2025). PMID: 41379429 ↗
L4Cited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [365]
Olcar S, Elverdi T, Bolayırlı İM et al.. “Citrullinated Histone 3 as a Marker of NETosis at Opposite Ends of Hemostasis: Evidence From Thrombosis-Prone MPN and Bleeding-Prone Hemophilia.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2026). PMID: 42330249 ↗
L4Cited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [366]
Morris JJ, Davidson RJ, Watson CT et al.. “Factor VIII Aurora: A Naturally Occurring Gain of Function FVIII Variant with Enhanced FIXa Affinity.” Blood (2026). PMID: 42446089 ↗
L5Cited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [367]
Galeotti C, Rauch A, Gatti H et al.. “Real-World Effectiveness and Safety of Concizumab Prophylaxis in Hemophilia: Results From a National French Cohort.” Haemophilia : the official journal of the World Federation of Hemophilia (2026). PMID: 42028818 ↗
L4Cited in: History and Evolution of Treatment - [368]
Reding MT, Alvarez Román MT, Castaman G et al.. “Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM-POWR Study.” European journal of haematology (2025). PMID: 41122986 ↗
L4Cited in: History and Evolution of Treatment - [369]
Çege MA, Öztürk Gündoğdu Ö, Kaya Z et al.. “Assessment of Mandibular Trabecular Bone by Fractal Analysis on Digital Panoramic Radiograph in Patients with Inherited Bleeding Disorder.” Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (2025). PMID: 40798846 ↗
L4Cited in: History and Evolution of Treatment - [370]
Santos S, Robinson TM, Trueman D. “Estimated Long-Term Durability of Valoctocogene Roxaparvovec Treatment in Male patients with Severe Hemophilia A: An Extrapolation of Clinical Data.” Advances in therapy (2025). PMID: 40986187 ↗
L4Cited in: History and Evolution of Treatment - [371]
Luo Z, Zhong X, Zhang C et al.. “Prophylactic Factor Replacement Versus on-Demand Factor Replacement Following Primary Total Knee Arthroplasty in Patients With Hemophilia: A Retrospective Study With an Average 10-Year Follow-up.” Haemophilia : the official journal of the World Federation of Hemophilia (2026). PMID: 42402972 ↗
L2bCited in: 11. Prognosis & Natural History - [372]
Calcaterra I, De Luca C, D'Errico G et al.. “Emicizumab in Acquired Hemophilia A: A Real-World Case Series with Patient-Level Outcome Analysis.” Seminars in thrombosis and hemostasis (2026). PMID: 41534873 ↗
L4Cited in: 11. Prognosis & Natural History - [373]
Di Minno MND, Baldacci E, Calcaterra IL et al.. “Changes in Hypertrophic Synovium Status in Adult Patients With Severe Hemophilia A Receiving Emicizumab Prophylaxis: The RESOLVE Study.” Haemophilia : the official journal of the World Federation of Hemophilia (2026). PMID: 42659051 ↗
L3bCited in: 11. Prognosis & Natural History - [374]
Angchaisuksiri P, von Mackensen S, Apte S et al.. “Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study.” Research and practice in thrombosis and haemostasis (2025). PMID: 40166710 ↗
L2bCited in: 11. Prognosis & Natural History - [375]
Ye L, Liu Z, Cao J et al.. “Assessing stigma in a predominantly male hemophilia population: a Chinese cross-sectional study.” Frontiers in psychiatry (2025). PMID: 40530051 ↗
L3bCited in: 11. Prognosis & Natural History - [376]
Mansouri Z, Ashtari S, Ghaemi M et al.. “Pregnancy outcomes among women with inherited bleeding disorders: A matched case-control study.” SAGE open medicine (2026). PMID: 42643529 ↗
L3bCited in: 11. Prognosis & Natural History - [377]
Franco VKB, Camelo RM, Dias MM et al.. “Cost of immune tolerance induction according to its outcome in people with hemophilia A and inhibitors: results from the Co$tIT study.” Thrombosis research (2025). PMID: 40344788 ↗
L3bCited in: 11. Prognosis & Natural History - [378]
Iorio A, Germini F, Ibrahim Q et al.. “Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry.” Blood advances (2026). PMID: 42466987 ↗
L3bCited in: 12. Special Populations & Prevention - [379]
Dutta A, Dutta TS, Borboruah L et al.. “Twelve-month follow-up of a real-world, noninterventional study evaluating the impact of emicizumab on bleeding episodes, joint health, and quality of life in people with hemophilia A.” Therapeutic advances in hematology (2026). PMID: 41695781 ↗
L3bCited in: 12. Special Populations & Prevention - [380]
Zhao Z, Zhao G, Li S et al.. “MLDP-AS: an optimized next-generation sequencing assay for enhanced detection of technically challenging variants in expanded carrier screening.” Journal of translational medicine (2026). PMID: 41691275 ↗
L3bCited in: 12. Special Populations & Prevention - [381]
Ye J, Huang K. “Transition to Emicizumab from standard-dose FVIII prophylaxis in young children with hemophilia A: a real-world study.” Thrombosis journal (2026). PMID: 42082983 ↗
L3bCited in: 12. Special Populations & Prevention - [382]
Kinai E, Yamaguchi M, Shirahata A. “Interfacility Collaboration for Hemophilia Care in Japan: A Retrospective Database Study Using a Japanese Healthcare Claims Database.” Health science reports (2026). PMID: 41552376 ↗
L3bCited in: 12. Special Populations & Prevention - [383]
Yi Y, Niu B, Duffett L et al.. “Neuraxial analgesia in pregnant individuals with bleeding disorders: a retrospective descriptive study of obstetric anesthesia practices and outcomes.” Research and practice in thrombosis and haemostasis (2025). PMID: 41208942 ↗
L4Cited in: 12. Special Populations & Prevention - [384]
Solgun HA, Ozay M. “Clinical and Surgical Experiences with Efmoroctocog Alfa in Pediatric Population with Hemophilia A.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2025). PMID: 40982238 ↗
L4Cited in: 12. Special Populations & Prevention - [385]
Yuan M, Nusrat S, Khan O. “Concizumab prophylaxis in a 2-year-old patient with severe hemophilia B and inhibitor: a case report.” Frontiers in pharmacology (2026). PMID: 42528704 ↗
L4Cited in: 12. Special Populations & Prevention - [386]
Montoro-Ronsano JB, Poveda-Andrés JL, Romero-Garrido JA et al.. “[Translated article] Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.” Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria (2023). PMID: 37150664 ↗
L1cCited in: 7. Acute & Emergency Management - [387]
Young L, Ban L, Chen Y et al.. “Clinical Burden and Healthcare Resource Use Among Adults Living with Hemophilia A: An Observational Study.” Drugs - real world outcomes (2025). PMID: 40888863 ↗
L3bCited in: 7. Acute & Emergency Management - [388]
Lee D, Le AO, Meganck M et al.. “Adding a Clinical Hemophilia Pharmacist to the Hemophilia Comprehensive Care Model Improves Health Care-Related Outcomes and Drug-Related Costs in an Integrated Health Care System.” The Permanente journal (2022). PMID: 35989427 ↗
L3bCited in: 7. Acute & Emergency Management - [389]
Huang D, Yang X, Zhang X et al.. “Balancing Thrombosis and Bleeding: A Case Report of Acute Myocardial Infarction in an Elderly Patient With Hemophilia A.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 42706764 ↗
L4Cited in: 7. Acute & Emergency Management - [390]
Wilson JA, Hayden S, Asamoah A et al.. “Emicizumab Associated Rhabdomyolysis in Hemophilia A.” Clinical hematology international (2020). PMID: 34595457 ↗
L4Cited in: 7. Acute & Emergency Management - [391]
Ferri Grazzi E, Sun SX, Burke T et al.. “The Impact of Pharmacokinetic-Guided Prophylaxis on Clinical Outcomes and Healthcare Resource Utilization in Hemophilia A Patients: Real-World Evidence from the CHESS II Study.” Journal of blood medicine (2022). PMID: 36157322 ↗
L3bCited in: 7. Acute & Emergency Management - [392]
Cafuir L, Estrin A, Chen E et al.. “Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors.” Journal of medical economics (2022). PMID: 35848992 ↗
L5Cited in: 7. Acute & Emergency Management - [393]
Kracht MJ, Stein A, Knoll C et al.. “A proposed algorithm for evaluation and management of pediatric hemophilia patients who present to the emergency department with head trauma.” Pediatric blood & cancer (2022). PMID: 35709337 ↗
L5Cited in: 7. Acute & Emergency Management - [394]
Alblaihed L, Dubbs SB, Koyfman A et al.. “High risk and low prevalence diseases: Hemophilia emergencies.” The American journal of emergency medicine (2022). PMID: 35349958 ↗
L5Cited in: 7. Acute & Emergency Management - [395]
Thornburg CD, Adamski K, Cook K et al.. “Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States.” Journal of managed care & specialty pharmacy (2021). PMID: 34958235 ↗
L5Cited in: 7. Acute & Emergency Management - [396]
Huang Q, Chen X, Wu X et al.. “Hemorrhagic Shock and Massive Abdominal Wall Hematoma After Cesarean Section in a Patient with Peripartum Acquired Hemophilia A:A Case Report.” International journal of women's health (2026). PMID: 41878716 ↗
L4Cited in: 7. Acute & Emergency Management - [397]
Kaminski TW, Swendrowski N, Katoch O et al.. “Neutrophil-dependent interferonopathy contributes to joint damage in hemophilia.” Blood (2026). PMID: 42728031 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [398]
Fischer K, Olivieri M, Ranta S et al.. “Inhibitor development according to FVIII concentrates in previously untreated patients with severe hemophilia A: update from the PedNet registry.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42119947 ↗
L4Cited in: 3. Epidemiology, Etiology & Risk Factors - [399]
Atarashi K, Nakamura H, Kaneko K et al.. “Factors associated with postextraction bleeding in patients with hemophilia: a multicenter retrospective cohort study.” Research and practice in thrombosis and haemostasis (2026). PMID: 42668549 ↗
L3bCited in: 3. Epidemiology, Etiology & Risk Factors - [400]
Borràs Agustí N, Garcia-Martínez I, de la Morena-Barrio B et al.. “Resolving structural variants in hemophilia: insights from long-read sequencing and molecular and clinical implications.” Blood advances (2026). PMID: 42815157 ↗
L5Cited in: 5. Diagnosis & Workup - [401]
Rebouças TO, Tavares AC, Costa AD et al.. “Artificial Intelligence and Machine Learning in the Context of Hemophilia: A Scope Review.” Haemophilia : the official journal of the World Federation of Hemophilia (2026). PMID: 42765167 ↗
L5Cited in: 5. Diagnosis & Workup - [402]
Li Z, Lu Y, Chen Z et al.. “Maternal microchimerism accelerates immune tolerance induction to factor VIII in children with hemophilia A and FVIII inhibitors.” Frontiers in immunology (2026). PMID: 42712373 ↗
L3bCited in: 12. Special Populations & Prevention - [403]
Chandra D, Singh MK, Gupta R et al.. “Utilizing Inhibitor Screening Assay Results to Predict Bethesda Titers in Patients With Hemophilia A: Cost-Effective Strategy in Resource-Constrained Setting.” International journal of laboratory hematology (2026). PMID: 42702755 ↗
L2bCited in: 12. Special Populations & Prevention - [404]
Teitel J, Carcao M, Sholzberg M et al.. “Plasma emicizumab concentrations and bleeding rates in children and adults with severe hemophilia A.” Research and practice in thrombosis and haemostasis (2026). PMID: 42756654 ↗
L4Cited in: 12. Special Populations & Prevention - [405]
Croteau SE, Castaman G, Fijnvandraat K et al.. “Assessment of documentation and reporting methods for annual bleeding rate in hemophilia clinical trials: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX, and Rare Coagulation Disorders.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42716225 ↗
L1cCited in: 11. Prognosis & Natural History - [406]
Kenet G, Berrueco R, Fijnvandraat K et al.. “Denecimig (Mim8) prophylaxis in children with hemophilia A with or without factor VIII inhibitors.” Research and practice in thrombosis and haemostasis (2026). PMID: 42835127 ↗
L2bCited in: 11. Prognosis & Natural History - [407]
Li Z, Chen Z, Zhang J et al.. “Isolated A1-domain F8 large deletions are associated with favorable immune tolerance induction outcomes in children with severe hemophilia A.” Research and practice in thrombosis and haemostasis (2026). PMID: 42840794 ↗
L4Cited in: 11. Prognosis & Natural History